,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,5,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
2,7,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
3,9,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
4,11,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,17,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
8,19,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
9,21,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
10,23,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
11,25,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
12,27,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
13,29,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
14,31,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
15,33,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
16,35,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
17,37,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
18,39,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
19,45,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
20,47,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
21,49,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
22,51,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line,Confirmatory,,
23,53,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
24,55,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
25,57,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line,Confirmatory,,
26,59,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
27,61,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line,Confirmatory,,
28,63,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
29,65,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
30,67,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
31,69,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
32,71,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
33,73,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
34,75,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line,Confirmatory,,
35,79,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
36,81,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
37,99,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
38,101,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
39,103,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
40,105,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
41,107,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
42,109,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
43,113,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
44,119,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
45,121,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
46,123,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
47,125,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
48,129,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
49,131,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
50,133,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
51,137,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
52,139,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
53,141,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
54,143,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
55,145,1,1,,105815,896,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
56,179,1,1,,410775,896,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
57,351,1,4,,7636333,896,Inactive,,,,,Tubulin destabilizers,Other,,
58,357,2,1,,11111467,896,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
59,357,2,1,,11111468,896,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
60,377,1,3,,10321385,896,Inconclusive,42741659.0,5243.0,,,MDR-1,Other,,
61,410,1,5,,11111467,896,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
62,410,1,5,,11111468,896,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
63,410,1,5,,11111469,896,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
64,411,2,1,,11111467,896,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
65,411,2,1,,11111468,896,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
66,411,2,1,,11111469,896,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
67,421,1,3,,17388930,896,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
68,421,1,3,,17389536,896,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
69,422,1,5,,17405348,896,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
70,426,1,2,,17388930,896,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
71,426,1,2,,17389536,896,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
72,427,1,1,,17388930,896,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
73,427,1,1,,17389536,896,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
74,429,1,5,,17405348,896,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
75,429,1,5,,17405348,896,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
76,433,1,1,,17388930,896,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
77,433,1,1,,17389536,896,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
78,434,1,2,,17388930,896,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
79,434,1,2,,17389536,896,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
80,435,1,2,,17388930,896,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
81,435,1,2,,17389536,896,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
82,436,2,1,,17405348,896,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
83,444,1,1,,11111467,896,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
84,444,1,1,,11111468,896,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
85,445,3,1,,11111467,896,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
86,445,3,1,,11111468,896,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
87,445,3,1,,11111469,896,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
88,445,3,1,,17388930,896,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
89,445,3,1,,17389536,896,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
90,446,1,1,,11111467,896,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
91,446,1,1,,11111468,896,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
92,447,1,1,,11111467,896,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
93,447,1,1,,11111468,896,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
94,447,1,1,,11111469,896,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
95,448,1,2,,11111467,896,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
96,448,1,2,,11111468,896,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
97,448,1,2,,11111469,896,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
98,450,1,2,,11111467,896,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
99,450,1,2,,11111468,896,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
100,450,1,2,,11111469,896,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
101,451,1,2,,11111467,896,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
102,451,1,2,,11111468,896,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
103,451,1,2,,11111469,896,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
104,526,1,1,,11111467,896,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
105,526,1,1,,11111468,896,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
106,526,1,1,,11111469,896,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
107,530,1,1,,11111467,896,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
108,530,1,1,,11111468,896,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
109,530,1,1,,11111469,896,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
110,530,1,1,,17388930,896,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
111,530,1,1,,17389536,896,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
112,540,1,1,,17388930,896,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
113,540,1,1,,17389536,896,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
114,541,1,1,,17388930,896,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
115,541,1,1,,17389536,896,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
116,542,1,1,,17388930,896,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
117,542,1,1,,17389536,896,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
118,543,1,1,,17388930,896,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
119,543,1,1,,17389536,896,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
120,544,2,1,,17388930,896,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
121,544,2,1,,17389536,896,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
122,545,1,1,,17388930,896,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
123,545,1,1,,17389536,896,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
124,546,1,1,,17388930,896,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
125,546,1,1,,17389536,896,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
126,547,1,4,,17405348,896,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
127,584,1,3,,11111467,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
128,584,1,3,,11111468,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
129,584,1,3,,11111469,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
130,584,1,3,,17388930,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
131,584,1,3,,17389536,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
132,585,1,4,,11111467,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
133,585,1,4,,11111468,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
134,585,1,4,,11111469,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
135,585,1,4,,17388930,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
136,585,1,4,,17389536,896,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
137,587,1,5,,11111467,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
138,587,1,5,,11111468,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
139,587,1,5,,11111469,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
140,588,1,4,,11111467,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
141,588,1,4,,11111468,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
142,588,1,4,,11111469,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
143,589,1,3,,11111467,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
144,589,1,3,,11111468,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
145,589,1,3,,11111469,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
146,590,1,3,,11111467,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
147,590,1,3,,11111468,896,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
148,590,1,3,,11111469,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
149,591,1,4,,11111467,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
150,591,1,4,,11111468,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
151,591,1,4,,11111469,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
152,592,1,6,,11111467,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
153,592,1,6,,11111468,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
154,592,1,6,,11111469,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
155,593,1,4,,11111467,896,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
156,593,1,4,,11111468,896,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
157,593,1,4,,11111469,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
158,594,1,4,,11111467,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
159,594,1,4,,11111468,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
160,594,1,4,,11111469,896,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
161,595,1,3,,11111467,896,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
162,595,1,3,,11111468,896,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
163,595,1,3,,11111469,896,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
164,595,1,3,,17388930,896,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
165,595,1,3,,17389536,896,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
166,596,1,2,,11111467,896,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
167,596,1,2,,11111468,896,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
168,596,1,2,,11111469,896,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
169,596,1,2,,17388930,896,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
170,596,1,2,,17389536,896,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
171,597,1,3,,11111467,896,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
172,597,1,3,,11111468,896,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
173,597,1,3,,11111469,896,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
174,603,1,2,,11111467,896,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
175,603,1,2,,11111468,896,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
176,603,1,2,,11111469,896,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
177,603,1,2,,17388930,896,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
178,603,1,2,,17389536,896,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
179,605,1,2,,11111467,896,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
180,605,1,2,,11111468,896,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
181,605,1,2,,11111469,896,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
182,605,1,2,,17388930,896,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
183,605,1,2,,17389536,896,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
184,607,1,3,,11111467,896,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
185,607,1,3,,11111468,896,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
186,607,1,3,,11111469,896,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
187,608,1,6,,11536797,896,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
188,608,1,6,,11537588,896,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
189,654,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
190,654,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
191,655,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
192,655,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
193,656,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
194,656,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
195,657,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
196,657,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
197,658,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
198,658,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
199,659,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
200,659,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
201,660,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
202,660,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
203,661,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
204,661,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
205,662,1,1,,11111467,896,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
206,662,1,1,,11111468,896,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
207,662,1,1,,11111469,896,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
208,662,1,1,,17388930,896,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
209,662,1,1,,17389536,896,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
210,663,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
211,663,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
212,664,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
213,664,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
214,665,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
215,665,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
216,666,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
217,666,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
218,667,1,1,,17388930,896,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
219,667,1,1,,17389536,896,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
220,694,1,1,,17405348,896,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
221,732,1,2,,17405348,896,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
222,875,1,2,,11111468,896,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
223,875,1,2,,17388930,896,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
224,875,1,2,,17389536,896,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
225,879,1,2,,17388930,896,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
226,879,1,2,,17388930,896,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
227,880,2,1,,11111468,896,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
228,880,2,1,,11111468,896,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
229,880,2,1,,17388930,896,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
230,880,2,1,,17388930,896,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
231,880,2,1,,17389536,896,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
232,880,2,1,,17389536,896,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
233,880,2,1,,26747238,896,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
234,880,2,1,,26747238,896,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
235,880,2,1,,26752764,896,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
236,880,2,1,,26752764,896,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
237,880,2,1,,50105414,896,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
238,880,2,1,,50105414,896,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
239,880,2,1,,50105415,896,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
240,880,2,1,,50105415,896,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
241,881,2,2,,11111468,896,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
242,881,2,2,,17388930,896,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
243,881,2,2,,17389536,896,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
244,883,1,3,,11111467,896,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
245,883,1,3,,11111468,896,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
246,883,1,3,,11111469,896,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
247,884,1,2,,11111468,896,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
248,884,1,2,,17388930,896,Active,13435386.0,1576.0,19.9526,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
249,884,1,2,,17389536,896,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
250,885,1,2,,11111468,896,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
251,885,1,2,,17388930,896,Inactive,13435386.0,1576.0,19.9526,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
252,885,1,2,,17389536,896,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
253,886,1,2,,11111467,896,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
254,886,1,2,,11111467,896,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
255,886,1,2,,11111468,896,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
256,886,1,2,,11111468,896,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
257,886,1,2,,11111469,896,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
258,886,1,2,,11111469,896,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
259,886,1,2,,17388930,896,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
260,886,1,2,,17388930,896,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
261,886,1,2,,17389536,896,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
262,886,1,2,,17389536,896,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
263,887,1,2,,11111468,896,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
264,887,1,2,,17388930,896,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
265,887,1,2,,17389536,896,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
266,889,1,3,,11111468,896,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
267,889,1,3,,17388930,896,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
268,889,1,3,,17389536,896,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
269,891,1,2,,11111467,896,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
270,891,1,2,,11111468,896,Inconclusive,40805836.0,1565.0,10.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
271,891,1,2,,11111469,896,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
272,892,1,2,,11111468,896,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
273,892,1,2,,17388930,896,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
274,892,1,2,,17389536,896,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
275,893,1,2,,11111468,896,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
276,893,1,2,,11111468,896,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
277,893,1,2,,17388930,896,Inconclusive,122921310.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
278,893,1,2,,17388930,896,Inconclusive,122921311.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
279,893,1,2,,17389536,896,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
280,893,1,2,,17389536,896,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
281,894,2,1,,11111468,896,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
282,894,2,1,,17388930,896,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
283,894,2,1,,17389536,896,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
284,894,2,1,,26747238,896,Inconclusive,31542939.0,3248.0,28.1838,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
285,894,2,1,,50105414,896,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
286,894,2,1,,50105415,896,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
287,895,1,2,,17388930,896,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
288,899,1,2,,11111467,896,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
289,899,1,2,,11111468,896,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
290,899,1,2,,11111469,896,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
291,900,1,3,,11111468,896,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
292,900,1,3,,17388930,896,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
293,900,1,3,,17389536,896,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
294,901,1,2,,11111468,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
295,901,1,2,,17388930,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
296,902,1,2,,11111468,896,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
297,902,1,2,,17388930,896,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
298,902,1,2,,17389536,896,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
299,910,1,2,,17388930,896,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
300,912,1,2,,11111467,896,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
301,912,1,2,,11111468,896,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
302,912,1,2,,11111469,896,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
303,912,1,2,,17388930,896,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
304,912,1,2,,17389536,896,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
305,914,1,3,,11111467,896,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
306,914,1,3,,11111468,896,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
307,915,1,3,,11111467,896,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
308,915,1,3,,11111468,896,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
309,917,1,3,,17388930,896,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
310,918,1,3,,17388930,896,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
311,921,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
312,921,1,2,,17389536,896,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-001,Confirmatory,,
313,923,1,2,,11111468,896,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
314,923,1,2,,17388930,896,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
315,923,1,2,,17389536,896,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
316,924,1,2,,11111468,896,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
317,924,1,2,,17388930,896,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
318,924,1,2,,17389536,896,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
319,925,1,2,,11111467,896,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
320,925,1,2,,11111468,896,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
321,925,1,2,,17388930,896,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
322,925,1,2,,17389536,896,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
323,926,1,2,,11111467,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
324,926,1,2,,11111468,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
325,926,1,2,,11111469,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
326,926,1,2,,17388930,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
327,926,1,2,,17389536,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
328,927,1,3,,11111468,896,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
329,927,1,3,,17388930,896,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
330,928,1,2,,17388930,896,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
331,930,1,2,,17388930,896,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
332,938,1,2,,11111467,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
333,938,1,2,,11111468,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
334,938,1,2,,11111469,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
335,938,1,2,,17388930,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
336,938,1,2,,17389536,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
337,940,1,2,,17405348,896,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
338,940,1,2,,26612030,896,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
339,943,1,2,,17388930,896,Inconclusive,18249941.0,25229.0,0.0631,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
340,944,1,2,,17388930,896,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
341,945,1,4,,17388930,896,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
342,946,1,2,,17388930,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
343,946,1,2,,17389536,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
344,947,1,2,,17388930,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
345,947,1,2,,17389536,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
346,948,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
347,948,1,2,,17389536,896,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
348,954,1,2,,17388930,896,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
349,955,1,2,,17388930,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
350,955,1,2,,17389536,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
351,957,1,2,,17388930,896,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
352,958,1,2,,17388930,896,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
353,959,1,4,,17388930,896,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
354,960,1,2,,17388930,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
355,960,1,2,,17389536,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
356,961,1,2,,17388930,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
357,961,1,2,,17389536,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
358,962,1,2,,17388930,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
359,962,1,2,,17389536,896,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
360,963,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
361,963,1,2,,17389536,896,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
362,964,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
363,964,1,2,,17389536,896,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
364,965,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
365,965,1,2,,17389536,896,Inconclusive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
366,966,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
367,966,1,2,,17389536,896,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-004,Confirmatory,,
368,967,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
369,967,1,2,,17389536,896,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
370,968,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
371,968,1,2,,17389536,896,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-009,Confirmatory,,
372,969,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
373,969,1,2,,17389536,896,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-011,Confirmatory,,
374,970,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
375,970,1,2,,17389536,896,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-013,Confirmatory,,
376,971,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
377,971,1,2,,17389536,896,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-015,Confirmatory,,
378,972,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
379,972,1,2,,17389536,896,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-017,Confirmatory,,
380,973,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
381,973,1,2,,17389536,896,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-019,Confirmatory,,
382,974,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
383,974,1,2,,17389536,896,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-021,Confirmatory,,
384,975,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
385,975,1,2,,17389536,896,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-023,Confirmatory,,
386,976,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
387,976,1,2,,17389536,896,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-025,Confirmatory,,
388,977,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
389,977,1,2,,17389536,896,Inconclusive,,,63.0957,Potency,Cell Viability - LYMP2-002,Confirmatory,,
390,978,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
391,978,1,2,,17389536,896,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-006,Confirmatory,,
392,979,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
393,979,1,2,,17389536,896,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-007,Confirmatory,,
394,980,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
395,980,1,2,,17389536,896,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-008,Confirmatory,,
396,981,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
397,981,1,2,,17389536,896,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-010,Confirmatory,,
398,982,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
399,982,1,2,,17389536,896,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP2-012,Confirmatory,,
400,983,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
401,983,1,2,,17389536,896,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-014,Confirmatory,,
402,984,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
403,984,1,2,,17389536,896,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-016,Confirmatory,,
404,985,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
405,985,1,2,,17389536,896,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-018,Confirmatory,,
406,986,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
407,986,1,2,,17389536,896,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-020,Confirmatory,,
408,987,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
409,987,1,2,,17389536,896,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-022,Confirmatory,,
410,988,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
411,988,1,2,,17389536,896,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP2-024,Confirmatory,,
412,989,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
413,989,1,2,,17389536,896,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-026,Confirmatory,,
414,992,1,3,,17388930,896,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
415,993,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
416,993,1,2,,17389536,896,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
417,994,1,2,,17388930,896,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
418,994,1,2,,17389536,896,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
419,995,1,2,,11111468,896,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
420,995,1,2,,17388930,896,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
421,995,1,2,,17389536,896,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
422,997,1,2,,17388930,896,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
423,998,1,2,,17388930,896,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
424,1030,2,1,,11111468,896,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
425,1030,2,1,,17388930,896,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
426,1030,2,1,,17389536,896,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
427,1030,2,1,,26747238,896,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
428,1030,2,1,,26752764,896,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
429,1030,2,1,,50105414,896,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
430,1030,2,1,,50105415,896,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
431,1033,2,2,,11536797,896,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
432,1033,2,2,,11537588,896,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
433,1195,1,2,,48416204,896,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
434,1204,1,2,,48421927,896,Inactive,,,,,DSSTox (NCTRER) National Center for Toxicological Research Estrogen Receptor Binding Database,Screening,,
435,1332,1,1,,49698838,896,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
436,1376,1,2,,46500483,896,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
437,1379,1,2,,11111468,896,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
438,1379,1,2,,26747238,896,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
439,1379,1,2,,50105414,896,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
440,1379,1,2,,50105415,896,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
441,1385,2,2,,46500483,896,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
442,1422,1,1,,17405348,896,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
443,1422,1,1,,26612030,896,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
444,1422,1,1,,46500483,896,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
445,1452,1,1,,11111468,896,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
446,1452,1,1,,17388930,896,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
447,1452,1,1,,17389536,896,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
448,1454,1,1,,11111468,896,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
449,1454,1,1,,26747238,896,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
450,1454,1,1,,50105414,896,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
451,1454,1,1,,50105415,896,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
452,1457,1,1,,11111468,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
453,1457,1,1,,17388930,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
454,1457,1,1,,17389536,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
455,1457,1,1,,26747238,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
456,1457,1,1,,26752764,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
457,1457,1,1,,50105414,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
458,1457,1,1,,50105415,896,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
459,1458,1,1,,11111468,896,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
460,1458,1,1,,17388930,896,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
461,1458,1,1,,17389536,896,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
462,1458,1,1,,26747238,896,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
463,1458,1,1,,26752764,896,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
464,1458,1,1,,50105414,896,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
465,1459,1,1,,50105414,896,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
466,1460,1,3,,26747238,896,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
467,1460,1,3,,26752764,896,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
468,1460,1,3,,50105414,896,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
469,1460,1,3,,50105415,896,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
470,1461,1,2,,50105414,896,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
471,1463,1,1,,26747238,896,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
472,1463,1,1,,26752764,896,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
473,1463,1,1,,50105414,896,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
474,1463,1,1,,50105415,896,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
475,1465,1,1,,46500483,896,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
476,1467,1,3,,11111468,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
477,1467,1,3,,26747238,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
478,1467,1,3,,50105414,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
479,1467,1,3,,50105415,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
480,1468,1,1,,26747238,896,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
481,1468,1,1,,26752764,896,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
482,1468,1,1,,50105414,896,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
483,1468,1,1,,50105415,896,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
484,1469,1,1,,11111468,896,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
485,1469,1,1,,17388930,896,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
486,1469,1,1,,17389536,896,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
487,1469,1,1,,26747238,896,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
488,1469,1,1,,26752764,896,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
489,1469,1,1,,26752765,896,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
490,1469,1,1,,50105414,896,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
491,1469,1,1,,50105415,896,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
492,1471,2,1,,11111467,896,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
493,1471,2,1,,11111468,896,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
494,1471,2,1,,11111469,896,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
495,1471,2,1,,17388930,896,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
496,1471,2,1,,17389536,896,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
497,1471,2,1,,26747238,896,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
498,1471,2,1,,26752764,896,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
499,1471,2,1,,50105415,896,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
500,1476,2,1,,11111468,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
501,1476,2,1,,17388930,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
502,1476,2,1,,17389536,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
503,1476,2,1,,26747238,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
504,1476,2,1,,50105414,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
505,1476,2,1,,50105415,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
506,1477,1,1,,11111468,896,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
507,1477,1,1,,17388930,896,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
508,1477,1,1,,17389536,896,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
509,1477,1,1,,26747238,896,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
510,1477,1,1,,26752764,896,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
511,1477,1,1,,50105414,896,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
512,1477,1,1,,50105415,896,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
513,1478,2,1,,11111468,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
514,1478,2,1,,17388930,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
515,1478,2,1,,17389536,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
516,1478,2,1,,26747238,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
517,1478,2,1,,50105414,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
518,1478,2,1,,50105415,896,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
519,1479,1,2,,11111468,896,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
520,1479,1,2,,17388930,896,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
521,1479,1,2,,17389536,896,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
522,1479,1,2,,26747238,896,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
523,1479,1,2,,26752764,896,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
524,1479,1,2,,26752765,896,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
525,1479,1,2,,50105414,896,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
526,1479,1,2,,50105415,896,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
527,1487,1,1,,11111468,896,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
528,1487,1,1,,26752764,896,Inconclusive,27436948.0,4000.0,0.0008,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
529,1487,1,1,,50105414,896,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
530,1490,2,1,,11111468,896,Inactive,10954339.0,,39.8107,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
531,1490,2,1,,26747238,896,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
532,1490,2,1,,26752764,896,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
533,1490,2,1,,50105415,896,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
534,1511,1,3,,46500483,896,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
535,1519,1,3,,11111468,896,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
536,1519,1,3,,26747238,896,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
537,1519,1,3,,50105414,896,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
538,1519,1,3,,50105415,896,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
539,1529,1,1,,46500483,896,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
540,1530,1,1,,46500483,896,Active,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
541,1531,1,1,,46500483,896,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
542,1532,1,1,,46500483,896,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
543,1549,1,2,,11536797,896,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
544,1549,1,2,,11537588,896,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
545,1552,1,3,,11536797,896,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
546,1552,1,3,,11537588,896,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
547,1554,1,1,,46500483,896,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
548,1580,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
549,1581,1,1,,8149639,896,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
550,1582,1,1,,8149639,896,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
551,1583,1,1,,8149639,896,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
552,1584,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
553,1585,1,1,,8149639,896,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
554,1586,1,1,,8149639,896,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
555,1587,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
556,1588,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
557,1589,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
558,1590,1,1,,8149639,896,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
559,1593,1,1,,8149639,896,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
560,1594,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
561,1595,1,1,,8149639,896,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
562,1596,1,1,,8149639,896,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
563,1597,1,1,,8149639,896,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
564,1598,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
565,1599,1,1,,8149639,896,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
566,1600,1,1,,8149639,896,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
567,1601,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
568,1602,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
569,1603,1,1,,8149639,896,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
570,1604,1,1,,8149639,896,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
571,1605,1,1,,8149639,896,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
572,1606,1,1,,8149639,896,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
573,1607,1,1,,8149639,896,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
574,1608,1,1,,8149639,896,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
575,1609,1,1,,8149639,896,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
576,1610,1,1,,8149639,896,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
577,1612,1,1,,8149639,896,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
578,1613,1,1,,8149639,896,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
579,1614,1,1,,8149639,896,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
580,1616,1,1,,8149639,896,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
581,1621,1,2,,46500483,896,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
582,1626,1,2,,46500483,896,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
583,1637,1,2,,11536797,896,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
584,1637,1,2,,11537588,896,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
585,1648,1,2,,11536797,896,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
586,1648,1,2,,11537588,896,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
587,1662,1,2,,46500483,896,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
588,1663,1,2,,46500483,896,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
589,1672,1,3,,46500483,896,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
590,1688,1,1,,26752764,896,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
591,1705,1,2,,50105414,896,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
592,1707,1,3,,50105414,896,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
593,1708,1,3,,50105414,896,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
594,1766,1,1,,11111468,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
595,1766,1,1,,11111468,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
596,1766,1,1,,26747238,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
597,1766,1,1,,26747238,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
598,1766,1,1,,26752764,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
599,1766,1,1,,26752764,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
600,1766,1,1,,50105414,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
601,1766,1,1,,50105414,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
602,1766,1,1,,50105415,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
603,1766,1,1,,50105415,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
604,1768,1,1,,11111468,896,Inconclusive,18860839.0,4221.0,12.5893,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
605,1768,1,1,,11111468,896,Inconclusive,56550039.0,4297.0,12.5893,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
606,1768,1,1,,26747238,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
607,1768,1,1,,26747238,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
608,1768,1,1,,26752764,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
609,1768,1,1,,26752764,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
610,1768,1,1,,50105414,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
611,1768,1,1,,50105414,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
612,1768,1,1,,50105415,896,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
613,1768,1,1,,50105415,896,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
614,1813,1,2,,46500483,896,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
615,1814,1,2,,46500483,896,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
616,1815,1,1,,50105414,896,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
617,1816,1,1,,50105414,896,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
618,1828,2,1,,50105414,896,Inactive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
619,1832,2,1,,46500483,896,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
620,1850,2,1,,46500483,896,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
621,1851,1,2,,11111468,896,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
622,1851,1,2,1.0,11111468,896,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
623,1851,1,2,2.0,11111468,896,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
624,1851,1,2,3.0,11111468,896,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
625,1851,1,2,4.0,11111468,896,Active,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
626,1851,1,2,5.0,11111468,896,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
627,1863,2,1,,46500483,896,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
628,1865,1,1,,11111468,896,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
629,1865,1,1,,26747238,896,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
630,1865,1,1,,26752764,896,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
631,1865,1,1,,50105414,896,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
632,1865,1,1,,50105415,896,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
633,1875,2,1,,46500483,896,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
634,1876,1,1,,50105414,896,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
635,1877,1,1,,50105414,896,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
636,1882,1,1,,50105414,896,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
637,1883,1,1,,50105414,896,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
638,1885,2,1,,46500483,896,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
639,1886,1,1,,50105414,896,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
640,1892,1,1,,46500483,896,Inactive,22035600.0,5871.0,,,"Single Concentration Confirmation Screen via Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
641,1893,1,1,,46500483,896,Inactive,22035600.0,5871.0,,,"Single Concentration Confirmation Screen via Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
642,1894,1,1,,46500483,896,Inactive,42794767.0,4215.0,,,"Single Concentration Confirmation Screen via Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
643,1899,1,3,,46500483,896,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
644,1903,2,3,,46500483,896,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
645,1906,1,3,,46500483,896,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
646,1910,1,2,,46500483,896,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
647,1947,1,2,,46500483,896,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
648,1948,1,1,,11111468,896,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
649,1948,1,1,,17388930,896,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
650,1948,1,1,,17389536,896,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
651,1948,1,1,,26747238,896,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
652,1948,1,1,,50105414,896,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
653,1948,1,1,,50105415,896,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
654,1950,1,3,,46500483,896,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
655,1956,1,1,,46500483,896,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
656,1962,1,2,,46500483,896,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
657,1967,1,1,,85231137,896,Inconclusive,4505907.0,5376.0,84.9214,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
658,1974,1,2,,46500483,896,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
659,1979,1,1,,46500483,896,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
660,1987,1,2,,46500483,896,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
661,1996,2,2,,46500483,896,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
662,2016,1,3,,46500483,896,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
663,2023,1,3,,46500483,896,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
664,2025,1,3,,46500483,896,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
665,2029,1,3,,46500483,896,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
666,2052,2,1,,46500483,896,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
667,2057,1,2,,46500483,896,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
668,2062,1,2,,85209925,896,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
669,2066,1,4,,46500483,896,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
670,2094,1,2,,46500483,896,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
671,2094,1,2,,46500483,896,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
672,2094,1,2,,46500483,896,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
673,2097,1,2,,46500483,896,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
674,2098,1,1,,46500483,896,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
675,2099,1,1,,46500483,896,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
676,2101,1,1,,11111468,896,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
677,2101,1,1,,17388930,896,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
678,2101,1,1,,17389536,896,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
679,2101,1,1,,26747238,896,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
680,2101,1,1,,26752764,896,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
681,2101,1,1,,50105414,896,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
682,2101,1,1,,50105415,896,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
683,2107,1,1,,11111468,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
684,2107,1,1,,17388930,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
685,2107,1,1,,17389536,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
686,2107,1,1,,26747238,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
687,2107,1,1,,26752764,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
688,2107,1,1,,50105414,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
689,2107,1,1,,50105415,896,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
690,2112,1,1,,11111468,896,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
691,2112,1,1,,17388930,896,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
692,2112,1,1,,17389536,896,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
693,2112,1,1,,26747238,896,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
694,2112,1,1,,26752764,896,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
695,2112,1,1,,50105414,896,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
696,2112,1,1,,50105415,896,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
697,2120,1,1,,17388930,896,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
698,2120,1,1,,17389536,896,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
699,2129,1,2,,46500483,896,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
700,2130,1,3,,46500483,896,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
701,2147,1,1,,11111468,896,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
702,2147,1,1,,26747238,896,Inconclusive,221046486.0,,22.3872,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
703,2147,1,1,,50105414,896,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
704,2147,1,1,,50105415,896,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
705,2156,2,2,,46500483,896,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
706,2174,1,3,,46500483,896,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
707,2177,1,3,,46500483,896,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
708,2216,1,3,,46500483,896,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
709,2221,1,2,,46500483,896,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
710,2227,1,2,,46500483,896,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
711,2234,1,2,,46500483,896,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
712,2235,1,2,,46500483,896,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
713,2237,1,2,,46500483,896,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
714,2239,1,2,,46500483,896,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
715,2240,1,1,,85788807,896,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
716,2241,1,1,,85788807,896,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
717,2247,1,2,,46500483,896,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
718,2275,1,1,,85788807,896,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
719,2280,2,3,,46500483,896,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
720,2300,1,3,,46500483,896,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
721,2313,1,1,,85788807,896,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
722,2322,1,1,,85788807,896,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
723,2323,1,1,,50105414,896,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
724,2326,1,1,,50105414,896,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
725,2330,1,1,,85788807,896,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
726,2353,1,3,,50105414,896,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
727,2364,1,2,,50105414,896,Inconclusive,4557365.0,641.0,0.0016,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
728,2380,1,2,,46500483,896,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
729,2391,1,1,,46500483,896,Inconclusive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
730,2435,1,2,,46500483,896,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
731,2445,1,2,,46500483,896,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
732,2451,1,2,,11111468,896,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
733,2451,1,2,,26747238,896,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
734,2451,1,2,,50105414,896,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
735,2451,1,2,,50105415,896,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
736,2462,1,1,,46500483,896,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
737,2462,1,1,,46500483,896,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
738,2472,1,2,,11111468,896,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
739,2472,1,2,,26747238,896,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
740,2472,1,2,,50105415,896,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
741,2517,2,1,,11111468,896,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
742,2517,2,1,,17388930,896,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
743,2517,2,1,,17389536,896,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
744,2517,2,1,,26747238,896,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
745,2517,2,1,,26752764,896,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
746,2517,2,1,,50105414,896,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
747,2517,2,1,,50105415,896,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
748,2520,1,4,,46500483,896,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
749,2521,1,3,,46500483,896,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
750,2524,1,2,,46500483,896,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
751,2528,1,2,,11111468,896,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
752,2528,1,2,,26747238,896,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
753,2528,1,2,,26752764,896,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
754,2528,1,2,,50105414,896,Inconclusive,4557365.0,641.0,0.0016,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
755,2528,1,2,,50105415,896,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
756,2540,1,2,,46500483,896,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
757,2544,1,2,,46500483,896,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
758,2546,1,1,,11111468,896,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
759,2546,1,1,,17388930,896,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
760,2546,1,1,,17389536,896,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
761,2546,1,1,,26747238,896,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
762,2546,1,1,,26752764,896,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
763,2546,1,1,,50105415,896,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
764,2549,1,1,,11111468,896,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
765,2549,1,1,,17388930,896,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
766,2549,1,1,,17389536,896,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
767,2549,1,1,,26747238,896,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
768,2549,1,1,,26752764,896,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
769,2549,1,1,,50105414,896,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
770,2549,1,1,,50105415,896,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
771,2550,1,3,,46500483,896,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
772,2551,1,1,,11111468,896,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
773,2551,1,1,,17388930,896,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
774,2551,1,1,,17389536,896,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
775,2551,1,1,,26747238,896,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
776,2551,1,1,,26752764,896,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
777,2551,1,1,,50105415,896,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
778,2553,1,2,,46500483,896,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
779,2557,1,3,,46500483,896,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
780,2563,1,1,,46500483,896,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
781,2599,1,2,,46500483,896,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
782,2606,1,2,,46500483,896,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
783,2629,1,1,,46500483,896,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
784,2642,1,2,,46500483,896,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
785,2648,1,2,,46500483,896,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
786,2650,2,1,,46500483,896,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
787,2660,1,1,,90340716,896,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
788,2661,1,1,,46500483,896,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
789,2662,2,1,,85231137,896,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
790,2666,1,1,,90340716,896,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
791,2667,1,1,,90340716,896,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
792,2668,1,1,,90340716,896,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
793,2675,1,1,,50105414,896,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
794,2690,1,2,,46500483,896,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
795,2716,1,1,,46500483,896,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
796,2717,1,2,,46500483,896,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
797,2718,1,1,,46500483,896,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
798,2732,1,1,,17405348,896,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
799,2751,2,2,,46500483,896,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
800,2774,1,3,,92304139,896,Inactive,,,,,LOPAC Circadian Assay,Screening,,
801,2796,1,4,,46500483,896,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
802,2797,1,2,,46500483,896,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
803,2805,2,2,,46500483,896,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
804,2806,2,2,,46500483,896,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
805,2825,1,2,,46500483,896,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
806,107381,3,3,,103166463,896,Active,,,,,Pigment aggregation response in Xenopus laevis Melanophores at 10e-8 M of concentration; Agonist response,Other,7707316.0,
807,107394,3,10,,103166463,896,Unspecified,1346543.0,396319.0,,,Percent maximum effect relative to melatonin (100%),Other,10090792.0,
808,107394,3,10,,103166463,896,Unspecified,1346550.0,396318.0,,,Percent maximum effect relative to melatonin (100%),Other,10090792.0,
809,107394,3,10,,103166463,896,Unspecified,1709047.0,396338.0,,,Percent maximum effect relative to melatonin (100%),Other,10090792.0,
810,107396,5,4,,103166463,896,Active,,,0.0226,EC50,Functional activity against melatonin receptor in lightening Xenopus laevis tadpole skin,Confirmatory,10090792.0,
811,107397,7,5,,103166463,896,Active,1346543.0,396319.0,0.0007,Ki,Inhibition of 2-[125I]- iodomelatonin from chicken brain melatonin receptors,Confirmatory,10090792.0,
812,107397,7,5,,103166463,896,Active,1346550.0,396318.0,0.0007,Ki,Inhibition of 2-[125I]- iodomelatonin from chicken brain melatonin receptors,Confirmatory,10090792.0,
813,107397,7,5,,103166463,896,Active,1709047.0,396338.0,0.0007,Ki,Inhibition of 2-[125I]- iodomelatonin from chicken brain melatonin receptors,Confirmatory,10090792.0,
814,107398,7,1,,103166463,896,Active,,,0.00059,Ki,"Binding affinity towards melatonin receptor, determined in chicken brain membranes using [2-125I]melatonin",Confirmatory,9484496.0,
815,107400,3,7,,103166463,896,Unspecified,,,,,Negative logarithm of relative affinity (pRA) towards melatonin receptor (relative to N-acetyl-5-methoxytryptamine (aMT)),Other,9748358.0,
816,107401,7,1,,103166463,896,Active,,,0.00059,Ki,Binding affinity towards melatonin receptor in chicken brain.,Confirmatory,8627603.0,
817,107535,7,2,,103166463,896,Active,,,0.00059,Ki,Binding affinity towards melatonin receptor using 2-[125I]iodomelatonin as radioligand in chick brain membranes,Confirmatory,,
818,107536,7,1,,103166463,896,Active,,,0.00059,Ki,Binding affinity in chicken brain membranes by using [2-125I]melatonin in a competition radioligand binding assay,Confirmatory,7707316.0,
819,107538,7,5,,103166463,896,Active,1346543.0,396319.0,0.00059,Ki,Binding affinity towards melatonin receptor was determined using 2-[125I]iodomelatonin as radioligand in chick brain membranes,Confirmatory,,
820,107538,7,5,,103166463,896,Active,1346550.0,396318.0,0.00059,Ki,Binding affinity towards melatonin receptor was determined using 2-[125I]iodomelatonin as radioligand in chick brain membranes,Confirmatory,,
821,107538,7,5,,103166463,896,Active,1709047.0,396338.0,0.00059,Ki,Binding affinity towards melatonin receptor was determined using 2-[125I]iodomelatonin as radioligand in chick brain membranes,Confirmatory,,
822,107539,7,1,,103166463,896,Active,,,0.00067,Ki,Competitive binding by the displacement of 2-[125I]- Iodomelatonin binding from melatonin receptors in chicken brain membranes,Confirmatory,7783136.0,
823,107540,7,1,,103166463,896,Active,,,0.00108,Ki,Effect of compound on Melatonin receptor in chicken brain in the presence of GTP-gamma-S,Confirmatory,7783136.0,
824,107541,7,1,,103166463,896,Active,,,0.000176,Ki,Effect of compound on Melatonin receptor in chicken brain in the presence of MnCl2,Confirmatory,7783136.0,
825,107542,7,1,,103166463,896,Active,,,0.00045999999999999996,Ki,In vitro binding affinity against melatonin receptor using 2-[125I]iodomelatonin (0.05 nM) and chicken brain membranes,Confirmatory,8759629.0,
826,107543,7,1,,103166463,896,Active,,,0.00057,Ki,Binding affinity to compete for 2-[125I]iodomelatonin binding to chicken retinal membranes,Confirmatory,8411005.0,
827,107545,3,6,,103166463,896,Unspecified,,,,,Relative binding affinity to chicken retinal membranes compared to 2-[125I]iodomelatonin.,Other,8411005.0,
828,107546,4,1,,103166463,896,Active,,,0.000676,Ki,Binding affinity against chicken brain melatonin receptors using 2-[125I]iodomelatonin as radioligand,Confirmatory,9057860.0,
829,107547,7,1,,103166463,896,Active,,,0.0007,Ki,Binding affinity is evaluated for chicken brain melatonin receptor using 2-[125I]iodomelatonin as radioligand,Confirmatory,11063602.0,
830,107548,3,6,,103166463,896,Active,,,,,Compound was tested in vivo for its activity against melatonin receptor in Syrian hamster gonadal regression model; Agonist,Other,8258829.0,
831,107554,4,6,,103166463,896,Active,,,0.00298,IC50,Agonist activity against melatonin receptor was tested in the absence of iodomelatonin,Confirmatory,9207941.0,
832,107556,4,6,,103166463,896,Active,,,0.0131,IC50,Agonist activity against melatonin receptor in the presence of iodomelatonin,Confirmatory,9207941.0,
833,107558,7,2,,103166463,896,Active,,,0.0022,IC50,Inhibitory activity against melatonin receptor in the quail optica tecta using 2-[125] iodomelatonin as labelled ligand,Confirmatory,9207941.0,
834,107559,7,2,,103166463,896,Active,,,0.0022,IC50,Inhibitory activity against melatonin receptor in the quail optica tecta using 2-[125] iodomelatonin as radiolabeled ligand,Confirmatory,9207940.0,
835,107560,4,6,,103166463,896,Active,,,0.0152,IC50,Inhibitory activity against melatonin receptor of quail optica tecta with 200 pM 2-[125] iodomelatonin as gamma-S (10e-4 M),Confirmatory,9207940.0,
836,107561,7,2,,103166463,896,Active,,,0.0031100000000000004,IC50,Inhibitory activity against melatonin receptor of quail optica tecta with 200 pM 2-[125] iodomelatonin,Confirmatory,9207940.0,
837,107562,7,2,,103166463,896,Active,,,0.0022,IC50,inhibitory concentration against Melatonin receptor,Confirmatory,9748358.0,
838,107563,3,6,,103166463,896,Unspecified,,,,,Inhibition of 2-[125I]iodomelatonin binding to melatonin receptor in quail brain,Other,8258829.0,
839,107564,7,2,,103166463,896,Active,,,0.00061,Ki,Binding affinity against melatonin receptor in the quail optica tecta using 2-[125] iodomelatonin (100 pM) as labelled ligand,Confirmatory,9207941.0,
840,107565,7,2,,103166463,896,Active,,,0.00061,Ki,Binding affinity against melatonin receptor in the quail optica tecta using 2-[125] iodomelatonin as labelled ligand,Confirmatory,9207940.0,
841,107566,7,2,,103166463,896,Active,,,0.00061,Ki,Binding affinity for Melatonin receptor using 2-[125I]iodomelatonin as radioligand,Confirmatory,9748358.0,
842,107567,9,1,,103166463,896,Active,,,0.0011,Ki,Inhibition of 2-[125I]iodomelatonin binding to melatonin receptor in quail brain as 1/Ka,Confirmatory,8258829.0,
843,107568,3,6,,103166463,896,Active,,,,,Compound was tested in vivo for its activity against melatonin receptor in rabbit parietal cortex model; Agonist,Other,8258829.0,
844,107701,3,7,,103166463,896,Active,,,,,Compound was evaluated for agonistic activity against cAMP production stimulated by forskolin; Agonist;,Other,,
845,107704,3,6,,103166463,896,Inactive,,,,,Blocking the inhibitory effect of 1 nM melatonin.,Other,7932550.0,
846,107706,9,1,,103166463,896,Active,,,0.000157,IC50,Monophasic inhibitory concentration against melatonin receptor was measured on ovine pars tuberalis membrane.,Confirmatory,7932550.0,
847,107707,4,1,,103166463,896,Unspecified,,,,,Binding affinity to melatonin receptor measured on ovine pars tuberalis membrane,Other,7932550.0,
848,107710,6,1,,103166463,896,Unspecified,,,,,Binding affinity against Melatonin receptor using ovine pars tuberalis membranes of the pituitary.,Other,1315395.0,
849,107712,9,3,,103166463,896,Active,,,9.15e-05,Ki,Binding affinity against ovine pars tuberalis melatonin receptor using 2-[125I]- melatonin radioligand binding assay,Confirmatory,,
850,107713,3,6,,103166463,896,Unspecified,,,,,Activity (expressed as cAMP index) measured by the melatonin-mediated inhibition of forskolin-stimulated cAMP production,Other,7932550.0,
851,107722,7,1,,103166463,896,Active,,,0.0276,Ki,Ability to inhibit 2-[125I]iodomelatonin specific binding to melatonin receptor 3 (MT3) of Syrian hamster brain.,Confirmatory,12213062.0,
852,107723,4,3,,103166463,896,Active,,,0.0276,Ki,Binding affinity against Melatonin receptor 3 (MT3) of Syrian hamster brain and peripheral organs,Confirmatory,12213063.0,
853,107724,7,1,,103166463,896,Active,,,0.0569,Ki,Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane,Confirmatory,11960497.0,
854,107726,8,1,,103166463,896,Active,,,0.0002,Ki,"Binding affinity for human melatonin receptor type 1A, expressed in HEK293 cells (2-[125I]iodomelatonin is used as radioligand)",Confirmatory,11063602.0,
855,107728,8,1,,103166463,896,Active,,,8.23e-05,Ki,Ability to inhibit 2-[125I]iodomelatonin specific binding to human melatonin receptor type 1A (MT1) expressed in CHO cells.,Confirmatory,12213062.0,
856,107729,7,1,,103166463,896,Active,,,8.23e-05,Ki,Binding affinity against human Melatonin receptor type 1A (MT1) in CHO cells,Confirmatory,12213063.0,
857,107730,7,2,,103166463,896,Active,,,0.0004,Ki,Binding affinity against human Melatonin receptor type 1A by using 2-[125I]iodomelatonin as radioligand,Confirmatory,15203165.0,
858,107731,7,2,,103166463,896,Active,,,0.00053,Ki,Binding affinity towards human melatonin receptor type 1A,Confirmatory,15013015.0,
859,107732,8,5,,103166463,896,Active,1346544.0,4543.0,0.00011999999999999999,Ki,Inhibition of 2-[125I]iodomelatonin binding to human Melatonin receptor type 1A expressed in HEK293 cells,Confirmatory,11960497.0,
860,107734,3,6,,103166463,896,Active,,,,,Inhibitory activity against human Melatonin receptor type 1A; agonist,Other,9733487.0,
861,107862,9,1,,103166463,896,Active,1346544.0,4543.0,0.00224,EC50,Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1A,Confirmatory,12646022.0,
862,107864,9,1,,103166463,896,Active,1346544.0,4543.0,0.0019199999999999998,EC50,"Intrinsic activity evaluated on [35S]GTP -gamma-S binding in hamster ovarian (CHO) cells, stably expressing human Melatonin receptor type 1A",Confirmatory,12061881.0,
863,107866,3,9,,103166463,896,Unspecified,1346544.0,4543.0,,,"Efficacy of [35S]GTP-gamma-S, binding to Melatonin receptor type 1A expressed in Chinese hamster ovarian (CHO) cells",Other,12061881.0,
864,107867,3,10,,103166463,896,Unspecified,1346544.0,4543.0,,,Maximal efficacy expressed as percentage of that observed with 1 uM melatonin for Melatonin receptor type 1A,Other,12646022.0,
865,107868,3,8,,103166463,896,Unspecified,,,,,"Specific binding of [35S]GTP-gamma-S, to the alpha subunit of the G-protein-coupled Melatonin receptor type 1A was measured; expressed as % G-protein activation.",Other,9733487.0,
866,107869,3,8,,103166463,896,Unspecified,,,,,Basal binding activity towards Melatonin receptor type 1A was measured by incubating with [35S]GTP-gamma-S (100 uM) and NaCl (700 mM).,Other,9733487.0,
867,107872,3,7,,103166463,896,Unspecified,,,,,The relative intrinsic values (IAr) obtained by dividing the maximal analogue-induced G-protein activation by that of melatonin-1,Other,11520198.0,
868,107873,7,2,,103166463,896,Active,,,0.0006,IC50,In vitro receptor binding at MT1 (Melatonin) receptor.,Confirmatory,12643943.0,
869,107874,3,7,,103166463,896,Unspecified,,,,,Intrinsic activity (IAr) towards human Melatonin receptor type 1A,Other,12672242.0,
870,107876,3,7,,103166463,896,Unspecified,,,,,"Relative Intrinsic activity evaluated on [35S]GTP-gamma-S, binding in NIH3T3 cells stably transfected with human Melatonin receptor type 1A",Other,12672242.0,
871,107877,5,9,,103166463,896,Unspecified,1346544.0,4543.0,,,Antagonist potency against effect of melatonin (30 nM) determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1A,Other,12646022.0,
872,107879,8,5,,103166463,896,Active,1346544.0,4543.0,0.00014,Ki,Binding affinity for human Melatonin receptor type 1A stably transfected in human embryonic kidney cells (HEK 293) using 2-[125I]iodomelatonin as radioligand,Confirmatory,12646022.0,
873,107880,7,2,,103166463,896,Active,,,0.00013000000000000002,Ki,Binding affinity against human Melatonin receptor type 1A by displacement of [125I]iodomelatonin stably expressed in CHO cells,Confirmatory,,
874,107881,7,1,,103166463,896,Active,,,0.00011999999999999999,Ki,Binding affinity on human melatonin receptor type 1A stably transfected in human embryonic kidney (HEK 293) using 2-[125I]iodomelatonin as radioligand.,Confirmatory,12061881.0,
875,107882,7,1,,103166463,896,Active,,,0.0004,Ki,Binding of 2-[125I]iodomelatonin to membrane preparations of NIH3T3 cells stably expressing human Melatonin receptor type 1A,Confirmatory,14980664.0,
876,107883,7,2,,103166463,896,Active,,,0.00066,Ki,Binding affinity towards recombinant human melatonin receptor type 1A expressed in NIH 3T3 cells using 2-[121I]iodomelatonin radioligand binding assay,Confirmatory,10737738.0,
877,107884,7,1,,103166463,896,Active,,,0.0004,Ki,Binding affinity against human MT1 melatonin receptor expressed in NIH3T3 cells.,Confirmatory,14643330.0,
878,107885,12,2,,103166463,896,Active,1346544.0,4543.0,0.0002,Ki,Displacement of 2-[125I]iodomelatonin from human Melatonin receptor type 1A expressed in CHO cells,Confirmatory,,
879,107886,7,1,,103166463,896,Active,,,8e-05,Ki,Inhibition of the 2-[125I]- iodomelatonin binding to Melatonin receptor type 1A expressed in CHO cells,Confirmatory,9435890.0,
880,107887,3,8,,103166463,896,Unspecified,,,,,"Specific binding of [35S]GTP-gamma-S, to the alpha subunit of the G-protein-coupled Melatonin receptor type 1A was measured expressed as % G-protein activation expressed as relative intrinsic activity with respect to MLT",Other,9733487.0,
881,107889,3,7,,103166463,896,Unspecified,,,,,IC50 to IC50 of Melatonin(MLT),Other,9733487.0,
882,107891,7,1,,103166463,896,Active,,,0.001,IC50,Binding affinity for melatonin 1A receptor was measured using 2-[125I]iodomelatonin on ovine pars tuberalis membrane homogenates.,Confirmatory,9804685.0,
883,107893,4,1,,103166463,896,Active,,,0.000166,Ki,Binding Affinity (pKi) towards human Melatonin receptor type 1A,Confirmatory,12672242.0,
884,107894,4,1,,103166463,896,Active,,,0.000288,Ki,Binding affinity towards melatonin receptor type 1A stably expressed in NIH3T3 rat fibroblast cells using 2-[125I]iodomelatonin (100 pM) as radioligand,Confirmatory,11520198.0,
885,107895,4,1,,103166463,896,Active,,,0.000295,Ki,Binding affinity was measured against cloned human Melatonin receptor type 1A subtype stably expressed in rat fibroblasts NIH3T3 cells,Confirmatory,9733487.0,
886,107896,3,7,,103166463,896,Unspecified,,,,,Negative logarithm of relative affinity against human Melatonin receptor type 1A,Other,9733487.0,
887,108023,3,6,,103166463,896,Unspecified,,,,,"Relative Binding Affinity (pRA1) to cloned human Melatonin receptor type 1A, stably expressed in NIH3T3 rat fibroblast cells, determined using 2-[125I]iodomelatonin",Other,12672242.0,
888,108025,9,5,,103166463,896,Active,1346544.0,4543.0,8.23e-05,Ki,Binding affinity against human Melatonin receptor type 1A (MT1),Confirmatory,12213063.0,
889,108026,7,1,,103166463,896,Active,,,0.00053,Ki,"Binding affinity for melatonin receptor type 1B, expressed in HEK293 cells (2-[125I]iodomelatonin is used as radioligand)",Confirmatory,11063602.0,
890,108030,9,1,,103166463,896,Active,1346548.0,4544.0,0.00049,EC50,Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1B,Confirmatory,12646022.0,
891,108032,9,1,,103166463,896,Active,1346548.0,4544.0,0.00047000000000000004,EC50,"Intrinsic activity at human Melatonin receptor type 1B evaluated on [35S]GTP-gamma-S, binding in Chinese hamster ovarian (CHO) cells",Confirmatory,12061881.0,
892,108033,3,9,,103166463,896,Unspecified,1346548.0,4544.0,,,"Efficacy of [35S]GTP-gamma-S, binding to Melatonin receptor type 1B expressed in Chinese hamster ovarian (CHO) cells",Other,12061881.0,
893,108034,3,10,,103166463,896,Unspecified,1346548.0,4544.0,,,Maximal efficacy expressed as percentage of that observed with 1 uM melatonin for Melatonin receptor type 1B,Other,12646022.0,
894,108036,3,7,,103166463,896,Unspecified,,,,,The relative intrinsic values (IAr) of melatonin receptor type 1B obtained by dividing the maximal analogue-induced G-protein activation by that MLT.,Other,11520198.0,
895,108037,7,2,,103166463,896,Active,,,0.0003,IC50,In vitro receptor binding at MT2 (Melatonin) receptor.,Confirmatory,12643943.0,
896,108038,3,7,,103166463,896,Unspecified,,,,,Intrinsic activity (IAr) towards human Melatonin receptor type 1B,Other,12672242.0,
897,108040,3,7,,103166463,896,Unspecified,,,,,"Relative Intrinsic activity evaluated on [35S]GTP-gamma-S, binding in NIH3T3 cells stably transfected with human Melatonin receptor type 1B",Other,12672242.0,
898,108041,5,9,,103166463,896,Unspecified,1346548.0,4544.0,,,Antagonist potency against effect of melatonin (3 nM) determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1B,Other,12646022.0,
899,108043,8,5,,103166463,896,Active,1346548.0,4544.0,0.00041,Ki,Binding affinity for human Melatonin receptor type 1B stably transfected in human embryonic kidney cells (HEK 293) using 2-[125I]iodomelatonin as radioligand,Confirmatory,12646022.0,
900,108044,7,2,,103166463,896,Active,,,0.00022999999999999998,Ki,Binding affinity against human Melatonin receptor type 1B by displacement of [125I]iodomelatonin stably expressed in CHO cells,Confirmatory,,
901,108045,7,1,,103166463,896,Active,,,0.00031,Ki,Binding affinity on human melatonin receptor type 1B stably transfected in human embryonic kidney (HEK 293) cells using 2-[125I]iodomelatonin as radioligand.,Confirmatory,12061881.0,
902,108046,7,1,,103166463,896,Active,,,0.0003,Ki,Binding of 2-[125I]iodomelatonin to membrane preparations of NIH3T3 cells stably expressing human Melatonin receptor type 1B,Confirmatory,14980664.0,
903,108047,7,2,,103166463,896,Active,,,0.00033,Ki,Binding affinity towards recombinant human melatonin receptor type 1B expressed in NIH 3T3 cells using 2-[121I]iodomelatonin radioligand binding assay,Confirmatory,10737738.0,
904,108048,7,1,,103166463,896,Active,,,0.0003,Ki,Binding affinity against human MT2 melatonin receptor expressed in NIH3T3 cells,Confirmatory,14643330.0,
905,108050,8,5,,103166463,896,Active,1346548.0,4544.0,0.00029,Ki,Inhibition of 2-[125I]iodomelatonin binding to human Melatonin receptor type 1B expressed in CHO cells,Confirmatory,,
906,108051,7,1,,103166463,896,Active,,,0.00011999999999999999,Ki,Inhibition of the 2-[125I]- iodomelatonin binding to Melatonin receptor type 1B expressed in CHO cells,Confirmatory,9435890.0,
907,108053,3,7,,103166463,896,Unspecified,,,,,Selectivity ratio of melatonin receptor type 1B with respect to melatonin receptor type 1A,Other,10737738.0,
908,108054,4,1,,103166463,896,Active,,,0.000295,Ki,Binding Affinity (pKi) towards human Melatonin receptor type 1B,Confirmatory,12672242.0,
909,108055,4,1,,103166463,896,Active,,,0.00028199999999999997,Ki,Binding affinity towards melatonin receptor type 1B stably expressed in NIH3T3 rat fibroblast cells using 2-[125I]iodomelatonin,Confirmatory,11520198.0,
910,108056,3,6,,103166463,896,Unspecified,,,,,"Relative Binding Affinity (pRA1) to cloned human Melatonin receptor type 1B, stably expressed in NIH3T3 rat fibroblast cells, determined using 2-[125I]iodomelatonin",Other,12672242.0,
911,108057,8,5,,103166463,896,Active,1346548.0,4544.0,0.000195,Ki,Binding affinity against human Melatonin receptor type 1B (MT2),Confirmatory,12213063.0,
912,108058,8,5,,103166463,896,Active,1346548.0,4544.0,0.0003,Ki,Binding affinity against human Melatonin receptor type 1B by using 2-[125I]iodomelatonin as radioligand,Confirmatory,15203165.0,
913,108059,7,2,,103166463,896,Active,,,0.00032,Ki,Binding affinity towards human melatonin receptor type 1B,Confirmatory,15013015.0,
914,108186,8,5,,103166463,896,Active,1346548.0,4544.0,0.00031,Ki,Inhibition of 2-[125I]iodomelatonin binding to human Melatonin receptor type 1B expressed in HEK293 cells,Confirmatory,11960497.0,
915,110866,2,5,,103166463,896,Active,,,,,Locomotor activity of the mice was determined at a dose of 50 ng/Kg after 30-45 min of intracerebroventricular (icv) injection; Significantly reduced,Other,,
916,111007,2,5,,103166463,896,Active,,,,,Locomotor activity of the mice was determined at a dose of 50 ng/Kg after 45-60 min of intracerebroventricular (icv) injection; Significantly reduced,Other,,
917,165366,5,4,,103166463,896,Active,,,1.7e-05,IC50,Inhibition of 2-[125I]iodomelatonin stimulated calcium dependent dopamine release from the rabbit retina.,Confirmatory,8411005.0,
918,165408,3,6,,103166463,896,Unspecified,,,,,Relative potency of inhibition of calcium-dependent release of [3H]dopamine from rabbit retina caused by 2-[125I]iodomelatonin.,Other,8411005.0,
919,166149,3,4,,103166463,896,Unspecified,,,,,Inhibition of spontaneous firing activity of single cortical neurons in the rabbit parietal cortex model at 1 x 10 e-6 M (agonist),Other,8258829.0,
920,179962,6,2,,103166463,896,Active,,,7.979999999999999e-05,IC50,Inhibition of forskolin stimulated cAMP production in neonatal rat pituitary,Confirmatory,12213063.0,
921,219765,3,4,,103166463,896,Active,,,,,Agonistic activity was determined in a pigment aggregation model using cultured melanophores isolated from the neural crest of Xenopus laevis embryos; agonist,Other,,
922,219775,4,4,,103166463,896,Active,,,0.00022999999999999998,EC50,Effective concentration required to produce 50% of the maximal pigment aggregation in Xenopus laevis dermal melanophore cell line,Confirmatory,9484496.0,
923,219897,8,2,,103166463,896,Inactive,,,,,Inhibitory concentration against melatonin-induced pigment aggregation by 50% in Xenopus laevis dermal melanophore cell line,Other,9484496.0,
924,219903,4,3,,103166463,896,Active,,,8e-05,EC50,Effective concentration for its agonist activity against melatonin of Xenopus melanophores,Confirmatory,10737738.0,
925,219906,3,4,,103166463,896,Inactive,,,,,Compound was evaluated for its agonistic activity against melatonin of Xenopus melanophores; NA= no activity,Other,10737738.0,
926,222168,7,1,,103166463,896,Active,,,0.0007,Ki,Binding affinity measured against Chicken brain melatonin receptor by using 2-[125I]iodomelatonin as radioligand,Confirmatory,9873728.0,
927,226459,3,4,,103166463,896,Unspecified,,,,,Ratio to that of aMT.,Other,9207940.0,
928,226460,3,4,,103166463,896,Unspecified,,,,,Ratio to that of aMT.,Other,9207941.0,
929,227173,3,3,,103166463,896,Active,,,,,Activity considered from GTP-gamma-S and cAMP index values; A = Agonist,Other,9207940.0,
930,227178,3,3,,103166463,896,Active,,,,,Activity considered from GTP-gamma-S index and cAMP index; A = Agonist,Other,9207941.0,
931,227185,3,3,,103166463,896,Active,,,,,Activity considered from GTP-gamma-S index; A = Agonist,Other,9207940.0,
932,227186,3,3,,103166463,896,Active,,,,,Activity considered from GTP-gamma-S index; A = Agonist,Other,9207941.0,
933,227388,3,6,,103166463,896,Unspecified,,,,,GTPgammaS index is the ratio of the IC50 of compound with GTP and without GTP to the IC50 of melatonin with GTP and without GTP,Other,9207940.0,
934,227389,3,6,,103166463,896,Unspecified,,,,,GTPgammaS index is the ratio of the IC50 of compound with GTP and without GTP to the IC50 of melatonin with GTP and without GTP,Other,9207941.0,
935,227390,3,6,,103166463,896,Unspecified,,,,,Inhibition of forskolin stimulated cAMP accumulation and represented as cAMP index which is the ratio of percent inhibition to percent inhibition of melatonin,Other,9207940.0,
936,227391,3,6,,103166463,896,Unspecified,,,,,Inhibition of forskolin stimulated cAMP accumulation and represented as cAMP index which is the ratio of percent inhibition to percent inhibition of melatonin,Other,9207941.0,
937,230718,3,7,,103166463,896,Unspecified,,,,,"Relative binding to melatonin receptor compared to melatonin, ratio of IC50",Other,9207940.0,
938,230719,3,7,,103166463,896,Unspecified,,,,,Ratio of the IC50 of compound to the IC50 of melatonin,Other,9207941.0,
939,231555,3,9,,103166463,896,Unspecified,1346544.0,4543.0,,,Ratio of binding of melatonin 2 receptor (MT2) to melatonin 1 receptor (MT1),Other,15203165.0,
940,231555,3,9,,103166463,896,Unspecified,1346548.0,4544.0,,,Ratio of binding of melatonin 2 receptor (MT2) to melatonin 1 receptor (MT1),Other,15203165.0,
941,231927,3,3,,103166463,896,Unspecified,,,,,Ratio calculated as IC50 in the presence of GTP-gamma-S.,Other,9207940.0,
942,231928,3,3,,103166463,896,Unspecified,,,,,Ratio calculated as IC50 in the presence of GTP-gamma-S.,Other,9207941.0,
943,232461,3,8,,103166463,896,Unspecified,,,,,Selectivity ratio between the binding affinities of MT1 to that of MT2 receptor,Other,15013015.0,
944,232480,3,10,,103166463,896,Unspecified,1346544.0,4543.0,,,Selectivity ratio for inhibition of human MT2 receptor to that of human MT1 receptor was determined,Other,12646022.0,
945,232480,3,10,,103166463,896,Unspecified,1346548.0,4544.0,,,Selectivity ratio for inhibition of human MT2 receptor to that of human MT1 receptor was determined,Other,12646022.0,
946,232612,3,7,,103166463,896,Unspecified,,,,,Ratio of IC50 against cAMP to that of Ki of human melatonin receptor (MT1).,Other,12213063.0,
947,232697,3,8,,103166463,896,Unspecified,,,,,Selectivity ratio of Ki for MT1 melatonin receptor to that of MT2 melatonin receptor,Other,14980664.0,
948,233512,3,7,,103166463,896,Unspecified,,,,,The difference (pKi1-pKi2) represents selectivity towards the melatonin receptors MT1 (positive values ) or the MT2 (negative values) subtype,Other,11520198.0,
949,233758,3,7,,103166463,896,Unspecified,,,,,Melatonin receptor type 1A/Melatonin receptor type 1B affinity ratio.,Other,12061881.0,
950,234655,3,5,,103166463,896,Unspecified,,,,,Selectivity ratio of binding affinity at MT1 receptor relative to MT3 receptor,Other,11960497.0,
951,234656,3,5,,103166463,896,Unspecified,,,,,Selectivity ratio of binding affinity at MT2 receptor relative to MT3 receptor,Other,11960497.0,
952,234713,3,7,,103166463,896,Unspecified,,,,,Ratio of IC50 to that IC50 aMT (aMT=melatonin N-acetyl-5-methoxytryptamine),Other,9748358.0,
953,236045,3,3,,103166463,896,Unspecified,,,,,Bioavailability in rat (dose 1 mg/kg p.o.),Other,15380218.0,
954,238024,3,9,,103166463,896,Unspecified,1346548.0,4544.0,,,"Intrinsic activity in [35S]GTP-gamma-S, binding at human melatonin receptor type 1B (MT2) relative to melatonin",Other,15943478.0,
955,239423,8,5,,103166463,896,Active,1346544.0,4543.0,0.0003,Ki,Binding affinity against Melatonin receptor type 1A stably expressed in NIH3T3 cells using 2-[125I]iodomelatonin,Confirmatory,15713384.0,
956,239424,8,5,,103166463,896,Active,1346548.0,4544.0,0.0007,Ki,Binding affinity against Melatonin receptor type 1B stably expressed in NIH3T3 cells using 2-[125I]iodomelatonin,Confirmatory,15713384.0,
957,239488,8,5,,103166463,896,Active,1346544.0,4543.0,0.0003,Ki,Inhibition of 2-[125I]iodomelatonin binding to membrane preparations of NIH3T3 cells stably expressing human Melatonin receptor type 1A,Confirmatory,15380218.0,
958,239489,8,5,,103166463,896,Active,1346548.0,4544.0,0.0007,Ki,Inhibition of 2-[125I]iodomelatonin binding to membrane preparations of NIH3T3 cells stably expressing human Melatonin receptor type 1B,Confirmatory,15380218.0,
959,239805,3,9,,103166463,896,Unspecified,1346544.0,4543.0,,,Relative intrinsic activity against human melatonin receptor type 1 compared to MLT,Other,15293992.0,
960,239806,3,9,,103166463,896,Unspecified,1346548.0,4544.0,,,Relative intrinsic activity against human melatonin receptor type 2 compared to MLT,Other,15293992.0,
961,239934,4,1,,103166463,896,Active,1346548.0,4544.0,0.00028199999999999997,Ki,Binding affinity for human recombinant Melatonin receptor type 2 expressed in NIH3T3 cells,Confirmatory,15293992.0,
962,239937,4,1,,103166463,896,Active,1346544.0,4543.0,0.000288,Ki,Binding affinity for human recombinant Melatonin receptor type 1 expressed in NIH3T3 cells,Confirmatory,15293992.0,
963,239989,4,1,,103166463,896,Active,1346544.0,4543.0,0.000288,Ki,Inhibition of 2-[125I]iodomelatonin binding to human melatonin receptor type 1A (MT1) expressed in NIH3T3 rat fibroblast cells,Confirmatory,15943478.0,
964,239990,4,1,,103166463,896,Active,1346548.0,4544.0,0.00028199999999999997,Ki,Inhibition of 2-[125I]iodomelatonin binding to human melatonin receptor type 1B (MT2) expressed in NIH3T3 rat fibroblast cells,Confirmatory,15943478.0,
965,257805,8,5,,103166463,896,Unspecified,14916950.0,540446.0,0.1,IC50,Inhibition of AchE from bovine erythrocytes,Confirmatory,16420031.0,
966,257806,8,5,,103166463,896,Unspecified,75074633.0,,0.1,IC50,Inhibition of BuChE from horse serum,Confirmatory,16420031.0,
967,257807,8,5,,103166463,896,Inconclusive,113037.0,43.0,,IC50,Inhibition of human AChE,Confirmatory,16420031.0,
968,257808,8,5,,103166463,896,Inconclusive,116353.0,590.0,,IC50,Inhibition of human BuChE,Confirmatory,16420031.0,
969,266017,8,5,,103166463,896,Active,1346544.0,4543.0,0.00039,Ki,Displacement of 2-[125I]iodomelatonin from human recombinant MT1 receptor expressed in NIH3T3 cells,Confirmatory,16759094.0,
970,266018,8,5,,103166463,896,Active,1346548.0,4544.0,0.00035,Ki,Displacement of 2-[125I]iodomelatonin from human recombinant MT2 receptor expressed in NIH3T3 cells,Confirmatory,16759094.0,
971,266019,4,10,,103166463,896,Unspecified,1346544.0,4543.0,,,Selectivity for human recombinant MT1 receptor over MT2 receptor,Other,16759094.0,
972,266019,4,10,,103166463,896,Unspecified,1346548.0,4544.0,,,Selectivity for human recombinant MT1 receptor over MT2 receptor,Other,16759094.0,
973,266020,5,3,,103166463,896,Active,,,6.3e-05,EC50,Agonist activity in Xenopus laevis melanophore assessed as potency for pigment aggregation,Confirmatory,16759094.0,
974,266023,3,11,,103166463,896,Active,1346544.0,4543.0,,,Activity at MT1 receptor expressed in NIH3T3 cells assessed as inhibition of forskolin-stimulated cAMP synthesis at 1 nM,Other,16759094.0,
975,266032,4,4,,103166463,896,Inactive,,,,,Antagonist activity in Xenopus laevis melanophore assessed as potency for pigment aggregation at 10 uM,Other,16759094.0,
976,274430,4,1,,103166463,896,Active,1346544.0,4543.0,0.000324,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in NIH3T3 cells,Confirmatory,17149869.0,
977,274431,4,1,,103166463,896,Active,1346548.0,4544.0,0.00025699999999999996,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in NIH3T3 cells,Confirmatory,17149869.0,
978,281656,6,2,,103166463,896,Unspecified,,,211.0,IC50,Hydroxyl radical scavenging activity after 2 hrs by ABTS competition assay,Confirmatory,15566297.0,
979,281657,3,3,,103166463,896,Unspecified,,,,,Differentiation activity of neural stem cell derived neurosphere into neurons at 10 nM after 3 days relative to control,Other,15566297.0,
980,288479,8,5,,103166463,896,Active,1346544.0,4543.0,0.0002,Ki,Displacement of 2-[125I]iodomelatonin from human cloned MT1 receptor expressed in rat NIH3T3 cells,Confirmatory,17481904.0,
981,288481,8,5,,103166463,896,Active,1346548.0,4544.0,0.0003,Ki,Displacement of 2-[125I]iodomelatonin from human cloned MT2 receptor expressed in rat NIH3T3 cells,Confirmatory,17481904.0,
982,295006,4,1,,103166463,896,Active,1346551.0,397808.0,8.51e-05,EC50,Agonist activity in Xenopus laevis melanophores assessed as melatoninergic activity,Confirmatory,17346859.0,
983,295009,4,1,,103166463,896,Active,1346544.0,4543.0,0.000389,Ki,Displacement of 2[125I]iodomelatonin from recombinant human MT1 receptor expressed in NIH 3T3 cells,Confirmatory,17346859.0,
984,295010,4,1,,103166463,896,Active,1346548.0,4544.0,0.00035499999999999996,Ki,Displacement of 2[125I]iodomelatonin from recombinant human MT2 receptor expressed in NIH 3T3 cells,Confirmatory,17346859.0,
985,295011,3,10,,103166463,896,Unspecified,1346544.0,4543.0,,,Selectivity for human recombinant MT2 receptor over human recombinant MT1 receptor,Other,17346859.0,
986,295011,3,10,,103166463,896,Unspecified,1346548.0,4544.0,,,Selectivity for human recombinant MT2 receptor over human recombinant MT1 receptor,Other,17346859.0,
987,295662,4,2,,103166463,896,Unspecified,,,,,"Inhibition of carrageenan-induced paw oedema in Sprague-Dawley rat at 4 mg/kg, sc after 1 hr",Other,17408809.0,
988,295663,4,2,,103166463,896,Unspecified,,,,,"Inhibition of carrageenan-induced paw oedema in Sprague-Dawley rat at 4 mg/kg, sc after 2 hrs",Other,17408809.0,
989,295664,4,2,,103166463,896,Unspecified,,,,,"Inhibition of carrageenan-induced paw oedema in Sprague-Dawley rat at 4 mg/kg, sc after 3 hrs",Other,17408809.0,
990,295665,4,2,,103166463,896,Unspecified,,,,,"Inhibition of carrageenan-induced paw oedema in Sprague-Dawley rat at 4 mg/kg, sc after 4 hrs",Other,17408809.0,
991,295670,3,3,,103166463,896,Unspecified,,,,,"Antinociceptive activity in Sprague-Dawley rat at 4 mg/kg, sc assessed as increase in latency time after 1 hr by hot plate method",Other,17408809.0,
992,295676,3,3,,103166463,896,Unspecified,,,,,"Antinociceptive activity in Sprague-Dawley rat at 4 mg/kg, sc assessed as increase in latency time after 2 hrs by hot plate method",Other,17408809.0,
993,295682,4,2,,103166463,896,Unspecified,,,,,"Antinociceptive activity in Swiss Albino mouse assessed as inhibition of acetic acid-induced writhes per 30 min at 4 mg/kg, ip",Other,17408809.0,
994,295687,3,3,,103166463,896,Unspecified,,,,,"Antinociceptive activity in Sprague-Dawley rat assessed as inhibition of number of indomethacin-induced gastric lesions at 4 mg/kg, sc",Other,17408809.0,
995,295692,3,3,,103166463,896,Unspecified,,,,,"Antinociceptive activity in Sprague-Dawley rat assessed as inhibition of indomethacin-induced gastric lesions severity at 4 mg/kg, sc",Other,17408809.0,
996,296292,4,1,,103166463,896,Active,1346544.0,4543.0,0.000263,Ki,Displacement of 2[125I]iodomelatonin from human recombinant MT1 receptor expressed in NIH3T3 cells,Confirmatory,17459711.0,
997,296293,4,1,,103166463,896,Active,1346548.0,4544.0,0.000339,Ki,Displacement of 2[125I]iodomelatonin from human recombinant MT2 receptor expressed in NIH3T3 cells,Confirmatory,17459711.0,
998,296294,4,1,,103166463,896,Active,1346551.0,397808.0,7.94e-05,EC50,Effect on pigment aggregation in Xenopus laevis melanophores,Confirmatory,17459711.0,
999,296296,3,10,,103166463,896,Unspecified,1346544.0,4543.0,,,Selectivity for human recombinant MT1 receptor over human recombinant MT2 receptor,Other,17459711.0,
1000,296296,3,10,,103166463,896,Unspecified,1346548.0,4544.0,,,Selectivity for human recombinant MT1 receptor over human recombinant MT2 receptor,Other,17459711.0,
1001,303954,4,1,,103166463,896,Active,,,8.51e-05,EC50,Agonist activity at melatonin receptor in Xenopus laevis melanophores assessed as effect on pigment granule distribution,Confirmatory,17988084.0,
1002,304734,4,1,,103166463,896,Active,1346544.0,4543.0,0.00014099999999999998,Ki,Displacement of 2-[125I]iodomelatonin from human cloned MT1 receptor expressed in rat NIH3T3 cells,Confirmatory,18052314.0,
1003,304735,4,1,,103166463,896,Active,1346548.0,4544.0,0.00023999999999999998,Ki,Displacement of 2-[125I]iodomelatonin from human cloned MT2 receptor expressed in rat NIH3T3 cells,Confirmatory,18052314.0,
1004,304736,3,10,,103166463,896,Unspecified,1346544.0,4543.0,,,Intrinsic activity at human cloned MT1 receptor expressed in rat NIH3T3 cells after 30 mins by [35S]GTP-gamma-S binding assay relative to melatonin,Other,18052314.0,
1005,304737,3,10,,103166463,896,Unspecified,1346548.0,4544.0,,,Intrinsic activity at human cloned MT2 receptor expressed in rat NIH3T3 cells after 30 mins by [35S]GTPgammaS binding assay relative to melatonin,Other,18052314.0,
1006,322957,4,2,,103166463,896,Unspecified,,,,,Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control,Other,17284452.0,
1007,322958,3,4,,103166463,896,Inactive,,,,,Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control,Other,17284452.0,
1008,340251,4,3,,103166463,896,Active,,,0.00018999999999999998,IC50,Inhibition of melatonin receptor 1,Confirmatory,18588282.0,
1009,346428,8,7,,103166463,896,Active,1346544.0,4543.0,,IC50,Displacement of radiolabeled melatonin from human MT1 receptor,Confirmatory,18983139.0,
1010,366474,11,2,,103166463,896,Active,1346544.0,4543.0,0.000525,Ki,Displacement of 2-[125I]iodomelatonin from human melatonin MT1 receptor expressed in CHO cells,Confirmatory,18657980.0,
1011,366475,11,2,,103166463,896,Active,1346548.0,4544.0,0.000741,Ki,Displacement of 2-[125I]iodomelatonin from human melatonin MT2 receptor expressed in CHO cells,Confirmatory,18657980.0,
1012,369281,11,2,,103166463,896,Active,1346544.0,4543.0,0.00045700000000000005,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in CHO cells,Confirmatory,19193160.0,
1013,369282,11,2,,103166463,896,Active,1346548.0,4544.0,0.0009550000000000001,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in CHO cells,Confirmatory,19193160.0,
1014,382163,8,5,,103166463,896,Active,1346544.0,4543.0,0.0002,IC50,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in HEK293 cells,Confirmatory,18372181.0,
1015,382164,8,5,,103166463,896,Active,1346548.0,4544.0,0.00053,IC50,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in HEK293 cells,Confirmatory,18372181.0,
1016,382165,4,3,,103166463,896,Active,,,0.0646,IC50,Inhibition of MT3 melatonin binding site from hamster brain membrane,Confirmatory,18372181.0,
1017,382167,3,3,,103166463,896,Unspecified,,,,,"Selectivity ratio, IC50 for human MT2 melatonin receptor to IC50 for hamster MT3 melatonin binding site",Other,18372181.0,
1018,382414,3,3,,103166463,896,Unspecified,,,,,"Selectivity ratio, IC50 for human MT1 melatonin receptor to IC50 for hamster MT3 melatonin binding site",Other,18372181.0,
1019,384324,3,3,,103166463,896,Unspecified,,,,,Inhibition of cyclophosphamide-induced increase in micronuclei/polychromatic erythrocytes count in mouse at 10 mg/kg administered intragastrically for 1 week by micronuclei assay,Other,17706326.0,
1020,384328,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in Albino mouse brain assessed as DNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1021,384332,3,4,,103166463,896,Unspecified,,,,,Antimutagenic activity in Albino mouse kidney assessed as DNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1022,384336,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in Albino mouse liver assessed as DNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1023,384340,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in Albino mouse testes assessed as DNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1024,384344,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in Albino mouse brain assessed as RNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1025,384348,3,4,,103166463,896,Unspecified,,,,,Antimutagenic activity in Albino mouse kidney assessed as RNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1026,384352,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in Albino mouse liver assessed as RNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1027,384356,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in Albino mouse testes assessed as RNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1028,384360,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in mouse brain assessed as protein level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1029,384364,3,4,,103166463,896,Unspecified,,,,,Antimutagenic activity in mouse kidney assessed as protein level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1030,384557,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in mouse liver assessed as protein level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1031,384561,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in mouse testes assessed as protein level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1032,384565,6,1,,103166463,896,Unspecified,,,,,Antimutagenic activity in mouse brain assessed as peroxidase activity per microgram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1033,384569,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity in mouse brain assessed as cholinesterase activity per microgram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1034,384574,3,4,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in Albino mouse kidney assessed as DNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1035,384580,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in Albino mouse brain assessed as DNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1036,384581,3,3,,103166463,896,Unspecified,,,,,Antimutagenic against cyclophosphamide-induced mutagenicity in Albino mouse liver assessed as DNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1037,384585,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in Albino mouse testes assessed as DNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1038,384589,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in Albino mouse brain assessed as RNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1039,384593,3,4,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in Albino mouse kidney assessed as RNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1040,384597,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in Albino mouse liver assessed as RNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1041,384601,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in Albino mouse testes assessed as RNA level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1042,384605,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in mouse brain assessed as protein level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1043,384609,3,4,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in mouse kidney assessed as protein level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1044,384772,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in mouse liver assessed as protein level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1045,384776,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in mouse testes assessed as protein level per gram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1046,384780,6,1,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in mouse brain assessed as peroxidase activity per microgram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1047,384784,3,3,,103166463,896,Unspecified,,,,,Antimutagenic activity against cyclophosphamide-induced mutagenicity in mouse brain assessed as cholinesterase activity per microgram of tissue at 10 mg/kg administered intragastrically for 1 week,Other,17706326.0,
1048,387606,8,5,,103166463,896,Active,1346544.0,4543.0,0.00014,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in HEK293 cells,Confirmatory,18778943.0,
1049,387607,8,5,,103166463,896,Active,1346548.0,4544.0,0.00041,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in CHO cells,Confirmatory,18778943.0,
1050,387608,3,3,,103166463,896,Unspecified,,,,,Selectivity ratio of Ki for human MT1 receptor to Ki for human MT2 receptor,Other,18778943.0,
1051,387609,9,1,,103166463,896,Active,1346548.0,4544.0,0.00049,EC50,Agonist activity at human MT2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay,Confirmatory,18778943.0,
1052,387611,4,10,,103166463,896,Inconclusive,1346548.0,4544.0,,,Antagonist activity at human MT2 receptor expressed in CHO cells assessed as inhibition of 3 nM melatonin-induced response by [35S]GTPgammaS binding assay,Other,18778943.0,
1053,396398,7,1,,103166463,896,Active,,,0.06457,IC50,Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells,Confirmatory,18400335.0,
1054,415403,4,3,,103166463,896,Active,,,0.00014,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor stably transfected in cells,Confirmatory,19329323.0,
1055,415404,4,4,,103166463,896,Active,,,0.00041,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor stably transfected in cells,Confirmatory,19329323.0,
1056,415405,3,3,,103166463,896,Unspecified,,,,,"Selectivity ratio, Ki for human MT1 receptor to Ki for human MT2 receptor",Other,19329323.0,
1057,415406,4,5,,103166463,896,Active,,,0.00224,EC50,Agonist activity at human MT1 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,19329323.0,
1058,415407,3,5,,103166463,896,Unspecified,,,,,Agonist activity at human MT1 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to melatonin,Other,19329323.0,
1059,415408,5,1,,103166463,896,Inconclusive,,,,,Antagonist activity at human MT1 receptor expressed in CHO cells assessed as inhibition of melatonin-stimulated of [35S]GTPgammaS binding,Other,19329323.0,
1060,415409,4,5,,103166463,896,Active,,,0.00049,EC50,Agonist activity at human MT2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,19329323.0,
1061,415410,3,5,,103166463,896,Unspecified,,,,,Agonist activity at human MT2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to melatonin,Other,19329323.0,
1062,415411,5,1,,103166463,896,Inconclusive,,,,,Antagonist activity at human MT2 receptor expressed in CHO cells assessed as inhibition of melatonin-stimulated of [35S]GTPgammaS binding,Other,19329323.0,
1063,418720,9,5,,103166463,896,Active,317373581.0,4835.0,11.3,IC50,Inhibition of human quinone reductase 2 expressed in Escherichia coli BL21(DE3) incubated at 23 degC by MTT assay,Confirmatory,19265439.0,
1064,418721,9,2,,103166463,896,Inconclusive,,,,IC50,Inhibition of aromatase after 30 mins by fluorescence assay,Confirmatory,19265439.0,
1065,418722,6,3,,103166463,896,Inconclusive,,,,IC50,Cytotoxicity against mouse Hepa-1c1c7 cells after 72 hrs by sulforhodamine B assay,Confirmatory,19265439.0,
1066,418723,6,2,,103166463,896,Inconclusive,,,,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay,Confirmatory,19265439.0,
1067,418724,6,2,,103166463,896,Inconclusive,,,,IC50,Cytotoxicity against human LNCAP cells after 72 hrs by sulforhodamine B assay,Confirmatory,19265439.0,
1068,418725,6,3,,103166463,896,Inconclusive,,,,IC50,Cytotoxicity against human Lu cells after 72 hrs by sulforhodamine B assay,Confirmatory,19265439.0,
1069,420682,4,6,,103166463,896,Unspecified,,,,,Inhibition of nNOS,Other,19117642.0,
1070,420685,8,1,,103166463,896,Unspecified,8473575.0,18125.0,,,"Inhibition of cytosolic nNOS in stantia nigra isolated from MPTP-induced parkinson's disease C57/Bl6 mouse model assessed as L-[3H]citrulline per mg of protein at 20 mg/kg, b.w 1 hr before MPTP challenge after 32 hrs by liquid scintillation spectroscopy",Other,19117642.0,
1071,420686,8,1,,103166463,896,Unspecified,266649.0,18126.0,,,"Inhibition of cytosolic iNOS in stantia nigra isolated from MPTP-induced parkinson's disease C57/Bl6 mouse model assessed as L-[3H]citrulline per mg of protein at 20 mg/kg, b.w 1 hr before MPTP challenge after 32 hrs by liquid scintillation spectroscopy",Other,19117642.0,
1072,420687,8,1,,103166463,896,Unspecified,8473575.0,18125.0,,,"Inhibition of constitutive mitochondrial NOS in stantia nigra isolated from MPTP-induced parkinson's disease C57/Bl6 mouse model assessed as L-[3H]citrulline per mg of protein at 20 mg/kg, b.w 1 hr before MPTP challenge after 32 hrs by liquid scintillation spectroscopy",Other,19117642.0,
1073,420688,8,1,,103166463,896,Unspecified,266649.0,18126.0,,,"Inhibition of inducible mitochondrial NOS in stantia nigra isolated from MPTP-induced parkinson's disease C57/Bl6 mouse model assessed as L-[3H]citrulline per mg of protein at 20 mg/kg, b.w 1 hr before MPTP challenge after 32 hrs by liquid scintillation spectroscopy",Other,19117642.0,
1074,426243,3,4,,103166463,896,Unspecified,,,,,Antioxidant activity against lipid peroxidation in chronic renal failure patient plasma assessed as reduction in malondialdehyde level at 2 mg/kg treated once day before night sleep by thiobarbituric acid based spectrophotometry (Rvb=2.68 +/- 0.44 umol/L),Other,19168264.0,
1075,426244,8,1,,103166463,896,Unspecified,,,,,Antioxidant activity against lipid peroxidation in chronic renal failure patient plasma assessed as malondialdehyde level at 2 mg/kg treated once day before night sleep measured after 1 month by thiobarbituric acid based spectrophotometry (Rvb=2.68 +/- 0.44 umol/L),Other,19168264.0,
1076,426245,8,1,,103166463,896,Unspecified,,,,,Antioxidant activity against lipid peroxidation in chronic renal failure patient plasma assessed as malondialdehyde level at 2 mg/kg treated once day before night sleep measured after 2 months by thiobarbituric acid based spectrophotometry (Rvb=2.68 +/- 0.44 umol/L),Other,19168264.0,
1077,426246,8,1,,103166463,896,Unspecified,,,,,Antioxidant activity against lipid peroxidation in chronic renal failure patient plasma assessed as malondialdehyde level at 2 mg/kg treated once day before night sleep measured after 3 months by thiobarbituric acid based spectrophotometry (Rvb=2.68 +/- 0.44 umol/L),Other,19168264.0,
1078,427409,11,2,,103166463,896,Unspecified,1346544.0,4543.0,,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in CHO cells by gamma counting,Confirmatory,19473848.0,
1079,427410,11,2,,103166463,896,Unspecified,1346548.0,4544.0,,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in CHO cells by gamma counting,Confirmatory,19473848.0,
1080,434955,1,2,,46500483,896,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1081,434959,1,1,,85788807,896,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1082,434962,1,2,,46500483,896,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1083,434973,1,3,,46500483,896,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1084,434989,1,1,,46500483,896,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1085,435003,1,3,,46500483,896,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1086,435022,2,2,,46500483,896,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1087,435030,1,2,,46500483,896,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1088,435030,1,2,,46500483,896,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1089,449728,1,2,,46500483,896,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1090,449762,1,2,,46500483,896,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1091,449763,1,3,,46500483,896,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1092,449768,1,1,,46500483,896,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1093,455151,3,3,,103166463,896,Unspecified,,,,,Inhibition of CuSO4-induced human LDL oxidation assessed as ratio of length of lag phase of conjugated diene formation in presence of compound to untreated control at 100 uM measured every 10 mins for 8 hrs by spectrophotometry,Other,19819150.0,
1094,455155,3,3,,103166463,896,Unspecified,,,,,Inhibition of CuSO4-induced human LDL oxidation assessed as length of lag phase of conjugated diene formation measured every 10 mins for 8 hrs by spectrophotometry,Other,19819150.0,
1095,455157,3,3,,103166463,896,Inactive,,,,,Cytoprotective activity against LDL-induced cytotoxicity in BAEC assessed as decrease in LDH release at 10 uM treated for 24 hrs before LDL challenge measured after 16 hrs by spectrometry,Other,19819150.0,
1096,455158,3,3,,103166463,896,Active,,,,,Cytoprotective activity against minimally oxidized LDL-induced cytotoxicity in BAEC assessed as decrease in number of detached and shrunk cells at 10 uM treated for 24 hrs before mO-LDL challenge measured after 16 hrs by spectrometry,Other,19819150.0,
1097,455159,3,3,,103166463,896,Unspecified,,,,,Cytoprotective activity against minimally oxidized LDL-induced cytotoxicity in BAEC assessed as cell vitality at 10 uM treated for 24 hrs before mO-LDL challenge measured after 16 hrs by MTT assay,Other,19819150.0,
1098,463079,1,2,,46500483,896,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1099,463082,1,1,,46500483,896,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1100,463096,1,1,,50105414,896,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1101,463097,1,1,,50105414,896,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1102,463104,1,2,,46500483,896,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1103,463106,1,2,,90340716,896,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1104,463111,1,1,,46500483,896,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1105,463141,1,2,,46500483,896,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1106,463165,1,1,,46500483,896,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1107,463189,1,1,,53777893,896,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1108,463190,1,2,,46500483,896,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1109,463195,1,2,,46500483,896,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1110,463210,1,2,,46500483,896,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1111,463212,1,1,,46500483,896,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1112,474095,3,3,,103166463,896,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,20227878.0,
1113,474096,7,5,,103166463,896,Active,1346544.0,4543.0,0.000296,Ki,Displacement of [3H]melatonin from human melatonin MT1 receptor expressed in CHO cells after 60 mins by scintillation counting,Confirmatory,20227878.0,
1114,474097,7,5,,103166463,896,Active,1346548.0,4544.0,0.000429,Ki,Displacement of [3H]melatonin from human melatonin MT2 receptor expressed in CHO cells after 60 mins by scintillation counting,Confirmatory,20227878.0,
1115,474098,3,3,,103166463,896,Unspecified,,,,,Selectivity ratio of Ki for human melatonin MT1 receptor to Ki for human melatonin MT2 receptor,Other,20227878.0,
1116,475504,3,3,,103166463,896,Active,,,,,Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
1117,475505,3,3,,103166463,896,Active,,,,,Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
1118,475508,4,3,,103166463,896,Inactive,,,,,Inhibition of amyloid beta (1 to 42) aggregation induced by thioflavin after 48 hrs by fluorescence imaging,Other,19640715.0,
1119,481610,6,1,,103166463,896,Inconclusive,1346544.0,4543.0,,,Antagonist activity at human MT1 receptor expressed in CHO cells assessed as inhibition of melatonin-induced response by [35S]GTPgamma binding assay,Other,20444610.0,
1120,481611,3,10,,103166463,896,Inconclusive,1346544.0,4543.0,,,Antagonist activity at human MT1 receptor expressed in CHO cells assessed as inhibition of melatonin-induced response by [35S]GTPgamma binding assay relative to control,Other,20444610.0,
1121,481612,11,1,,103166463,896,Active,1346544.0,4543.0,0.0022,EC50,Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay,Confirmatory,20444610.0,
1122,481613,3,10,,103166463,896,Unspecified,1346544.0,4543.0,,,Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay relative to melatonin,Other,20444610.0,
1123,481614,6,1,,103166463,896,Inconclusive,1346548.0,4544.0,,,Antagonist activity at human MT2 receptor expressed in CHO cells assessed as inhibition of melatonin-induced response by [35S]GTPgamma binding assay,Other,20444610.0,
1124,481615,3,10,,103166463,896,Inconclusive,1346548.0,4544.0,,,Antagonist activity at human MT2 receptor expressed in CHO cells assessed as inhibition of melatonin-induced response by [35S]GTPgamma binding assay relative to control,Other,20444610.0,
1125,481616,11,1,,103166463,896,Active,1346548.0,4544.0,0.00049,EC50,Agonist activity at human MT2 receptor expressed in CHO cells by [35S]GTPgamma binding assay,Confirmatory,20444610.0,
1126,481617,3,10,,103166463,896,Unspecified,1346548.0,4544.0,,,Agonist activity at human MT2 receptor expressed in CHO cells by [35S]GTPgamma binding assay relative to melatonin,Other,20444610.0,
1127,482867,3,7,,103166463,896,Unspecified,,,,,Neuroprotective activity in human SH-SY5Y cells assessed as protection against rotenone/oligomycin A-induced cell death at 1 uM after 24 hrs by LDH release assay,Other,20575555.0,
1128,485270,1,1,,46500483,896,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1129,485272,1,1,,46500483,896,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1130,485273,2,1,,46500483,896,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1131,485275,1,3,,46500483,896,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1132,485281,1,1,,11111468,896,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1133,485290,1,1,,11111468,896,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1134,485290,1,1,,17388930,896,Inactive,20150581.0,,56.2341,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1135,485290,1,1,,17389536,896,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1136,485290,1,1,,26747238,896,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1137,485290,1,1,,26752764,896,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1138,485290,1,1,,50105414,896,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1139,485290,1,1,,50105415,896,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1140,485295,1,2,,90340716,896,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1141,485297,1,1,,90340716,896,Inconclusive,4759012.0,9367.0,14.1254,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1142,485298,1,1,,90340716,896,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1143,485313,1,2,,90340716,896,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1144,485314,1,1,,50105414,896,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1145,485317,1,2,,46500483,896,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1146,485342,1,2,,90340716,896,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1147,485345,1,2,,90340716,896,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1148,485346,1,1,,46500483,896,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1149,485346,1,1,,46500483,896,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1150,485350,1,2,,92124328,896,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1151,485350,1,2,,92125502,896,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1152,485366,1,2,,90340716,896,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1153,485368,1,2,,90340716,896,Inconclusive,72386991.0,3656265.0,8.4921,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1154,485395,1,2,,92239934,896,Inactive,150392496.0,,,,A screen for compounds that inhibit the activity of Staphylococcus aureus DNA helicase,Other,,
1155,488745,1,4,,85231137,896,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1156,488752,1,4,,85231137,896,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1157,488772,1,1,,90340716,896,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1158,488773,1,2,,90340716,896,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1159,488816,1,1,,90340716,896,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1160,488837,1,1,,90340716,896,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1161,488839,1,1,,49718192,896,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1162,488839,1,1,,49718192,896,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1163,488847,1,3,,46500483,896,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1164,488862,1,1,,49718192,896,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1165,488890,1,2,,46500483,896,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1166,488895,1,2,,49718192,896,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1167,488896,1,1,,49718192,896,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1168,488899,1,1,,49718192,896,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1169,488922,1,2,,46500483,896,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1170,488949,1,2,,85231137,896,Inactive,41055989.0,54737.0,0.1778,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1171,488949,1,2,,90340716,896,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1172,488953,1,1,,90340716,896,Inactive,187960037.0,10951.0,28.1838,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1173,488965,1,2,,49718192,896,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1174,488966,1,1,,49718192,896,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1175,488975,1,2,,46500483,896,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1176,488977,1,2,,46500483,896,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1177,488978,1,1,,90340716,896,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1178,488979,1,1,,50105414,896,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1179,488980,1,1,,85231137,896,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1180,488981,1,1,,90340716,896,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1181,488982,1,1,,90340716,896,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1182,488983,1,1,,90340716,896,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1183,489030,2,1,,46500483,896,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1184,489031,2,1,,46500483,896,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1185,492953,1,1,,49718192,896,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1186,492956,1,1,,49718192,896,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1187,492967,1,2,,92125502,896,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1188,492967,1,2,,92239934,896,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1189,492967,1,2,,99301441,896,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1190,492972,1,1,,49718192,896,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1191,493005,1,1,,46500483,896,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1192,493008,1,1,,49718192,896,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1193,493008,1,1,,49718192,896,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1194,493008,1,1,,49718192,896,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1195,493008,1,1,,49718192,896,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1196,493011,1,1,,46500483,896,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1197,493012,1,1,,46500483,896,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1198,493033,1,2,,92124328,896,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1199,493033,1,2,,92125502,896,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1200,493036,1,2,,46500483,896,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1201,493087,1,1,,49718192,896,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1202,493091,1,1,,46500483,896,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1203,493098,1,1,,46500483,896,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1204,493106,1,1,,90340716,896,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1205,493107,1,1,,90340716,896,Inconclusive,116283940.0,79915.0,29.081,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1206,493127,1,1,,50105414,896,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1207,493131,1,1,,49718192,896,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1208,493140,1,1,,103913882,896,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1209,493153,1,1,,90340716,896,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1210,493153,1,1,,90340716,896,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1211,493160,1,1,,46500483,896,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1212,493162,1,2,,99301441,896,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1213,493164,1,2,,90340716,896,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1214,493164,1,2,,90340716,896,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1215,493164,1,2,,90340716,896,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1216,493187,1,2,,46500483,896,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1217,493189,1,1,,50105414,896,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1218,493244,1,1,,49718192,896,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1219,493244,1,1,,49718192,896,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1220,493244,1,1,,49718192,896,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1221,493244,1,1,,49718192,896,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1222,502005,7,5,,103166463,896,Active,1346544.0,4543.0,0.000331,Ki,Displacement of [125I]iodomelatonin from human cloned MT1 receptor expressed in rat NIH3T3 cells after 90 mins,Confirmatory,20674373.0,
1223,502006,7,5,,103166463,896,Active,1346548.0,4544.0,0.000617,Ki,Displacement of [125I]iodomelatonin from human cloned MT2 receptor expressed in rat NIH3T3 cells after 90 mins,Confirmatory,20674373.0,
1224,504326,1,2,,49718192,896,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1225,504326,1,2,,49718192,896,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1226,504327,1,1,,11111468,896,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1227,504327,1,1,,90340716,896,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1228,504329,1,1,,49718192,896,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1229,504332,1,1,,11111468,896,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1230,504332,1,1,,50105414,896,Inactive,168985070.0,,10.0,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1231,504332,1,1,,90340716,896,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1232,504339,1,1,,46500483,896,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1233,504357,1,1,,49718192,896,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1234,504357,1,1,,49718192,896,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1235,504364,1,1,,85231137,896,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1236,504406,1,1,,46500483,896,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1237,504408,2,1,,46500483,896,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1238,504411,1,1,,49718192,896,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1239,504414,1,1,,49718192,896,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1240,504414,1,1,,49718192,896,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1241,504423,1,1,,49718192,896,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1242,504441,1,1,,49718192,896,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1243,504444,1,1,,46500483,896,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1244,504454,1,3,,49718192,896,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1245,504462,1,1,,46500483,896,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1246,504490,1,2,,49718192,896,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1247,504523,1,1,,49718192,896,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1248,504523,1,1,,49718192,896,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1249,504536,1,1,,90340716,896,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1250,504547,1,1,,90340716,896,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1251,504548,1,2,,90340716,896,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1252,504558,1,1,,49718192,896,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1253,504577,2,2,,49718192,896,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1254,504582,2,1,,49718192,896,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1255,504621,1,1,,49718192,896,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1256,504634,1,1,,49718192,896,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1257,504648,1,1,,46500483,896,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1258,504690,1,3,,46500483,896,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1259,504692,2,2,,49718192,896,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1260,504700,1,1,,49718192,896,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1261,504700,1,1,,49718192,896,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1262,504707,1,1,,49718192,896,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1263,504707,1,1,,49718192,896,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1264,504720,1,1,,46500483,896,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1265,504734,1,1,,49718192,896,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1266,504749,1,3,,26752764,896,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1267,504749,1,3,,104171188,896,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1268,504749,1,3,1.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1269,504749,1,3,2.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1270,504749,1,3,3.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1271,504749,1,3,4.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1272,504749,1,3,5.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1273,504749,1,3,6.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1274,504749,1,3,7.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1275,504749,1,3,8.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1276,504749,1,3,9.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1277,504749,1,3,10.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1278,504749,1,3,11.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1279,504749,1,3,12.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1280,504749,1,3,13.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1281,504749,1,3,14.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1282,504749,1,3,15.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1283,504749,1,3,16.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1284,504749,1,3,17.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1285,504749,1,3,18.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1286,504749,1,3,19.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1287,504749,1,3,20.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1288,504749,1,3,21.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1289,504749,1,3,22.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1290,504749,1,3,23.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1291,504749,1,3,24.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1292,504749,1,3,25.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1293,504749,1,3,26.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1294,504749,1,3,27.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1295,504749,1,3,28.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1296,504749,1,3,29.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1297,504749,1,3,30.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1298,504749,1,3,31.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1299,504749,1,3,32.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1300,504749,1,3,33.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1301,504749,1,3,34.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1302,504749,1,3,35.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1303,504749,1,3,36.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1304,504749,1,3,37.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1305,504749,1,3,38.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1306,504749,1,3,39.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1307,504749,1,3,40.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1308,504749,1,3,41.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1309,504749,1,3,42.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1310,504749,1,3,43.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1311,504749,1,3,44.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1312,504749,1,3,45.0,104171188,896,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1313,504749,1,3,46.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1314,504749,1,3,47.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1315,504749,1,3,48.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1316,504749,1,3,49.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1317,504749,1,3,50.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1318,504749,1,3,51.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1319,504749,1,3,52.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1320,504749,1,3,53.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1321,504749,1,3,54.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1322,504749,1,3,55.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1323,504749,1,3,56.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1324,504749,1,3,57.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1325,504749,1,3,58.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1326,504749,1,3,59.0,104171188,896,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1327,504749,1,3,60.0,104171188,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1328,504749,1,3,61.0,26752764,896,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1329,504766,2,1,,49718192,896,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1330,504770,1,2,,92124328,896,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1331,504770,1,2,,92239934,896,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1332,504775,1,1,,49718192,896,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1333,504803,1,1,,49718192,896,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1334,504810,1,2,,90340716,896,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1335,504812,1,2,,90340716,896,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1336,504821,1,1,,85231137,896,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
1337,504832,1,1,,104171188,896,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1338,504834,1,1,,104171188,896,Inactive,,,9.5283,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1339,504836,1,2,,90340716,896,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
1340,504845,1,1,,46500483,896,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1341,504845,1,1,,90340716,896,Inactive,86301163.0,5999.0,2.1192,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1342,504845,1,1,,104171188,896,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1343,504847,1,1,,11111468,896,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1344,504847,1,1,,46500483,896,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1345,504847,1,1,,90340716,896,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1346,504847,1,1,,104171188,896,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1347,504865,1,1,,11111468,896,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1348,504865,1,1,,90340716,896,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1349,504865,1,1,,104171188,896,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1350,504884,1,2,,49718192,896,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1351,504891,1,1,,46500483,896,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1352,504894,1,1,,46500483,896,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1353,504937,1,2,,46500483,896,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1354,515499,2,4,,103166463,896,Unspecified,,,,,"Antiinflammatory activity against ischemia-reperfused lung tissue edema Wistar rat assessed as ratio of wet tissue weight to dry tissue weight at 20 mg/kg, ip",Other,20731361.0,
1355,515509,2,3,,103166463,896,Unspecified,,,,,"Antiinflammatory activity in ischemia-reperfused Wistar rat assessed as TNFalpha level at 20 mg/kg, ip (RVb = 123.4 +/- 8.9 pg/mL)",Other,20731361.0,
1356,515510,2,4,,103166463,896,Unspecified,,,,,"Antiinflammatory activity in ischemia-reperfused Wistar rat assessed as plasma MDA level at 20 mg/kg, ip (RVb = 3.53 +/- 0.34 nmol/mL)",Other,20731361.0,
1357,515511,2,4,,103166463,896,Unspecified,,,,,"Antiinflammatory activity in ischemia-reperfused Wistar rat assessed as lung MDA level at 20 mg/kg, ip measured per gram of tissue (RVb = 72.4 +/- 5.1 nmol)",Other,20731361.0,
1358,515512,2,3,,103166463,896,Unspecified,,,,,"Antiinflammatory activity in ischemia-reperfused Wistar rat assessed as MPO level at 20 mg/kg, ip (RVb = 17.3 +/- 0.8 U/g)",Other,20731361.0,
1359,515513,2,4,,103166463,896,Unspecified,,,,,"Antiinflammatory activity against ischemia-reperfused muscle tissue edema Wistar rat assessed as ratio of wet tissue weight to dry tissue weight at 20 mg/kg, ip",Other,20731361.0,
1360,521220,3,3,,103166463,896,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1361,538341,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced decrease in adrenaline level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by ELISA (Rvb = -40%)",Other,20870314.0,
1362,538342,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced decrease in noradrenaline level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by ELISA (Rvb = -21%)",Other,20870314.0,
1363,538343,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced decrease in dopamine level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by spectrofluorometrically (Rvb = -16%)",Other,20870314.0,
1364,538344,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced increase of malondialdehyde level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by spectrofluorometrically (Rvb = 31%)",Other,20870314.0,
1365,538345,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced decrease of glutathione level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by spectrofluorometrically (Rvb = -27%)",Other,20870314.0,
1366,538346,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced decrease of glutathione peroxidase level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by spectrofluorometrically (Rvb = -43%)",Other,20870314.0,
1367,538347,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced decrease of superoxide dismutase level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by spectrofluorometrically (Rvb = -32%)",Other,20870314.0,
1368,538348,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced increase of LDH level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by spectrofluorometrically (Rvb = 67%)",Other,20870314.0,
1369,538349,2,3,,103166463,896,Unspecified,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced decrease of creatine kinase level at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by spectrofluorometrically (Rvb = -73%)",Other,20870314.0,
1370,538350,2,3,,103166463,896,Active,,,,,"Neuroprotective activity in Sprague-Dawley rat assessed as protection against acrylamide-induced neuronal damage at 50 mg/kg, ip administered 10 mins before acrylamide challenge for 3 days per week for 2 weeks by histopathology analysis",Other,20870314.0,
1371,540253,1,1,,46500483,896,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1372,540253,1,1,,46500483,896,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1373,540253,1,1,,46500483,896,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1374,540256,1,2,,50105414,896,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1375,540256,1,2,,90340716,896,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1376,540263,1,1,,46500483,896,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1377,540263,1,1,,46500483,896,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1378,540267,1,1,,46500483,896,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1379,540276,1,2,,11111467,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1380,540276,1,2,,11111468,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1381,540276,1,2,,11111469,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1382,540276,1,2,,17388930,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1383,540276,1,2,,17389536,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1384,540276,1,2,,26747238,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1385,540276,1,2,,26747239,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1386,540276,1,2,,26752764,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1387,540276,1,2,,26752765,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1388,540276,1,2,,46500483,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1389,540276,1,2,,50105414,896,Inconclusive,420597.0,,0.3162,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1390,540276,1,2,,50105415,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1391,540276,1,2,,50105416,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1392,540276,1,2,,85231137,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1393,540276,1,2,,90340716,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1394,540276,1,2,,104171188,896,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1395,540295,1,1,,49718192,896,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1396,540299,1,2,,92124328,896,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1397,540299,1,2,,92125502,896,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1398,540303,1,1,,46500483,896,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1399,540303,1,1,,46500483,896,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1400,540303,1,1,,46500483,896,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1401,540308,1,1,,49718192,896,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1402,540317,1,1,,46500483,896,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1403,540336,1,1,,49718192,896,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1404,540336,1,1,,49718192,896,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1405,540364,1,2,,49718192,896,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1406,551413,2,6,,103166463,896,Unspecified,,,,,Neuroprotective activity against rotenone/oligomycin-A-induced death in human SH-SY5Y cells assessed as increase of cell viability at 10 nM after 2 hrs by MTT assay,Other,21190861.0,
1407,551416,2,6,,103166463,896,Unspecified,,,,,Neuroprotective activity against rotenone/oligomycin-A-induced death in human SH-SY5Y cells assessed as protective effect at 10 nM after 2 hrs by MTT assay,Other,21190861.0,
1408,567992,2,3,,103166463,896,Active,,,0.00056,EC50,Binding affinity to rat MT1 receptor expressed in CHO-Galpha16 cells assessed as Ca2+ mobilization after 20 mins by FLIPR assay,Confirmatory,21237644.0,
1409,567993,2,4,,103166463,896,Active,,,0.0011,EC50,Binding affinity to rat MT2 receptor expressed in CHO-Galpha16 cells assessed as Ca2+ mobilization after 20 mins by FLIPR assay,Confirmatory,21237644.0,
1410,567994,2,3,,103166463,896,Unspecified,,,,,Intrinsic activity at rat MT1 receptor expressed in CHO-Galpha16 cells assessed as Ca2+ mobilization after 20 mins by FLIPR assay relative to ramelteon,Other,21237644.0,
1411,567995,2,4,,103166463,896,Unspecified,,,,,Intrinsic activity at rat MT2 receptor expressed in CHO-Galpha16 cells assessed as Ca2+ mobilization after 20 mins by FLIPR assay relative to agomelatine,Other,21237644.0,
1412,567996,2,3,,103166463,896,Active,,,,IC50,Displacement of [3H]melatonin from rat MT1 receptor expressed in CHO-Galpha16 cells,Confirmatory,21237644.0,
1413,567997,2,4,,103166463,896,Active,,,,IC50,Displacement of [3H]melatonin from rat MT2 receptor expressed in CHO-Galpha16 cells,Confirmatory,21237644.0,
1414,588209,2,3,,103166463,896,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1415,588210,2,4,,103166463,896,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1416,588334,1,1,,49718192,896,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1417,588335,1,1,,49718192,896,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1418,588349,1,1,,90340716,896,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
1419,588352,1,2,,49718192,896,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1420,588354,1,1,,49718192,896,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1421,588358,1,2,,49718192,896,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1422,588378,1,1,,90340716,896,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
1423,588379,1,2,,124880736,896,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
1424,588391,1,1,,49718192,896,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1425,588405,1,1,,49718192,896,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1426,588413,1,2,,46500483,896,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1427,588436,1,1,,49718192,896,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1428,588453,1,1,,46500483,896,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1429,588453,1,1,,85231137,896,Inactive,8659577.0,58819.0,37.6858,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1430,588453,1,1,,90340716,896,Inactive,8659577.0,58819.0,0.7943,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1431,588456,1,1,,46500483,896,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1432,588456,1,1,,90340716,896,Inactive,8659577.0,58819.0,2.8184,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1433,588458,1,1,,49718192,896,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1434,588473,1,1,,46500483,896,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1435,588473,1,1,,46500483,896,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1436,588475,1,2,,46500483,896,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1437,588475,1,2,,46500483,896,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1438,588478,1,2,,124800427,896,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1439,588489,1,1,,49718192,896,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1440,588492,1,1,,49718192,896,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1441,588493,1,2,,49718192,896,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1442,588497,1,2,,49718192,896,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1443,588497,1,2,,49718192,896,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1444,588497,1,2,,49718192,896,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1445,588499,1,3,,49718192,896,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1446,588499,1,3,,49718192,896,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1447,588499,1,3,,49718192,896,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1448,588501,1,2,,49718192,896,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1449,588501,1,2,,49718192,896,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1450,588501,1,2,,49718192,896,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1451,588511,1,2,,46500483,896,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1452,588513,1,1,,17388930,896,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1453,588513,1,1,,17389536,896,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1454,588513,1,1,,26752765,896,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1455,588514,1,1,,17388930,896,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1456,588514,1,1,,17389536,896,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1457,588514,1,1,,26752765,896,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1458,588515,1,1,,17388930,896,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1459,588515,1,1,,17389536,896,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1460,588515,1,1,,26752765,896,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1461,588516,1,1,,17388930,896,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1462,588516,1,1,,17389536,896,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1463,588516,1,1,,26752765,896,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1464,588519,1,2,,92124328,896,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1465,588519,1,2,,92125502,896,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1466,588526,1,1,,17388930,896,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1467,588526,1,1,,17389536,896,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1468,588526,1,1,,26752765,896,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1469,588527,1,1,,17388930,896,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1470,588527,1,1,,17389536,896,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1471,588527,1,1,,26752765,896,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1472,588532,1,1,,17388930,896,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1473,588532,1,1,,17389536,896,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1474,588532,1,1,,26752765,896,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1475,588533,1,1,,17388930,896,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1476,588533,1,1,,17389536,896,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1477,588533,1,1,,26752765,896,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1478,588534,1,1,,17388930,896,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1479,588534,1,1,,17389536,896,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1480,588534,1,1,,26752765,896,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1481,588535,1,1,,17388930,896,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1482,588535,1,1,,17389536,896,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1483,588535,1,1,,26752765,896,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1484,588536,1,1,,17388930,896,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1485,588536,1,1,,17389536,896,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1486,588536,1,1,,26752765,896,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1487,588537,1,1,,17388930,896,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1488,588537,1,1,,17389536,896,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1489,588537,1,1,,26752765,896,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1490,588541,1,1,,17388930,896,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1491,588541,1,1,,17389536,896,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1492,588541,1,1,,26752765,896,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1493,588543,1,1,,17388930,896,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1494,588543,1,1,,17389536,896,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1495,588543,1,1,,26752765,896,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1496,588544,1,1,,17388930,896,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1497,588544,1,1,,17389536,896,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1498,588544,1,1,,26752765,896,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1499,588545,1,1,,17388930,896,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1500,588545,1,1,,17389536,896,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1501,588545,1,1,,26752765,896,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1502,588546,1,1,,17388930,896,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1503,588546,1,1,,17389536,896,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1504,588546,1,1,,26752765,896,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1505,588547,1,1,,17388930,896,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1506,588547,1,1,,17389536,896,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1507,588547,1,1,,26752765,896,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1508,588549,1,1,,49718192,896,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1509,588579,1,1,,11111468,896,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1510,588579,1,1,,46500483,896,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1511,588579,1,1,,90340716,896,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1512,588579,1,1,,104171188,896,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1513,588579,1,1,,124880734,896,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1514,588579,1,1,,124880736,896,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1515,588590,1,1,,46500483,896,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1516,588590,1,1,,50105414,896,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1517,588591,1,1,,46500483,896,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1518,588591,1,1,,50105414,896,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1519,588621,1,1,,49718192,896,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1520,588627,1,1,,46500483,896,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1521,588664,1,2,,49718192,896,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1522,588664,1,2,,49718192,896,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1523,588674,1,2,,49718192,896,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1524,588675,1,1,,46500483,896,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1525,588676,1,1,,46500483,896,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1526,588689,1,1,,49718192,896,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1527,588692,2,1,,49718192,896,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1528,588726,1,2,,49718192,896,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1529,588727,1,1,,49718192,896,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1530,588795,1,1,,46500483,896,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1531,588795,1,1,,90340716,896,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1532,588812,1,1,,17389536,896,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1533,588812,1,1,1.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1534,588812,1,1,2.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1535,588812,1,1,3.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1536,588812,1,1,4.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1537,588812,1,1,5.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1538,588812,1,1,6.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1539,588812,1,1,7.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1540,588812,1,1,8.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1541,588812,1,1,9.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1542,588812,1,1,10.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1543,588812,1,1,11.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1544,588812,1,1,12.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1545,588812,1,1,13.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1546,588812,1,1,14.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1547,588812,1,1,15.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1548,588812,1,1,16.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1549,588812,1,1,17.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1550,588812,1,1,18.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1551,588812,1,1,19.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1552,588812,1,1,20.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1553,588812,1,1,21.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1554,588812,1,1,22.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1555,588812,1,1,23.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1556,588812,1,1,24.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1557,588812,1,1,25.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1558,588812,1,1,26.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1559,588812,1,1,27.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1560,588812,1,1,28.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1561,588812,1,1,29.0,17389536,896,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1562,588812,1,1,30.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1563,588812,1,1,31.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1564,588812,1,1,32.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1565,588812,1,1,33.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1566,588812,1,1,34.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1567,588812,1,1,35.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1568,588812,1,1,36.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1569,588812,1,1,37.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1570,588812,1,1,38.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1571,588812,1,1,39.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1572,588812,1,1,40.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1573,588812,1,1,41.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1574,588812,1,1,42.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1575,588812,1,1,43.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1576,588812,1,1,44.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1577,588812,1,1,45.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1578,588812,1,1,46.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1579,588812,1,1,47.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1580,588812,1,1,48.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1581,588812,1,1,49.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1582,588812,1,1,50.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1583,588812,1,1,51.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1584,588812,1,1,52.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1585,588812,1,1,53.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1586,588812,1,1,54.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1587,588812,1,1,55.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1588,588812,1,1,56.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1589,588812,1,1,57.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1590,588812,1,1,58.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1591,588812,1,1,59.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1592,588812,1,1,60.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1593,588812,1,1,61.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1594,588812,1,1,62.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1595,588812,1,1,63.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1596,588812,1,1,64.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1597,588812,1,1,65.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1598,588812,1,1,66.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1599,588812,1,1,67.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1600,588812,1,1,68.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1601,588812,1,1,69.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1602,588812,1,1,70.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1603,588812,1,1,71.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1604,588812,1,1,72.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1605,588812,1,1,73.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1606,588812,1,1,74.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1607,588812,1,1,75.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1608,588812,1,1,76.0,17389536,896,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1609,588812,1,1,77.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1610,588812,1,1,78.0,17389536,896,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1611,588812,1,1,79.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1612,588812,1,1,80.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1613,588812,1,1,81.0,17389536,896,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1614,588813,1,1,,17389536,896,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1615,588813,1,1,1.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1616,588813,1,1,2.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1617,588813,1,1,3.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1618,588813,1,1,4.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1619,588813,1,1,5.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1620,588813,1,1,6.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1621,588813,1,1,7.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1622,588813,1,1,8.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1623,588813,1,1,9.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1624,588813,1,1,10.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1625,588813,1,1,11.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1626,588813,1,1,12.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1627,588813,1,1,13.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1628,588813,1,1,14.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1629,588813,1,1,15.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1630,588813,1,1,16.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1631,588813,1,1,17.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1632,588813,1,1,18.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1633,588813,1,1,19.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1634,588813,1,1,20.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1635,588813,1,1,21.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1636,588813,1,1,22.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1637,588813,1,1,23.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1638,588813,1,1,24.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1639,588813,1,1,25.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1640,588813,1,1,26.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1641,588813,1,1,27.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1642,588813,1,1,28.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1643,588813,1,1,29.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1644,588813,1,1,30.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1645,588813,1,1,31.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1646,588813,1,1,32.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1647,588813,1,1,33.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1648,588813,1,1,34.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1649,588813,1,1,35.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1650,588813,1,1,36.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1651,588813,1,1,37.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1652,588813,1,1,38.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1653,588813,1,1,39.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1654,588813,1,1,40.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1655,588813,1,1,41.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1656,588813,1,1,42.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1657,588813,1,1,43.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1658,588813,1,1,44.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1659,588813,1,1,45.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1660,588813,1,1,46.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1661,588813,1,1,47.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1662,588813,1,1,48.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1663,588813,1,1,49.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1664,588813,1,1,50.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1665,588813,1,1,51.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1666,588813,1,1,52.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1667,588813,1,1,53.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1668,588813,1,1,54.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1669,588813,1,1,55.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1670,588813,1,1,56.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1671,588813,1,1,57.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1672,588813,1,1,58.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1673,588813,1,1,59.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1674,588813,1,1,60.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1675,588813,1,1,61.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1676,588813,1,1,62.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1677,588813,1,1,63.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1678,588813,1,1,64.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1679,588813,1,1,65.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1680,588813,1,1,66.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1681,588813,1,1,67.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1682,588813,1,1,68.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1683,588813,1,1,69.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1684,588813,1,1,70.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1685,588813,1,1,71.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1686,588813,1,1,72.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1687,588813,1,1,73.0,17389536,896,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1688,588813,1,1,74.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1689,588813,1,1,75.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1690,588813,1,1,76.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1691,588813,1,1,77.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1692,588813,1,1,78.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1693,588813,1,1,79.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1694,588813,1,1,80.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1695,588813,1,1,81.0,17389536,896,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1696,588814,1,3,,49718192,896,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1697,588819,1,4,,49718192,896,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1698,588834,2,1,,17388930,896,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1699,588834,2,1,,17389536,896,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1700,588834,2,1,,26752764,896,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1701,588834,2,1,,50105414,896,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1702,588850,1,1,,49718192,896,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1703,588852,1,3,,49718192,896,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1704,588855,1,1,,46500483,896,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1705,588856,1,1,,46500483,896,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1706,590021,1,3,,103166463,896,Active,,,,,Induction of disassembly of preformed amyloid beta (1 to 40) fibrils assessed as decrease in fibril amount at 10:1 compound to amyloid beta ratio by thioflavin T fluorescence method,Other,21354796.0,
1707,590026,1,3,,103166463,896,Active,,,,,Induction of disassembly of preformed amyloid beta (1 to 40) fibrils assessed as disaggregated fibrils at 10:1 compound to amyloid beta ratio for 4 days by fourier-transform infrared spectroscopy,Other,21354796.0,
1708,590762,6,1,,103166463,896,Unspecified,1346544.0,4543.0,,EC50,Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay,Confirmatory,21420861.0,
1709,590763,6,1,,103166463,896,Unspecified,1346548.0,4544.0,,EC50,Agonist activity at human MT2 receptor expressed in CHO cells by [35S]GTPgamma binding assay,Confirmatory,21420861.0,
1710,590764,1,3,,103166463,896,Unspecified,,,,,Selectivity ratio of Ki for human MT1 receptor to Ki for human MT2 receptor,Other,21420861.0,
1711,591353,5,5,,103166463,896,Active,1346544.0,4543.0,0.00025,Ki,Displacement of 2-[125I]-iodomelatonin from human MT1 receptor expressed in HEK293 cells,Confirmatory,21420861.0,
1712,591354,5,5,,103166463,896,Active,1346548.0,4544.0,0.00033999999999999997,Ki,Displacement of 2-[125I]-iodomelatonin from human MT2 receptor expressed in HEK293 cells,Confirmatory,21420861.0,
1713,594256,5,5,,103166463,896,Active,1346544.0,4543.0,0.0002,IC50,Binding affinity to human MT1 receptor,Confirmatory,21377769.0,
1714,594257,5,5,,103166463,896,Active,1346548.0,4544.0,0.00053,IC50,Binding affinity to human MT2 receptor,Confirmatory,21377769.0,
1715,594258,5,5,,103166463,896,Active,317373581.0,4835.0,0.0646,IC50,Binding affinity to human low affinity melatonin (MT3) site of quinone reductase 2,Confirmatory,21377769.0,
1716,594259,1,3,,103166463,896,Unspecified,,,,,Selectivity ratio of IC50 for human MT1 to IC50 for human MT3,Other,21377769.0,
1717,594260,1,3,,103166463,896,Unspecified,,,,,Selectivity ratio of IC50 for human MT2 to IC50 for human MT3,Other,21377769.0,
1718,595896,5,5,,103166463,896,Active,1346544.0,4543.0,0.00023999999999999998,Ki,Displacement of [125I]-2-iodomelatonin from human MT1 receptor expressed on CHO cells by microscintillation counting,Confirmatory,21473625.0,
1719,595899,5,5,,103166463,896,Active,1346548.0,4544.0,0.00021,Ki,Displacement of [125I]-2-iodomelatonin from human MT2 receptor expressed on CHO cells microscintillation counting,Confirmatory,21473625.0,
1720,595901,1,4,,103166463,896,Unspecified,,,,,"Selectivity ratio, ratio of Ki for human MT1 receptor over Ki for human MT2 receptor",Other,21473625.0,
1721,595902,4,6,,103166463,896,Active,1346544.0,4543.0,2.57e-05,EC50,Agonist activity at human MT1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by EnVision Multilabel Plate Readers,Confirmatory,21473625.0,
1722,595903,4,6,,103166463,896,Active,1346548.0,4544.0,0.000851,EC50,Agonist activity at human MT2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by EnVision Multilabel Plate Readers,Confirmatory,21473625.0,
1723,598253,5,5,,103166463,896,Active,1346544.0,4543.0,0.00022,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in CHO cells,Confirmatory,21392858.0,
1724,598254,5,5,,103166463,896,Active,1346548.0,4544.0,0.00035,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in CHO cells,Confirmatory,21392858.0,
1725,598255,1,4,,103166463,896,Unspecified,,,,,Selectivity ratio of Ki for human MT1 receptor to Ki for human MT2 receptor,Other,21392858.0,
1726,602123,1,1,,49718192,896,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1727,602141,1,1,,49718192,896,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1728,602162,1,1,,49718192,896,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1729,602163,1,1,,49718192,896,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1730,602179,1,2,,46500483,896,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1731,602229,1,1,,49718192,896,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1732,602233,1,1,,46500483,896,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1733,602244,1,2,,49718192,896,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1734,602247,1,2,,49718192,896,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1735,602248,1,2,,49718192,896,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1736,602250,1,2,,49718192,896,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1737,602252,1,1,,49718192,896,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1738,602252,1,1,,49718192,896,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1739,602261,1,1,,49718192,896,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1740,602274,1,2,,49718192,896,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1741,602281,1,1,,49718192,896,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1742,602281,1,1,,49718192,896,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1743,602310,1,2,,46500483,896,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1744,602313,1,1,,46500483,896,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1745,602314,1,2,,92124328,896,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1746,602314,1,2,,92125502,896,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1747,602329,1,1,,49718192,896,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1748,602332,1,1,,11111468,896,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1749,602332,1,1,,46500483,896,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1750,602332,1,1,,90340716,896,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1751,602332,1,1,,104171188,896,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1752,602332,1,1,,124880734,896,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1753,602332,1,1,,124880736,896,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1754,602340,1,2,,49718192,896,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1755,602342,2,1,,49718192,896,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1756,602346,1,1,,49718192,896,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1757,602363,1,1,,49718192,896,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1758,602393,1,1,,49718192,896,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1759,602396,1,2,,49718192,896,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1760,602399,1,2,,49718192,896,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1761,602405,1,1,,49718192,896,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1762,602410,1,1,,49718192,896,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1763,602429,1,1,,49718192,896,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1764,602438,1,1,,49718192,896,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1765,602440,1,1,,49718192,896,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1766,602449,1,2,,49718192,896,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1767,602481,1,1,,49718192,896,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1768,605960,5,5,,103166463,896,Active,1346544.0,4543.0,0.00023999999999999998,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in CHO cells,Confirmatory,21568291.0,
1769,605961,5,5,,103166463,896,Active,1346548.0,4544.0,0.00021,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in CHO cells,Confirmatory,21568291.0,
1770,605962,1,3,,103166463,896,Unspecified,,,,,"Lipophilicity, log D of the compound at pH 7.4 by HPLC analysis",Other,21568291.0,
1771,605963,3,3,,103166463,896,Unspecified,,,,,Metabolic clearance in rat hepatic microsomes after 20 mins by HPLC-UV analysis,Other,21568291.0,
1772,605977,2,6,,103166463,896,Active,1346544.0,4543.0,2.6000000000000002e-05,EC50,Agonist activity at human MT1 receptor expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP release after 30 mins by multilabel plate reader,Confirmatory,21568291.0,
1773,605978,2,6,,103166463,896,Active,1346548.0,4544.0,0.00082,EC50,Agonist activity at human MT2 receptor expressed in CHO cells assessed as decrease in forskolin-stimulated cAMP release after 30 mins by multilabel plate reader,Confirmatory,21568291.0,
1774,611931,4,5,,103166463,896,Active,1346544.0,4543.0,0.00037,Ki,Displacement of [125I]2-iodomelatonin from human MT1 receptor,Confirmatory,21726069.0,
1775,612341,6,5,,103166463,896,Active,1346544.0,4543.0,0.000263,Ki,Displacement of 2-[125I]iodomelatonin from human cloned MT1 receptor expressed in mouse NIH-3T3 cell membrane,Confirmatory,21775151.0,
1776,612342,6,5,,103166463,896,Active,1346548.0,4544.0,0.000339,Ki,Displacement of 2-[125I]iodomelatonin from human cloned MT2 receptor expressed in mouse NIH-3T3 cell membrane,Confirmatory,21775151.0,
1777,612343,1,3,,103166463,896,Unspecified,,,,,"Selectivity index, ratio of Ki for human cloned MT2 receptor to Ki for human cloned MT1 receptor",Other,21775151.0,
1778,616792,8,2,,103166463,896,Active,1346544.0,4543.0,0.00025,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in human HEK293 cells by radioligand binding assay,Confirmatory,21764185.0,
1779,616793,5,5,,103166463,896,Active,1346548.0,4544.0,0.00033999999999999997,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in human HEK293 cells by radioligand binding assay,Confirmatory,21764185.0,
1780,616794,1,4,,103166463,896,Unspecified,,,,,Selectivity ratio of Ki for human MT1 receptor expressed in human HEK293 cells to Ki for human MT2 receptor expressed in human HEK293 cells,Other,21764185.0,
1781,623870,1,1,,49718192,896,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1782,623870,1,1,,49718192,896,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1783,623877,1,1,,49718192,896,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1784,623901,1,1,,49718192,896,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1785,624030,1,2,,104171188,896,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1786,624031,1,2,,104171188,896,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1787,624032,1,2,,104171188,896,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1788,624037,1,3,,49718192,896,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1789,624038,1,3,,49718192,896,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1790,624040,1,3,,49718192,896,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1791,624044,1,2,,104171188,896,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1792,624125,1,4,,49718192,896,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1793,624126,1,3,,49718192,896,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1794,624127,1,2,,49718192,896,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1795,624146,1,1,,90340716,896,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
1796,624147,1,1,,90340716,896,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
1797,624148,1,2,,90340716,896,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
1798,624149,1,1,,90340716,896,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
1799,624156,1,1,,85788807,896,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1800,624168,1,1,,49718192,896,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1801,624169,1,1,,49718192,896,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1802,624170,1,1,,46500483,896,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1803,624170,1,1,,104171188,896,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1804,624171,1,1,,46500483,896,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1805,624172,1,1,,46500483,896,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1806,624172,1,1,,104171188,896,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1807,624173,1,3,,46500483,896,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1808,624173,1,3,,104171188,896,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1809,624178,1,1,,46500483,896,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1810,624202,1,1,,46500483,896,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1811,624204,1,2,,49718192,896,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1812,624218,1,1,,135651518,896,Active,222080049.0,3357.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B,Other,12750432.0,
1813,624246,1,1,,46500483,896,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1814,624256,1,2,,49718192,896,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1815,624263,1,1,,46500483,896,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1816,624263,1,1,,46500483,896,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1817,624267,1,2,,49718192,896,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1818,624267,1,2,,49718192,896,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1819,624268,1,3,,49718192,896,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1820,624288,1,1,,46500483,896,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1821,624296,1,1,,26752764,896,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1822,624296,1,1,,46500483,896,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1823,624296,1,1,,104171188,896,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1824,624297,1,1,,26752764,896,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1825,624297,1,1,,46500483,896,Inconclusive,7705682.0,51053.0,0.5623,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1826,624297,1,1,,104171188,896,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1827,624304,1,2,,49718192,896,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1828,624330,1,2,,49718192,896,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1829,624349,1,2,,92124328,896,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1830,624349,1,2,,92125502,896,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1831,624349,1,2,,92308785,896,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1832,624349,1,2,,121363173,896,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1833,624352,1,1,,49718192,896,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1834,624354,1,1,,49718192,896,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1835,624377,1,1,,49718192,896,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1836,624414,1,1,,46500483,896,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1837,624415,1,2,,46500483,896,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1838,624416,1,1,,49718192,896,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1839,624417,1,1,,46500483,896,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1840,624418,1,1,,46500483,896,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1841,624455,1,1,,90340716,896,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
1842,624463,1,1,,46500483,896,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1843,624464,1,1,,46500483,896,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1844,624465,1,1,,46500483,896,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1845,624466,1,3,,49718192,896,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1846,624467,1,1,,49718192,896,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1847,624483,1,1,,49718192,896,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1848,625144,5,5,,103166463,896,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1849,625145,4,7,,103166463,896,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1850,625146,5,5,,103166463,896,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1851,625147,4,7,,103166463,896,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1852,625148,4,7,,103166463,896,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1853,625149,4,7,,103166463,896,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1854,625150,5,5,,103166463,896,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1855,625151,4,7,,103166463,896,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1856,625152,4,7,,103166463,896,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1857,625153,4,7,,103166463,896,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1858,625154,4,7,,103166463,896,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1859,625155,4,7,,103166463,896,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1860,625156,1,9,,103166463,896,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1861,625157,6,2,,103166463,896,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1862,625158,3,4,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1863,625159,5,5,,103166463,896,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1864,625160,1,9,,103166463,896,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1865,625161,4,7,,103166463,896,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1866,625162,4,7,,103166463,896,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1867,625163,4,7,,103166463,896,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1868,625164,1,6,,103166463,896,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1869,625165,3,4,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1870,625166,3,4,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1871,625167,5,5,,103166463,896,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1872,625168,4,7,,103166463,896,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1873,625169,1,6,,103166463,896,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1874,625170,3,4,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1875,625171,4,7,,103166463,896,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1876,625172,4,7,,103166463,896,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1877,625173,5,5,,103166463,896,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1878,625174,5,5,,103166463,896,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1879,625175,5,5,,103166463,896,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1880,625176,1,9,,103166463,896,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1881,625177,5,5,,103166463,896,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1882,625178,5,5,,103166463,896,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1883,625179,1,9,,103166463,896,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1884,625180,5,5,,103166463,896,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1885,625181,5,5,,103166463,896,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1886,625182,5,5,,103166463,896,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1887,625183,5,5,,103166463,896,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1888,625184,5,5,,103166463,896,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1889,625185,5,5,,103166463,896,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1890,625186,5,5,,103166463,896,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1891,625187,5,5,,103166463,896,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1892,625188,1,9,,103166463,896,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1893,625189,1,7,,103166463,896,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1894,625190,4,5,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1895,625191,4,7,,103166463,896,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1896,625192,4,7,,103166463,896,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1897,625193,5,5,,103166463,896,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1898,625194,4,7,,103166463,896,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1899,625195,4,7,,103166463,896,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1900,625196,5,6,,103166463,896,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1901,625197,3,4,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1902,625198,4,7,,103166463,896,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1903,625199,4,7,,103166463,896,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1904,625200,4,7,,103166463,896,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1905,625201,4,7,,103166463,896,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1906,625202,4,7,,103166463,896,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1907,625203,4,7,,103166463,896,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1908,625204,4,7,,103166463,896,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1909,625205,4,7,,103166463,896,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1910,625206,4,7,,103166463,896,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1911,625207,4,7,,103166463,896,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1912,625208,5,5,,103166463,896,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1913,625209,4,7,,103166463,896,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1914,625210,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1915,625211,1,6,,103166463,896,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1916,625212,3,4,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1917,625213,4,7,,103166463,896,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1918,625214,1,9,,103166463,896,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1919,625215,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1920,625216,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1921,625217,4,7,,103166463,896,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1922,625218,4,7,,103166463,896,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1923,625219,3,4,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1924,625220,4,7,,103166463,896,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1925,625221,4,7,,103166463,896,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1926,625222,4,7,,103166463,896,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1927,625223,4,7,,103166463,896,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1928,625224,3,4,,103166463,896,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1929,625225,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1930,625226,4,7,,103166463,896,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1931,625227,4,7,,103166463,896,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1932,625228,4,7,,103166463,896,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1933,625229,5,5,,103166463,896,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1934,625230,1,6,,103166463,896,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1935,625231,4,7,,103166463,896,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1936,625232,1,9,,103166463,896,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1937,625233,4,7,,103166463,896,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1938,625234,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1939,625235,4,7,,103166463,896,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1940,625236,5,5,,103166463,896,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1941,625237,4,7,,103166463,896,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1942,625238,4,7,,103166463,896,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1943,625239,4,7,,103166463,896,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1944,625240,1,9,,103166463,896,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1945,625241,4,7,,103166463,896,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1946,625242,4,7,,103166463,896,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1947,625243,5,5,,103166463,896,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1948,625244,5,5,,103166463,896,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1949,625245,5,5,,103166463,896,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1950,625246,1,9,,103166463,896,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1951,625247,5,5,,103166463,896,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1952,625248,5,5,,103166463,896,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1953,625249,5,5,,103166463,896,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1954,625250,5,5,,103166463,896,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1955,625251,5,5,,103166463,896,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1956,625252,4,7,,103166463,896,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1957,625253,4,7,,103166463,896,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1958,625254,4,7,,103166463,896,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1959,625255,4,7,,103166463,896,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1960,625256,4,7,,103166463,896,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1961,625257,4,7,,103166463,896,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1962,625258,4,7,,103166463,896,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1963,625259,4,7,,103166463,896,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1964,625260,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1965,625261,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1966,625262,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1967,625263,4,7,,103166463,896,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1968,625264,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1969,625265,1,6,,103166463,896,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1970,625266,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1971,625267,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1972,625268,4,2,,103166463,896,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1973,625268,4,2,,103166463,896,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1974,625268,4,2,,103166463,896,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1975,625268,4,2,,103166463,896,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1976,625269,4,7,,103166463,896,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1977,625270,4,7,,103166463,896,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1978,625271,5,5,,103166463,896,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1979,625272,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1980,625273,4,6,,103166463,896,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1981,625274,1,6,,103166463,896,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1982,625275,3,4,,103166463,896,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1983,625295,1,3,,103166463,896,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data,Other,22194678.0,
1984,633136,1,5,,103166463,896,Inactive,,,,,Antioxidant activity in Wistar rat erythrocytes assessed as prolongation of initial inhibition period-lag phase of t-BuOOH-induced hemolysis at 100 uM preincubated for 30 mins before induction measured up to 5 hrs by spectrophotometry,Other,22037047.0,
1985,635414,5,5,,103166463,896,Inconclusive,14916521.0,,,IC50,Inhibition of electric eel AChE using acetylcholine chloride as substrate preincubated for 15 mins by Ellman's method,Confirmatory,22041172.0,
1986,635415,5,5,,103166463,896,Inconclusive,75074633.0,,,IC50,Inhibition of equine serum BuChE using butyrylthiocholine chloride as substrate preincubated for 15 mins by Ellman's method,Confirmatory,22041172.0,
1987,635417,5,5,,103166463,896,Inconclusive,75074633.0,,,IC50,Inhibition of equine serum BuChE using acetylcholine as substrate preincubated for 15 mins by Ellman's method,Confirmatory,22041172.0,
1988,635418,1,4,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as trolox equivalent of APPH-induced radical scavenging activity at 0.5 to 10 uM measured every 60 sec for 4 hrs by ORAC fluorescence assay relative to trolox,Other,22041172.0,
1989,639467,1,6,,103166463,896,Unspecified,,,,,Neuroprotective activity against amyloid beta 1 to 42-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 10 nM pre-incubated for 24 hrs before amyloid beta 1 to 42 challenge measured after 24 hrs by MTT assay relative to control,Other,21420206.0,
1990,643757,3,2,,103166463,896,Active,,,0.000263,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in rat NIH3T3 cells after 90 mins,Confirmatory,22047556.0,
1991,643760,3,2,,103166463,896,Active,,,0.000339,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in rat NIH3T3 cells after 90 mins,Confirmatory,22047556.0,
1992,651550,1,1,,46500483,896,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1993,651560,1,1,,49718192,896,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1994,651572,1,2,,49718192,896,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1995,651582,1,1,,49718192,896,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1996,651602,1,1,,49718192,896,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1997,651602,1,1,,49718192,896,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1998,651602,1,1,,49718192,896,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1999,651610,2,1,,49718192,896,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2000,651631,4,1,,144203746,896,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2001,651631,4,1,,144208725,896,Inconclusive,269849759.0,7157.0,0.5531,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2002,651631,4,1,,144213243,896,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2003,651632,4,1,,144203746,896,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2004,651632,4,1,,144208725,896,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2005,651632,4,1,,144213243,896,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2006,651633,4,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2007,651633,4,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2008,651633,4,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2009,651634,4,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2010,651634,4,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2011,651634,4,1,,144213243,896,Inactive,,,68.5896,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2012,651635,1,3,,11111468,896,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2013,651635,1,3,,46500483,896,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2014,651635,1,3,,90340716,896,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2015,651636,1,1,,49718192,896,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2016,651640,1,1,,49718192,896,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2017,651644,1,1,,46500483,896,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2018,651647,1,1,,49718192,896,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2019,651654,1,1,,49718192,896,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2020,651658,1,1,,49718192,896,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2021,651661,2,1,,49718192,896,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2022,651687,1,1,,49718192,896,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2023,651699,1,1,,49718192,896,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2024,651699,1,1,,49718192,896,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2025,651702,1,2,,49718192,896,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2026,651704,2,1,,49718192,896,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2027,651710,1,1,,49718192,896,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2028,651711,2,1,,49718192,896,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2029,651718,1,2,,49718192,896,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2030,651719,1,2,,49718192,896,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
2031,651723,1,1,,49718192,896,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2032,651724,1,1,,46500483,896,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2033,651725,1,1,,46500483,896,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2034,651741,1,1,,17388930,896,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2035,651741,1,1,,17389536,896,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2036,651741,1,1,,124880738,896,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2037,651743,1,1,,17388930,896,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2038,651743,1,1,,17389536,896,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2039,651743,1,1,,26752765,896,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2040,651749,1,1,,17388930,896,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2041,651749,1,1,,17389536,896,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2042,651749,1,1,,26752765,896,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2043,651751,1,1,,17388930,896,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2044,651751,1,1,,17389536,896,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2045,651751,1,1,,26752765,896,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2046,651754,1,1,,17388930,896,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2047,651754,1,1,,17389536,896,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2048,651755,1,1,,17388930,896,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2049,651755,1,1,,17389536,896,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2050,651757,1,1,,17388930,896,Inconclusive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2051,651757,1,1,,17389536,896,Inconclusive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2052,651758,1,1,,17388930,896,Inconclusive,186368.0,3576.0,74.97800000000001,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2053,651758,1,1,,17389536,896,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2054,651768,1,2,,46500483,896,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2055,651777,1,1,,17388930,896,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2056,651777,1,1,,17389536,896,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2057,651777,1,1,,26752765,896,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2058,651778,1,1,,17388930,896,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2059,651778,1,1,,17389536,896,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2060,651778,1,1,,26752765,896,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2061,651800,1,1,,49718192,896,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2062,651802,1,1,,17388930,896,Inactive,49066040.0,6097.0,74.97800000000001,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2063,651802,1,1,,17389536,896,Inconclusive,49066040.0,6097.0,42.1632,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2064,651819,1,1,,46500483,896,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2065,651820,1,1,,46500483,896,Inconclusive,,,35.4813,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2066,651821,2,4,,49718192,896,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2067,651828,1,2,,92308785,896,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2068,651828,1,2,,121361700,896,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2069,651838,1,1,,17388930,896,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2070,651838,1,1,,17389536,896,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2071,651838,1,1,,26752765,896,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2072,651838,1,1,1.0,17388930,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2073,651838,1,1,1.0,17389536,896,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2074,651838,1,1,1.0,26752765,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2075,651838,1,1,2.0,17388930,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2076,651838,1,1,2.0,17389536,896,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2077,651838,1,1,2.0,26752765,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2078,651838,1,1,3.0,17388930,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2079,651838,1,1,3.0,17389536,896,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2080,651838,1,1,3.0,26752765,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2081,651838,1,1,4.0,17388930,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2082,651838,1,1,4.0,17389536,896,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2083,651838,1,1,4.0,26752765,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2084,651838,1,1,5.0,17388930,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2085,651838,1,1,5.0,17389536,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2086,651838,1,1,5.0,26752765,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2087,651838,1,1,6.0,17388930,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2088,651838,1,1,6.0,17389536,896,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2089,651838,1,1,6.0,26752765,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2090,651838,1,1,7.0,17388930,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2091,651838,1,1,7.0,17389536,896,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2092,651838,1,1,7.0,26752765,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2093,651838,1,1,8.0,17388930,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2094,651838,1,1,8.0,17389536,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2095,651838,1,1,8.0,26752765,896,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2096,651957,1,1,,49718192,896,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2097,651958,1,1,,49718192,896,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2098,651965,1,1,,46500483,896,Inconclusive,2668494.0,,28.1838,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2099,651999,1,1,,49718192,896,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2100,652010,1,1,,49718192,896,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2101,652017,1,1,,49718192,896,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2102,652025,1,1,,46500483,896,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2103,652039,1,1,,49718192,896,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2104,652048,1,2,,46500483,896,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2105,652048,1,2,,144203746,896,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2106,652051,1,1,,46500483,896,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2107,652051,1,1,,144203746,896,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2108,652054,1,1,,46500483,896,Inconclusive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2109,652067,1,4,,49718192,896,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2110,652104,1,1,,46500483,896,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2111,652105,1,1,,46500483,896,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2112,652106,1,1,,46500483,896,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2113,652106,1,1,,90340716,896,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2114,652115,1,1,,49718192,896,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2115,652126,1,3,,49718192,896,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2116,652154,1,1,,49718192,896,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2117,652162,2,1,,49718192,896,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2118,652163,1,1,,49718192,896,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2119,652197,1,1,,49718192,896,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2120,652257,1,1,,49718192,896,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2121,656041,4,5,,103166463,896,Inconclusive,113037.0,43.0,,IC50,Inhibition of human erythrocytes AChE by Ellman's method,Confirmatory,22243648.0,
2122,656042,4,5,,103166463,896,Inconclusive,116353.0,590.0,,IC50,Inhibition of human serum BChE by Ellman's method,Confirmatory,22243648.0,
2123,656043,1,3,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as trolox equivalent of peroxyl radical scavenging activity in phosphate buffer at pH 7.4 by ORAC assay,Other,22243648.0,
2124,656044,3,1,,103166463,896,Inconclusive,,,,,Permeability of the compound in phosphate buffer at pH 7.4 by PAMPA,Other,22243648.0,
2125,664045,1,5,,103166463,896,Unspecified,,,,,Neuroprotective activity in rotenone/oligomycin-induced cell death in human SH-SY5Y cells assessed as LDH release at 10 nM pretreated for 1 hr before rotenone/oligomycin challenge measured after 24 hrs by spectrophotometric method (Rvb = 13 %),Other,21715067.0,
2126,681400,1,7,,103166463,896,Unspecified,81872813.0,83500.0,,,"TP_TRANSPORTER: inhibition of Indoxyl sulfate uptake (Indoxyl sulfate: 2 uM, Melatonin: 1000 uM) in Xenopus laevis oocytes",Other,12358729.0,
2127,681428,1,7,,103166463,896,Unspecified,81872813.0,83500.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, Malatonin: 1000 uM) in Xenopus laevis oocytes",Other,10224140.0,
2128,686940,1,1,,49718192,896,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2129,686964,1,1,,49718192,896,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2130,686970,1,2,,46500483,896,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2131,686971,1,2,,46500483,896,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2132,686977,2,1,,49698838,896,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2133,686978,1,1,,46500483,896,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2134,686978,1,1,,124880734,896,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2135,686978,1,1,,124880736,896,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2136,686978,1,1,,144203746,896,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2137,686979,1,1,,46500483,896,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2138,686979,1,1,,124880734,896,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2139,686979,1,1,,124880736,896,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2140,686979,1,1,,144203746,896,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2141,686992,2,1,,49718192,896,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2142,687014,1,1,,49718192,896,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2143,687016,1,1,,49718192,896,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2144,687035,1,1,,163564741,896,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2145,687037,1,3,,163564741,896,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
2146,697852,1,7,,103166463,896,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
2147,697853,1,7,,103166463,896,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
2148,710230,1,3,,103166463,896,Inconclusive,,,,,Antioxidant activity of the compound assessed as DPPH radical scavenging at 10 uM after 30 secs by spectrophotometry,Other,23151013.0,
2149,710231,2,3,,103166463,896,Unspecified,,,1024.0,IC50,Antioxidant activity assessed as scavenging of morpholino sydononimine based nitric oxide release by chemiluminescence assay,Confirmatory,23151013.0,
2150,710232,2,2,,103166463,896,Unspecified,,,537.0,IC50,Antioxidant activity of the compound assessed as scavenging of hydroxyl radical by chemiluminometric method,Confirmatory,23151013.0,
2151,710234,2,2,,103166463,896,Unspecified,,,127.0,IC50,Antioxidant activity of the compound assessed as scavenging of peroxynitrite by chemiluminometric method,Confirmatory,23151013.0,
2152,710235,2,2,,103166463,896,Unspecified,,,95.8,IC50,Antioxidant activity assessed as scavenging of glucose oxidase-generated H2O2 and hydroxyl radicals by chemiluminescence assay,Confirmatory,23151013.0,
2153,714528,1,3,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as trolox equivalent of AAPH-induced radical scavenging activity incubated for 15 mins prior to AAPH induction measured every 1 min for 80 mins by ORAC-FL assay,Other,22795665.0,
2154,718788,1,6,,103166463,896,Unspecified,,,,,Inhibition of quinine reductase 2 using MTT and NMeH as substrates,Other,23131339.0,
2155,718789,1,7,,103166463,896,Unspecified,317373581.0,4835.0,,,Inhibition of human recombinant quinine reductase 2 expressed in Escherichia coli BL21 (DE3) using menadione and NMeH as substrates at 0.5 to 50 uM,Other,23131339.0,
2156,718790,3,3,,103166463,896,Active,,,6.6,IC50,Binding affinity to quinine reductase 2 using MTT and NMeH as substrates,Confirmatory,23131339.0,
2157,718791,4,5,,103166463,896,Active,317373581.0,4835.0,11.3,IC50,Binding affinity to human recombinant quinine reductase 2 expressed in Escherichia coli BL21 (DE3) using menadione and NMeH as substrates,Confirmatory,23131339.0,
2158,720504,1,1,,46500483,896,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2159,720508,1,1,,49718192,896,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2160,720509,1,1,,49718192,896,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2161,720511,1,1,,49718192,896,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2162,720516,2,1,,144203746,896,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2163,720516,2,1,,144208725,896,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2164,720516,2,1,,144213243,896,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2165,720532,1,1,,11111468,896,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2166,720532,1,1,,124880734,896,Inactive,420597.0,,5.6234,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2167,720532,1,1,,124880736,896,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2168,720532,1,1,,144203746,896,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2169,720533,1,1,,11111468,896,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2170,720533,1,1,,124880734,896,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2171,720533,1,1,,124880736,896,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2172,720533,1,1,,144203746,896,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2173,720538,1,2,,90340716,896,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2174,720542,1,2,,46500483,896,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2175,720543,1,1,,49718192,896,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2176,720551,1,2,,46500483,896,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2177,720552,2,1,,144203746,896,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2178,720552,2,1,,144208725,896,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2179,720552,2,1,,144213243,896,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2180,720553,1,2,,46500483,896,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2181,720559,1,2,,90340716,896,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2182,720572,1,2,,90340716,896,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2183,720573,1,2,,90340716,896,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2184,720579,2,1,,46500483,896,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2185,720579,2,1,,124880734,896,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2186,720580,1,1,,46500483,896,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2187,720580,1,1,,124880734,896,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2188,720582,1,1,,49718192,896,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2189,720596,1,1,,49718192,896,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2190,720634,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2191,720634,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2192,720634,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2193,720635,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2194,720635,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2195,720635,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2196,720636,1,1,,17388930,896,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2197,720636,1,1,,17389536,896,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2198,720636,1,1,,124880738,896,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2199,720637,2,1,,144203746,896,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2200,720637,2,1,,144208725,896,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2201,720637,2,1,,144213243,896,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2202,720641,1,2,,92239934,896,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2203,720641,1,2,,92308785,896,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2204,720647,1,2,,49718192,896,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2205,720648,1,1,,49718192,896,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2206,720652,1,1,,17388930,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2207,720652,1,1,,17389536,896,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2208,720653,1,1,,17388930,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2209,720653,1,1,,17389536,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2210,720653,1,1,,26752765,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2211,720659,1,1,,17388930,896,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2212,720659,1,1,,17389536,896,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2213,720659,1,1,,26752765,896,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2214,720674,2,2,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2215,720674,2,2,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2216,720674,2,2,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2217,720675,2,2,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2218,720675,2,2,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2219,720675,2,2,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2220,720678,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2221,720678,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2222,720678,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2223,720679,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2224,720679,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2225,720679,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2226,720680,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2227,720680,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2228,720680,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2229,720681,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2230,720681,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2231,720681,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2232,720682,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2233,720682,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2234,720682,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2235,720683,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2236,720683,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2237,720683,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2238,720684,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2239,720684,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2240,720684,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2241,720685,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2242,720685,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2243,720685,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2244,720686,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2245,720686,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2246,720686,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2247,720687,2,2,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2248,720687,2,2,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2249,720687,2,2,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2250,720691,4,1,,144203746,896,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2251,720691,4,1,,144208725,896,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2252,720691,4,1,,144213243,896,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2253,720692,3,1,,144203746,896,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2254,720692,3,1,,144208725,896,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2255,720692,3,1,,144213243,896,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2256,720693,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2257,720693,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2258,720693,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2259,720700,1,4,,49718192,896,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2260,720702,1,1,,49718192,896,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2261,720704,1,4,,49718192,896,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2262,720707,1,2,,46500483,896,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2263,720708,1,2,,46500483,896,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2264,720709,1,2,,46500483,896,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2265,720711,1,2,,46500483,896,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2266,720717,1,3,,92124328,896,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2267,720717,1,3,,92125502,896,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2268,720717,1,3,,92308785,896,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2269,720719,2,1,,144203746,896,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2270,720719,2,1,,144208725,896,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2271,720719,2,1,,144213243,896,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2272,720725,2,1,,144203746,896,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2273,720725,2,1,,144208725,896,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2274,720725,2,1,,144213243,896,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2275,721109,1,2,,103166463,896,Active,,,0.00054,Ki,Displacement of [125I]2-iodomelatonin from melatonin receptor in chicken brain membranes after 60 mins by gamma counting,Confirmatory,23265885.0,
2276,725222,2,5,,103166463,896,Active,1346544.0,4543.0,0.0002,Ki,Displacement of [125I]2-iodomelatonin from human recombinant MT1 receptor expressed in HEK293 cells after 2 hrs by gamma counting,Confirmatory,23265885.0,
2277,725223,2,5,,103166463,896,Active,1346548.0,4544.0,0.0005,Ki,Displacement of [125I]2-iodomelatonin from human recombinant MT2 receptor expressed in HEK293 cells after 2 hrs by gamma counting,Confirmatory,23265885.0,
2278,726928,1,4,,103166463,896,Unspecified,,,,,Intrinsic clearance in human liver microsomes after 30 mins by HPLC/MS analysis,Other,23228808.0,
2279,726929,1,4,,103166463,896,Unspecified,,,,,Elimination half life in human liver microsomes by HPLC/MS analysis,Other,23228808.0,
2280,726930,1,4,,103166463,896,Unspecified,,,,,Elimination half life in rat liver microsomes by HPLC/MS analysis,Other,23228808.0,
2281,726931,1,4,,103166463,896,Unspecified,,,,,Intrinsic clearance in rat liver microsomes after 30 mins by HPLC/MS analysis,Other,23228808.0,
2282,726935,1,2,,103166463,896,Unspecified,,,,,Selectivity ratio of Ki for human MT1 receptor to Ki for human MT2 receptor,Other,23228808.0,
2283,726936,2,5,,103166463,896,Active,1346548.0,4544.0,0.000429,Ki,Displacement of [3H]melatonin from human MT2 receptor expressed in CHO cells after 60 mins by microbeta scintillation method,Confirmatory,23228808.0,
2284,726937,2,5,,103166463,896,Active,1346544.0,4543.0,0.000296,Ki,Displacement of [3H]melatonin from human MT1 receptor expressed in CHO cells after 60 mins by microbeta scintillation method,Confirmatory,23228808.0,
2285,730112,1,2,,103166463,896,Unspecified,,,128.0,IC50,Inhibition of active recombinant full-length CaMK2 (unknown origin) using Autocamtide substrate and [gamma32P]ATP after 30 mins by scintillation counting method,Confirmatory,23332368.0,
2286,730113,1,3,,103166463,896,Inconclusive,,,,,Antioxidant activity assessed as DPPH radical scavenging activity,Other,23332368.0,
2287,730114,1,3,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 1 mM,Other,23332368.0,
2288,730115,1,3,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 5.5 mM,Other,23332368.0,
2289,730116,1,3,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 0.1 mM,Other,23332368.0,
2290,730117,1,2,,103166463,896,Unspecified,,,271.0,IC50,Antioxidant activity in human HepG2 cells assessed as reduction in H2O2-induced oxidation by DCFH-DA assay,Confirmatory,23332368.0,
2291,743012,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2292,743012,3,1,,144208725,896,Inconclusive,,,15.5898,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2293,743012,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2294,743014,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2295,743014,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2296,743014,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2297,743015,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2298,743015,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2299,743015,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2300,743033,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2301,743033,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2302,743033,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2303,743035,2,1,,144203746,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2304,743035,2,1,,144208725,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2305,743035,2,1,,144213243,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2306,743036,2,1,,144203746,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2307,743036,2,1,,144208725,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2308,743036,2,1,,144213243,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2309,743040,3,1,,144203746,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2310,743040,3,1,,144208725,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2311,743040,3,1,,144213243,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2312,743041,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2313,743041,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2314,743041,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2315,743042,3,1,,144203746,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2316,743042,3,1,,144208725,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2317,743042,3,1,,144213243,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2318,743053,2,1,,144203746,896,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2319,743053,2,1,,144208725,896,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2320,743053,2,1,,144213243,896,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2321,743054,2,1,,144203746,896,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2322,743054,2,1,,144208725,896,Inconclusive,124375976.0,367.0,52.2206,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2323,743054,2,1,,144213243,896,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2324,743063,2,1,,144203746,896,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2325,743063,2,1,,144208725,896,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2326,743063,2,1,,144213243,896,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2327,743064,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2328,743064,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2329,743064,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2330,743065,3,1,,144203746,896,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2331,743065,3,1,,144208725,896,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2332,743065,3,1,,144213243,896,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2333,743066,3,1,,144203746,896,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2334,743066,3,1,,144208725,896,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2335,743066,3,1,,144213243,896,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2336,743067,2,1,,144203746,896,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2337,743067,2,1,,144208725,896,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2338,743067,2,1,,144213243,896,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2339,743069,2,1,,144203746,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2340,743069,2,1,,144208725,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2341,743069,2,1,,144213243,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2342,743074,2,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2343,743074,2,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2344,743074,2,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2345,743075,2,1,,144203746,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2346,743075,2,1,,144208725,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2347,743075,2,1,,144213243,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2348,743077,2,1,,144203746,896,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2349,743077,2,1,,144208725,896,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2350,743077,2,1,,144213243,896,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2351,743078,2,1,,144203746,896,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2352,743078,2,1,,144208725,896,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2353,743078,2,1,,144213243,896,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2354,743079,3,1,,144203746,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2355,743079,3,1,,144208725,896,Active,348019627.0,2099.0,55.3148,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2356,743079,3,1,,144213243,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2357,743080,3,1,,144203746,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2358,743080,3,1,,144208725,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2359,743080,3,1,,144213243,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2360,743081,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2361,743081,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2362,743081,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2363,743083,3,1,,144203746,896,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2364,743083,3,1,,144208725,896,Inactive,119597822.0,1588.0,62.0642,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2365,743083,3,1,,144213243,896,Inactive,119597822.0,1588.0,38.5708,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2366,743084,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2367,743084,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2368,743084,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2369,743085,3,1,,144203746,896,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2370,743085,3,1,,144208725,896,Inconclusive,51095037.0,196.0,87.6681,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2371,743085,3,1,,144213243,896,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2372,743086,3,1,,144203746,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2373,743086,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2374,743086,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2375,743091,2,1,,144203746,896,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2376,743091,2,1,,144208725,896,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2377,743091,2,1,,144213243,896,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2378,743094,3,1,,144203746,896,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2379,743094,3,1,,144208725,896,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2380,743094,3,1,,144213243,896,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2381,743122,2,1,,144203746,896,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2382,743122,2,1,,144208725,896,Active,51095037.0,196.0,49.2994,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2383,743122,2,1,,144213243,896,Inconclusive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2384,743126,1,1,,49718192,896,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2385,743139,2,1,,144203746,896,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2386,743139,2,1,,144208725,896,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2387,743139,2,1,,144213243,896,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2388,743140,2,1,,144203746,896,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2389,743140,2,1,,144208725,896,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2390,743140,2,1,,144213243,896,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2391,743191,3,1,,144208725,896,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2392,743191,3,1,,144213243,896,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2393,743191,3,1,,170465589,896,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2394,743194,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2395,743194,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2396,743194,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2397,743199,2,1,,144208725,896,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2398,743199,2,1,,144213243,896,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2399,743199,2,1,,170465589,896,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2400,743202,4,1,,144208725,896,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2401,743202,4,1,,144213243,896,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2402,743202,4,1,,170465589,896,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2403,743203,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2404,743203,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2405,743203,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2406,743205,1,1,,90340716,896,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2407,743205,1,1,,90340716,896,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2408,743206,1,1,,90340716,896,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2409,743206,1,1,,90340716,896,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2410,743207,1,1,,90340716,896,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2411,743207,1,1,,90340716,896,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2412,743209,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2413,743209,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2414,743209,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2415,743210,4,1,,144208725,896,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2416,743210,4,1,,144213243,896,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2417,743210,4,1,,170465589,896,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2418,743211,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2419,743211,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2420,743211,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2421,743212,3,1,,144208725,896,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2422,743212,3,1,,144213243,896,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2423,743212,3,1,,170465589,896,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2424,743213,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2425,743213,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2426,743213,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2427,743215,3,1,,144208725,896,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2428,743215,3,1,,144213243,896,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2429,743215,3,1,,170465589,896,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2430,743217,3,1,,144208725,896,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2431,743217,3,1,,144213243,896,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2432,743217,3,1,,170465589,896,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2433,743218,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2434,743218,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2435,743218,3,1,,170465589,896,Inconclusive,,,10.5901,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2436,743219,3,1,,144208725,896,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2437,743219,3,1,,144213243,896,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2438,743219,3,1,,170465589,896,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2439,743220,3,1,,144208725,896,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2440,743220,3,1,,144213243,896,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2441,743220,3,1,,170465589,896,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2442,743221,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2443,743221,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2444,743221,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2445,743222,3,1,,144208725,896,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2446,743222,3,1,,144213243,896,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2447,743222,3,1,,170465589,896,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2448,743223,3,1,,144208725,896,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2449,743223,3,1,,144213243,896,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2450,743223,3,1,,170465589,896,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2451,743224,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2452,743224,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2453,743224,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2454,743225,3,1,,144208725,896,Inconclusive,,,55.8093,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2455,743225,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2456,743225,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2457,743226,2,1,,144208725,896,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2458,743226,2,1,,144213243,896,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2459,743226,2,1,,170465589,896,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2460,743227,2,1,,144208725,896,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2461,743227,2,1,,144213243,896,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2462,743227,2,1,,170465589,896,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2463,743228,3,1,,144208725,896,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2464,743228,3,1,,144213243,896,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2465,743228,3,1,,170465589,896,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2466,743238,1,1,,49718192,896,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2467,743239,2,1,,144208725,896,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2468,743239,2,1,,144213243,896,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2469,743239,2,1,,170465589,896,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2470,743240,2,1,,144208725,896,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2471,743240,2,1,,144213243,896,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2472,743240,2,1,,170465589,896,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2473,743241,2,1,,144208725,896,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2474,743241,2,1,,144213243,896,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2475,743241,2,1,,170465589,896,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2476,743242,2,1,,144208725,896,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2477,743242,2,1,,144213243,896,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2478,743242,2,1,,170465589,896,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2479,743244,1,1,,90340716,896,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2480,743244,1,1,,144203746,896,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2481,743247,1,2,,49718192,896,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2482,743255,1,1,,46500483,896,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2483,743266,1,2,,46500483,896,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2484,743269,1,1,,49718192,896,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2485,743269,1,1,,49718192,896,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2486,743279,1,2,,46500483,896,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2487,743287,1,1,,49718192,896,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
2488,743288,1,1,,17388930,896,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2489,743288,1,1,,17389536,896,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2490,743288,1,1,,26752765,896,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2491,743292,1,1,,17388930,896,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2492,743292,1,1,,17389536,896,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2493,743292,1,1,,26752765,896,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2494,743344,1,1,,90340716,896,Inactive,,,0.006,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2495,743344,1,1,,124880739,896,Inactive,,,2.3694,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2496,743345,1,1,,90340716,896,Inactive,,,5.3045,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2497,743345,1,1,,124880739,896,Inactive,,,0.0007,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2498,743346,1,1,,90340716,896,Inactive,,,1.0584,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2499,743346,1,1,,124880739,896,Inactive,,,4.7277,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2500,743347,1,1,,90340716,896,Inactive,,,0.0168,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2501,743347,1,1,,124880739,896,Inactive,,,0.0017,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2502,743397,1,1,,49718192,896,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2503,743398,1,1,,49718192,896,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2504,744932,1,1,,103166463,896,Unspecified,,,,,Antioxidant activity in Wistar rat liver assessed as inhibition of Fe2+/ascorbate-induced lipid peroxidation at 0.1 mM after 1 hr by TBARS assay relative to control,Other,23540647.0,
2505,744933,1,1,,103166463,896,Unspecified,,,,,Antioxidant activity in Wistar rat liver assessed as inhibition of Fe2+/ascorbate-induced lipid peroxidation at 1 mM after 1 hr by TBARS assay relative to control,Other,23540647.0,
2506,744934,1,1,,103166463,896,Unspecified,,,,,Antioxidant activity of the compound assessed as inhibition of xanthine-xanthine oxidase-mediated superoxide radical formation at 0.1 mM after 3 mins by NBT reduction assay relative to control,Other,23540647.0,
2507,744935,1,1,,103166463,896,Unspecified,,,,,Antioxidant activity of the compound assessed as inhibition of xanthine-xanthine oxidase-mediated superoxide radical formation at 1 mM after 3 mins by NBT reduction assay relative to control,Other,23540647.0,
2508,744936,1,2,,103166463,896,Unspecified,,,,,Antioxidant activity of the compound assessed as DPPH free radical scavenging activity at 0.1 mM after 30 mins by spectrophotometric analysis relative to control,Other,23540647.0,
2509,744937,1,2,,103166463,896,Unspecified,,,,,Antioxidant activity of the compound assessed as DPPH free radical scavenging activity at 1 mM after 30 mins by spectrophotometric analysis relative to control,Other,23540647.0,
2510,751667,1,1,,103166463,896,Active,,,0.00021,IC50,Displacement of [125I]2-iodomelatonin from human recombinant melatonin receptor 1 expressed in CHOK1 cells after 3 hrs,Confirmatory,23403082.0,
2511,751733,1,1,,103166463,896,Unspecified,,,,,Displacement of [125I]2-iodomelatonin from human recombinant melatonin receptor 1 expressed in CHOK1 cells at 10 uM after 3 hrs relative to control,Other,23403082.0,
2512,751877,2,3,,103166463,896,Active,1346544.0,4543.0,,IC50,Binding affinity to human MT1A receptor by radioligand displacement assay,Confirmatory,23466604.0,
2513,752239,2,3,,103166463,896,Active,1346544.0,4543.0,0.00053,IC50,Binding affinity to human ML1A receptor by radioligand displacement assay,Confirmatory,23582449.0,
2514,767821,1,1,,103166463,896,Active,,,1.92,IC50,Antioxidant activity assessed as ABTS free radical scavenging activity after 6 mins by spectrophotometry,Confirmatory,23978359.0,
2515,933202,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020401,Other,,
2516,933203,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020401,Other,,
2517,933204,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020401,Other,,
2518,933205,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020401,Other,,
2519,933206,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020401,Other,,
2520,933207,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020401,Other,,
2521,933208,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020401,Other,,
2522,933209,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020401,Other,,
2523,933210,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020401,Other,,
2524,933211,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020401",Other,,
2525,933212,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020401,Other,,
2526,935223,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020401,Other,,
2527,935224,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020401,Other,,
2528,935225,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020401,Other,,
2529,935226,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020401,Other,,
2530,935227,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020401,Other,,
2531,935228,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020401,Other,,
2532,935229,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020401,Other,,
2533,935230,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020401,Other,,
2534,938051,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020401,Other,,
2535,938052,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020401,Other,,
2536,938053,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020401,Other,,
2537,938054,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020401,Other,,
2538,938055,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020401,Other,,
2539,938056,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020401,Other,,
2540,938057,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020401,Other,,
2541,938058,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020401,Other,,
2542,938059,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020401,Other,,
2543,938060,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020401,Other,,
2544,938061,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020401,Other,,
2545,946765,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020401,Other,,
2546,946766,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020401",Other,,
2547,946767,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020401,Other,,
2548,946768,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020401,Other,,
2549,946769,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020401,Other,,
2550,946770,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020401,Other,,
2551,946771,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020401,Other,,
2552,946772,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020401,Other,,
2553,956807,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020401,Other,,
2554,956808,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020401,Other,,
2555,956809,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020401,Other,,
2556,956810,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020401,Other,,
2557,956811,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020401,Other,,
2558,956812,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020401,Other,,
2559,956813,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020401,Other,,
2560,956814,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020401,Other,,
2561,956815,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020401,Other,,
2562,956816,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020401,Other,,
2563,956817,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020401,Other,,
2564,956818,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020401,Other,,
2565,956819,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020401,Other,,
2566,956820,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020401,Other,,
2567,956821,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020401,Other,,
2568,956822,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020401,Other,,
2569,956823,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020401,Other,,
2570,956824,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020401,Other,,
2571,956825,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020401,Other,,
2572,971584,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020401,Other,,
2573,971585,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020401,Other,,
2574,971586,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020401,Other,,
2575,971587,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020401,Other,,
2576,971588,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020401,Other,,
2577,971589,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020401,Other,,
2578,971590,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020401,Other,,
2579,972221,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020401,Other,,
2580,972222,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020401,Other,,
2581,972223,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020401,Other,,
2582,972224,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020401,Other,,
2583,972225,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020401,Other,,
2584,972226,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020401,Other,,
2585,972227,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020401,Other,,
2586,972228,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020401,Other,,
2587,972229,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020401,Other,,
2588,972230,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020401,Other,,
2589,972231,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020401,Other,,
2590,972232,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020401,Other,,
2591,977599,1,1,,103166463,896,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2592,977602,1,2,,103166463,896,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2593,996244,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2594,996828,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020401",Other,,
2595,996829,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020401",Other,,
2596,996830,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020401",Other,,
2597,996831,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2598,996832,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2599,996833,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020401,Other,,
2600,996834,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020401",Other,,
2601,996835,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020401,Other,,
2602,996836,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020401",Other,,
2603,996837,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2604,996838,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020401",Other,,
2605,996839,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020401",Other,,
2606,996840,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2607,996841,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2608,996842,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020401",Other,,
2609,996843,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020401",Other,,
2610,996844,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2611,996845,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2612,998706,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2613,998707,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2614,998708,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2615,998709,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2616,998710,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020401",Other,,
2617,998711,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2618,998712,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2619,998713,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020401",Other,,
2620,998714,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2621,998715,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020401,Other,,
2622,998716,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020401,Other,,
2623,998717,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020401",Other,,
2624,998718,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2625,998719,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2626,998720,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020401",Other,,
2627,998721,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020401,Other,,
2628,998722,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2629,998723,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2630,999304,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2631,999305,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020401",Other,,
2632,999306,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020401,Other,,
2633,999307,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2634,999308,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020401",Other,,
2635,999309,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020401",Other,,
2636,999310,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2637,999311,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2638,999312,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020401",Other,,
2639,999313,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020401",Other,,
2640,999314,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020401",Other,,
2641,999315,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020401,Other,,
2642,999316,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2643,999317,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020401",Other,,
2644,999318,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020401",Other,,
2645,999319,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020401,Other,,
2646,999320,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2647,999321,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020401",Other,,
2648,999322,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2649,999323,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2650,999324,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2651,999325,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020401",Other,,
2652,1015281,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2653,1015282,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2654,1015283,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2655,1015284,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2656,1015285,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2657,1015286,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020401",Other,,
2658,1015287,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2659,1015288,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2660,1015289,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020401",Other,,
2661,1015290,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020401,Other,,
2662,1015291,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020401,Other,,
2663,1015292,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020401",Other,,
2664,1015293,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2665,1015294,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2666,1015295,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020401",Other,,
2667,1015296,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020401,Other,,
2668,1015297,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2669,1015298,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2670,1015299,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2671,1015300,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020401",Other,,
2672,1015301,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020401,Other,,
2673,1017021,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2674,1017022,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020401",Other,,
2675,1017023,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020401",Other,,
2676,1017024,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2677,1017025,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2678,1017026,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2679,1017027,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020401",Other,,
2680,1017028,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020401",Other,,
2681,1017614,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020401",Other,,
2682,1017615,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020401,Other,,
2683,1017616,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2684,1017617,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020401",Other,,
2685,1017618,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020401",Other,,
2686,1017619,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020401,Other,,
2687,1017620,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2688,1017621,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020401",Other,,
2689,1017622,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2690,1017623,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2691,1017624,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2692,1017625,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020401",Other,,
2693,1024587,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2694,1024588,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020401",Other,,
2695,1024589,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020401",Other,,
2696,1024590,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020401",Other,,
2697,1024591,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2698,1024592,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020401,Other,,
2699,1024593,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020401",Other,,
2700,1024594,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020401,Other,,
2701,1024595,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020401",Other,,
2702,1024596,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2703,1024597,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020401",Other,,
2704,1024598,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020401",Other,,
2705,1024599,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2706,1024600,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2707,1024601,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020401",Other,,
2708,1024602,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020401",Other,,
2709,1024603,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2710,1024604,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2711,1027286,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020401",Other,,
2712,1027287,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020401,Other,,
2713,1027288,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2714,1027289,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020401",Other,,
2715,1027290,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020401",Other,,
2716,1027291,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2717,1027292,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2718,1027293,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020401",Other,,
2719,1027294,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020401",Other,,
2720,1027295,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020401",Other,,
2721,1027296,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020401,Other,,
2722,1027297,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2723,1027298,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020401",Other,,
2724,1027299,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020401",Other,,
2725,1027300,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020401,Other,,
2726,1027301,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2727,1027302,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020401",Other,,
2728,1027303,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2729,1027304,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2730,1027305,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2731,1027306,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020401",Other,,
2732,1034707,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2733,1034708,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020401",Other,,
2734,1034709,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020401",Other,,
2735,1034710,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020401",Other,,
2736,1034711,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2737,1034712,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020401,Other,,
2738,1034713,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020401",Other,,
2739,1034714,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020401,Other,,
2740,1034715,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020401",Other,,
2741,1034716,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2742,1034717,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020401",Other,,
2743,1034718,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020401",Other,,
2744,1034719,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2745,1034720,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2746,1034721,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020401",Other,,
2747,1034722,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020401",Other,,
2748,1034723,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
2749,1034724,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2750,1034725,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2751,1034726,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
2752,1034727,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2753,1034728,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2754,1034729,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2755,1034730,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020401",Other,,
2756,1034731,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2757,1034732,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
2758,1035315,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020401",Other,,
2759,1035316,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2760,1035317,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020401,Other,,
2761,1035318,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020401,Other,,
2762,1035319,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020401",Other,,
2763,1035320,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
2764,1035321,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2765,1035322,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020401",Other,,
2766,1035323,1,3,,103166463,896,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020401,Other,,
2767,1035324,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
2768,1035325,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
2769,1035326,1,3,,103166463,896,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020401",Other,,
2770,1053175,2,1,,178126079,896,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
2771,1053197,1,1,,49718192,896,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2772,1064770,1,1,,103166463,896,Active,,,,,"Anxiolytic activity in C3H/he mouse assessed as increase in number of transitions at 20 to 40 mg/kg, po by light/dark box test",Other,24417958.0,
2773,1064772,1,1,,103166463,896,Active,,,,,"Anxiolytic activity in C3H/he mouse assessed as increase in time spent in light box at 20 to 40 mg/kg, po by light/dark box test",Other,24417958.0,
2774,1064774,1,1,,103166463,896,Active,,,,,"Increase of neophobia in C3H/he mouse assessed as time spent in unfamiliar compartment at 1 to 10 mg/kg, po",Other,24417958.0,
2775,1064778,1,2,,103166463,896,Active,,,0.0004,EC50,Intrinsic activity at human melatonin MT2 receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 1 hr,Confirmatory,24417958.0,
2776,1064780,1,2,,103166463,896,Active,,,0.0017,EC50,Intrinsic activity at human melatonin MT1 receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 1 hr,Confirmatory,24417958.0,
2777,1064781,1,1,,103166463,896,Active,,,0.00022999999999999998,Ki,Displacement of 2-[I]iodomelatonin from human melatonin MT1 receptor after 120 mins,Confirmatory,24417958.0,
2778,1064782,1,1,,103166463,896,Active,,,0.0005200000000000001,Ki,Displacement of 2-[I]iodomelatonin from human melatonin MT2 receptor after 120 mins,Confirmatory,24417958.0,
2779,1079931,1,1,,103166463,896,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2780,1079932,1,1,,103166463,896,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2781,1079933,1,1,,103166463,896,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2782,1079934,1,1,,103166463,896,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2783,1079935,1,1,,103166463,896,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2784,1079936,1,1,,103166463,896,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2785,1079937,1,1,,103166463,896,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2786,1079938,1,1,,103166463,896,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2787,1079939,1,1,,103166463,896,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2788,1079940,1,1,,103166463,896,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2789,1079941,1,1,,103166463,896,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2790,1079942,1,1,,103166463,896,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2791,1079943,1,1,,103166463,896,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2792,1079944,1,1,,103166463,896,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2793,1079945,1,1,,103166463,896,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2794,1079946,1,1,,103166463,896,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2795,1079947,1,1,,103166463,896,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2796,1079948,1,1,,103166463,896,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2797,1079949,1,1,,103166463,896,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2798,1093497,1,2,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as superoxide radical scavenging activity at 10 '-3 M measured for 3 min by spectrophotometry relative to control,Other,,
2799,1093498,1,2,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as superoxide radical scavenging activity at 10 '-4 M measured for 3 min by spectrophotometry relative to control,Other,,
2800,1093499,1,3,,103166463,896,Unspecified,,,,,Antioxidant activity in Rattus norvegicus (rat) liver homogenate assessed as inhibition of lipid peroxidation measuring TBARS production at 10 '-3 M after 1 hr by spectrophotometry relative to control,Other,,
2801,1093500,1,3,,103166463,896,Unspecified,,,,,Antioxidant activity in Rattus norvegicus (rat) liver homogenate assessed as inhibition of lipid peroxidation measuring TBARS production at 10 '-4 M after 1 hr by spectrophotometry relative to control,Other,,
2802,1117298,1,2,,170465589,896,Inactive,,,1.7783,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2803,1117304,1,2,,170465589,896,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2804,1117305,1,2,,170465589,896,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2805,1117310,1,1,,170465589,896,Inactive,,,1.7782799999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2806,1117312,1,1,,170465589,896,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2807,1117314,1,1,,170465589,896,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2808,1117326,1,1,,170465589,896,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2809,1117329,1,1,,170465589,896,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2810,1117336,1,1,,170465589,896,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2811,1117340,1,1,,170465589,896,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2812,1117341,1,1,,170465589,896,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2813,1117342,1,1,,170465589,896,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2814,1117343,1,1,,170465589,896,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2815,1117346,1,1,,170465589,896,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2816,1118958,2,2,,103166463,896,Active,1346544.0,4543.0,0.00045700000000000005,Ki,Displacement of 2-[125I]-iodomelatonin from human MT1 receptor expressed in CHO cells,Confirmatory,,
2817,1118960,2,2,,103166463,896,Active,1346548.0,4544.0,0.0009550000000000001,Ki,Displacement of 2-[125I]-iodomelatonin from human MT2 receptor expressed in CHO cells,Confirmatory,,
2818,1122944,1,1,,103166463,896,Unspecified,,,,,Neuroprotective activity in human SH-SY5Y cells under oxygen and glucose deprived condition assessed as protection against oxidative stress at 0.1 uM co-incubated for 4 hrs under anaerobic condition measured after 20 hrs by MTT assay relative to control,Other,,
2819,1122947,1,1,,103166463,896,Unspecified,,,,,Neuroprotective activity in human SH-SY5Y cells under oxygen and glucose deprived condition assessed as cell survival at 0.1 uM co-incubated for 4 hrs under anaerobic condition measured after 20 hrs by MTT assay relative to control,Other,,
2820,1123750,1,1,,103166463,896,Unspecified,,,,,Half life in iv dosed mouse at 40 uCi after 10 mins,Other,423184.0,
2821,1123751,1,1,,103166463,896,Unspecified,,,,,Half life in iv dosed mouse at 40 uCi after 40 mins,Other,423184.0,
2822,1123752,1,2,,103166463,896,Unspecified,,,,,Half life in rat plasma after 30 mins,Other,423184.0,
2823,1123753,1,2,,103166463,896,Unspecified,,,,,Half life in rat plasma after 2 hrs,Other,423184.0,
2824,1123754,1,1,,103166463,896,Unspecified,,,,,Half life in serum (unknown origin) after first 2 hrs post iv dose,Other,423184.0,
2825,1127073,1,1,,103166463,896,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum 3D7 infected in erythrocytes assessed as parasitemia level at 100 nM after 48 hrs by YOYO-1 staining-based flow cytometry relative to control,Other,24699367.0,
2826,1127074,1,1,,103166463,896,Unspecified,,,,,Antiplasmodial activity against asynchronous culture of Plasmodium falciparum 3D7 infected in erythrocytes assessed as reduction of melatonin-induced increase in parasitemia level at 500 nM after 48 hrs by YOYO-1 staining-based flow cytometry (Rvb = 23.5 +/- 6.8 %),Other,24699367.0,
2827,1138157,3,2,,103166463,896,Unspecified,116241312.0,1576.0,,,Half life of the compound assessed as CYP3A4 (unknown origin)-mediated drug metabolism,Other,24228714.0,
2828,1140646,1,1,,103166463,896,Inconclusive,,,,,Permeability of the compound by PAMPA,Other,24738476.0,
2829,1140647,1,1,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as oxygen radical absorbance capacity after 15 mins fluorescence assay relative to trolox,Other,24738476.0,
2830,1140652,1,1,,103166463,896,Active,,,,,Neurogenic activity in Wistar rat Primary neural stem cells assessed as cell maturation by measuring TuJ1 at 10 uM after 48 hrs by DAPI staining-based immunohistochemistry,Other,24738476.0,
2831,1140653,1,1,,103166463,896,Active,,,,,Neurogenic activity in Wistar rat Primary neural stem cells assessed as cell maturation by measuring MAP-2 at 10 uM after 48 hrs by DAPI staining-based immunohistochemistry,Other,24738476.0,
2832,1141127,1,1,,103166463,896,Unspecified,,,,,Neuroprotective activity against rotenone-oligomycin A-induced oxidative stress in human SH-SY5Y cells assessed as survival at 0.3 uM co-incubated rot/oligo for 24 hrs by MTT assay (Rvb =65.6 +/- 1.3%),Other,24754640.0,
2833,1141128,1,1,,103166463,896,Unspecified,,,,,Neuroprotective activity against rotenone-oligomycin A-induced oxidative stress in human SH-SY5Y cells assessed as protection at 0.3 uM co-incubated rot/oligo for 24 hrs by MTT assay relative to control,Other,24754640.0,
2834,1141129,1,1,,103166463,896,Unspecified,,,,,Neuroprotective activity against rotenone-oligomycin A-induced oxidative stress in human SH-SY5Y cells assessed as survival incubated with rot/oligo for 8 hrs followed by treated with compound at 0.3 uM for 16 hrs by MTT assay (Rvb =70.6 +/- 1.8%),Other,24754640.0,
2835,1141130,1,1,,103166463,896,Unspecified,,,,,Neuroprotective activity against rotenone-oligomycin A-induced oxidative stress in human SH-SY5Y cells assessed as protection incubated with rot/oligo for 8 hrs followed by treated with compound at 0.3 uM for 16 hrs by MTT assay relative to control,Other,24754640.0,
2836,1159509,1,1,,144208725,896,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2837,1159509,1,1,,144213243,896,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2838,1159509,1,1,,170465589,896,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2839,1159515,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2840,1159515,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2841,1159515,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2842,1159516,1,1,,144208725,896,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2843,1159516,1,1,,144213243,896,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2844,1159516,1,1,,170465589,896,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2845,1159517,1,1,,144208725,896,Inconclusive,,,4.974,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2846,1159517,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2847,1159517,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2848,1159518,1,1,,144208725,896,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2849,1159518,1,1,,144213243,896,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2850,1159518,1,1,,170465589,896,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2851,1159519,1,1,,144208725,896,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2852,1159519,1,1,,144213243,896,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2853,1159519,1,1,,170465589,896,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2854,1159520,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2855,1159520,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2856,1159520,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2857,1159521,1,1,,144208725,896,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2858,1159521,1,1,,144213243,896,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2859,1159521,1,1,,170465589,896,Inactive,15928672.0,19885.0,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2860,1159523,1,1,,144208725,896,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2861,1159523,1,1,,144213243,896,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2862,1159523,1,1,,170465589,896,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2863,1159524,1,1,,46500483,896,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2864,1159524,1,1,,124880734,896,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2865,1159525,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2866,1159525,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2867,1159525,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2868,1159526,1,1,,144208725,896,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2869,1159526,1,1,,144213243,896,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2870,1159526,1,1,,170465589,896,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2871,1159527,1,1,,144208725,896,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2872,1159527,1,1,,144213243,896,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2873,1159527,1,1,,170465589,896,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2874,1159528,1,1,,144208725,896,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2875,1159528,1,1,,144213243,896,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2876,1159528,1,1,,170465589,896,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2877,1159529,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2878,1159529,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2879,1159529,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2880,1159531,1,1,,144208725,896,Inconclusive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2881,1159531,1,1,,144213243,896,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2882,1159531,1,1,,170465589,896,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2883,1159550,3,1,,252401243,896,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
2884,1159551,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2885,1159551,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2886,1159551,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2887,1159552,1,1,,144208725,896,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2888,1159552,1,1,,144213243,896,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2889,1159552,1,1,,170465589,896,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2890,1159553,2,1,,144208725,896,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2891,1159553,2,1,,144213243,896,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2892,1159553,2,1,,170465589,896,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2893,1159555,1,1,,144208725,896,Inconclusive,325495463.0,5914.0,39.1599,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2894,1159555,1,1,,144213243,896,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2895,1159555,1,1,,170465589,896,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2896,1159580,2,1,,268735744,896,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2897,1159580,2,1,,273002888,896,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2898,1159583,2,1,,178126079,896,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
2899,1159606,1,1,,49718192,896,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2900,1159607,2,1,,312590081,896,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2901,1159614,1,2,,170465589,896,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2902,1159620,1,1,,103166463,896,Active,,,,,Summary of drug indications.,Other,,
2903,1164730,1,2,,103166463,896,Active,1346544.0,4543.0,0.00014,Ki,Displacement of 2-[125I]iodomelatonin from human MT1 receptor stably transfected in HEK293 cells after 120 mins by scintillation counting,Confirmatory,25232966.0,
2904,1164731,1,2,,103166463,896,Active,1346548.0,4544.0,0.00041,Ki,Displacement of 2-[125I]iodomelatonin from human MT2 receptor stably transfected in HEK293 cells after 120 mins by scintillation counting,Confirmatory,25232966.0,
2905,1179897,1,2,,103166463,896,Active,1346544.0,4543.0,0.00014,Ki,Displacement of [125L]iodomelatonin from human MT1 receptor expressed in HEK293 cells,Confirmatory,24930835.0,
2906,1179897,1,2,,103166463,896,Active,1346548.0,4544.0,0.00014,Ki,Displacement of [125L]iodomelatonin from human MT1 receptor expressed in HEK293 cells,Confirmatory,24930835.0,
2907,1179898,1,2,,103166463,896,Active,1346544.0,4543.0,0.00041,Ki,Displacement of [125L]iodomelatonin from human MT2 receptor expressed in HEK293 cells,Confirmatory,24930835.0,
2908,1179898,1,2,,103166463,896,Active,1346548.0,4544.0,0.00041,Ki,Displacement of [125L]iodomelatonin from human MT2 receptor expressed in HEK293 cells,Confirmatory,24930835.0,
2909,1186320,1,1,,103166463,896,Unspecified,,,,IC50,Antioxidant activity assessed as ABTS radical cation scavenging activity,Confirmatory,25082512.0,
2910,1190484,1,1,,103166463,896,Unspecified,,,,,Cytoprotective activity against H2O2-induced cytotoxicity in mouse C2 cells assessed as cell viability at 15 uM after 24 hrs by MTT assay (Rvb = 83.1 +/- 3.5%),Other,25577709.0,
2911,1190487,1,1,,103166463,896,Unspecified,,,,,Cytotoxic activity against mouse C2 cells assessed as cell viability at 15 uM after 24 hrs by MTT assay (Rvb = 100%),Other,25577709.0,
2912,1190489,1,1,,103166463,896,Unspecified,,,,,Cytoprotective activity against curcumin-induced cytotoxicity in mouse C2 cells assessed as cell viability at 15 uM after 24 hrs by MTT assay (Rvb = 83.8 +/- 0.4%),Other,25577709.0,
2913,1190494,1,1,,103166463,896,Unspecified,,,,,Inhibition of curcumin-induced ERK phosphorylation in mouse C2 cells at 15 uM pre-incubated for 30 mins before curcumin exposure for 15 mins by SDS-PAGE and immunoblotting method,Other,25577709.0,
2914,1190496,1,1,,103166463,896,Unspecified,,,,,Inhibition of curcumin-induced JNK phosphorylation in mouse C2 cells at 15 uM pre-incubated for 30 mins before curcumin exposure for 15 mins by SDS-PAGE and immunoblotting method,Other,25577709.0,
2915,1190498,1,1,,103166463,896,Unspecified,,,,,Inhibition of curcumin-induced JNK in mouse C2 cells assessed as reduction in c-Jun phosphorylation at 15 uM pre-incubated for 30 mins before curcumin exposure for 4 hrs by Western blotting method,Other,25577709.0,
2916,1224818,1,1,,312344912,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
2917,1224819,1,1,,312344912,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
2918,1224820,1,1,,312344912,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
2919,1224821,1,1,,312344912,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
2920,1224822,1,1,,312344912,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
2921,1224823,1,1,,312344912,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
2922,1224824,1,1,,124880739,896,Inactive,,,0.0166,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
2923,1224825,1,1,,124880739,896,Inactive,,,37.2212,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
2924,1224834,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2925,1224834,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2926,1224834,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2927,1224835,1,1,,144208725,896,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2928,1224835,1,1,,144213243,896,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2929,1224835,1,1,,170465589,896,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2930,1224836,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2931,1224836,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2932,1224836,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2933,1224837,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2934,1224837,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2935,1224837,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2936,1224838,1,1,,144208725,896,Inactive,66775687.0,9970.0,31.1058,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2937,1224838,1,1,,144213243,896,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2938,1224838,1,1,,170465589,896,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2939,1224839,1,1,,144208725,896,Inconclusive,66775687.0,9970.0,62.0642,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2940,1224839,1,1,,144213243,896,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2941,1224839,1,1,,170465589,896,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2942,1224840,3,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2943,1224840,3,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2944,1224840,3,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2945,1224841,3,1,,144208725,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2946,1224841,3,1,,144213243,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2947,1224841,3,1,,170465589,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2948,1224842,3,1,,144208725,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2949,1224842,3,1,,144213243,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2950,1224842,3,1,,170465589,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2951,1224843,1,1,,144208725,896,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2952,1224843,1,1,,144213243,896,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2953,1224843,1,1,,170465589,896,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2954,1224844,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2955,1224844,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2956,1224844,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2957,1224845,1,1,,144208725,896,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2958,1224845,1,1,,144213243,896,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2959,1224845,1,1,,170465589,896,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2960,1224846,1,1,,144208725,896,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2961,1224846,1,1,,144213243,896,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2962,1224846,1,1,,170465589,896,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2963,1224847,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2964,1224847,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2965,1224847,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2966,1224848,3,1,,144208725,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2967,1224848,3,1,,144213243,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2968,1224848,3,1,,170465589,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2969,1224849,3,1,,144208725,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2970,1224849,3,1,,144213243,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2971,1224849,3,1,,170465589,896,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2972,1224857,2,1,,124880739,896,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2973,1224857,2,1,,170465589,896,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2974,1224857,2,1,,312344912,896,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2975,1224859,2,1,,90340716,896,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2976,1224859,2,1,,124880739,896,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2977,1224859,2,1,,170465589,896,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2978,1224863,1,1,,176484108,896,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2979,1224865,1,2,,49718192,896,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
2980,1224867,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2981,1224867,1,1,,144213243,896,Inconclusive,,,21.8751,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2982,1224867,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2983,1224868,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2984,1224868,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2985,1224868,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2986,1224869,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2987,1224869,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2988,1224869,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2989,1224870,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2990,1224870,1,1,,144213243,896,Inconclusive,,,21.8751,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2991,1224870,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2992,1224871,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2993,1224871,1,1,,144213243,896,Inconclusive,,,19.4962,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2994,1224871,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2995,1224872,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2996,1224872,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2997,1224872,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2998,1224873,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2999,1224873,1,1,,144213243,896,Inconclusive,,,21.8751,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3000,1224873,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3001,1224874,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3002,1224874,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3003,1224874,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3004,1224875,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3005,1224875,1,1,,144213243,896,Inconclusive,,,19.4962,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3006,1224875,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3007,1224876,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3008,1224876,1,1,,144213243,896,Inactive,,,21.8751,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3009,1224876,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3010,1224877,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3011,1224877,1,1,,144213243,896,Inconclusive,,,21.8751,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3012,1224877,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3013,1224878,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3014,1224878,1,1,,144213243,896,Inactive,,,21.8751,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3015,1224878,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3016,1224879,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3017,1224879,1,1,,144213243,896,Inactive,,,21.8751,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3018,1224879,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3019,1224880,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3020,1224880,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3021,1224880,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3022,1224881,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3023,1224881,1,1,,144213243,896,Inconclusive,,,19.4962,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3024,1224881,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3025,1224882,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3026,1224882,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3027,1224882,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3028,1224883,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3029,1224883,1,1,,144213243,896,Inactive,,,21.8751,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3030,1224883,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3031,1224884,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3032,1224884,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3033,1224884,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3034,1224885,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3035,1224885,1,1,,144213243,896,Inconclusive,,,21.8751,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3036,1224885,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3037,1224886,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3038,1224886,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3039,1224886,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3040,1224887,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3041,1224887,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3042,1224887,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3043,1224888,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3044,1224888,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3045,1224888,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3046,1224889,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3047,1224889,1,1,,144213243,896,Inconclusive,,,21.8751,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3048,1224889,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3049,1224890,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3050,1224890,1,1,,144213243,896,Inactive,,,21.8751,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3051,1224890,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3052,1224892,1,1,,144208725,896,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3053,1224892,1,1,,144213243,896,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3054,1224892,1,1,,170465589,896,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3055,1224893,1,1,,144208725,896,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3056,1224893,1,1,,144213243,896,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3057,1224893,1,1,,170465589,896,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3058,1224894,1,1,,144208725,896,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3059,1224894,1,1,,144213243,896,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3060,1224894,1,1,,170465589,896,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3061,1224895,1,1,,144208725,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3062,1224895,1,1,,144213243,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3063,1224895,1,1,,170465589,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3064,1224896,1,1,,144208725,896,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3065,1224896,1,1,,144213243,896,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3066,1224896,1,1,,170465589,896,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3067,1224905,2,1,,92239934,896,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3068,1224905,2,1,,92239934,896,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3069,1224905,2,1,,92308785,896,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3070,1224905,2,1,,92308785,896,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3071,1224905,2,1,,121361700,896,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3072,1224905,2,1,,121361700,896,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3073,1227426,1,1,,103166463,896,Active,,,0.00045700000000000005,Ki,Displacement of 2-[125I]-iodomelatonin from human MT1 receptor expressed in CHO cells by Gamma counting,Confirmatory,,
3074,1227427,1,1,,103166463,896,Active,,,0.0009550000000000001,Ki,Displacement of 2-[125I]-iodomelatonin from human MT2 receptor expressed in CHO cells by Gamma counting,Confirmatory,,
3075,1229570,1,1,,103166463,896,Active,1346544.0,4543.0,9.1e-05,Ki,Displacement of 2-[125I]-iodomelatonin from human melatonin receptor-1 transfected in CHO cell membranes after 120 mins,Confirmatory,26023814.0,
3076,1229571,1,1,,103166463,896,Active,1346548.0,4544.0,0.00015,Ki,Displacement of 2-[125I]-iodomelatonin from human melatonin receptor-2 transfected in CHO cell membranes after 120 mins,Confirmatory,26023814.0,
3077,1229572,1,1,,103166463,896,Unspecified,,,,,Selectivity ratio of Ki for human melatonin receptor-1 to Ki for human melatonin receptor-2,Other,26023814.0,
3078,1229573,1,1,,103166463,896,Active,1346544.0,4543.0,9.8e-05,EC50,Agonist activity at human melatonin receptor-1 transfected in CHO cell membranes after 1 hr by GTPgammaS binding assay,Confirmatory,26023814.0,
3079,1229575,1,1,,103166463,896,Active,1346548.0,4544.0,6.9e-05,EC50,Agonist activity at human melatonin receptor-2 transfected in CHO cell membranes after 1 hr by GTPgammaS binding assay,Confirmatory,26023814.0,
3080,1229577,1,1,,103166463,896,Inconclusive,,,,,Thermodynamic solubility in buffer at pH 5.5 after 24 hrs by UV spectra analysis,Other,26023814.0,
3081,1229578,1,1,,103166463,896,Unspecified,,,,,Thermodynamic solubility in phosphate buffer at pH 7.4 after 24 hrs by UV spectra analysis,Other,26023814.0,
3082,1229579,1,1,,103166463,896,Inconclusive,,,,,Thermodynamic solubility in NH4Cl buffer at pH 9.3 after 24 hrs by UV spectra analysis,Other,26023814.0,
3083,1229580,1,1,,103166463,896,Active,,,,,Induction of primary neuronal stem cell differentiation derived from subgranular zone of dentate gyrus of Wistar rat hippocampus assessed as upregulation of TuJ1 expression at 10 uM incubated for 7 days followed by 48 hrs incubation in presence of serum and absence of EGF by DAPI staining-based fluorescence microscopic analysis,Other,26023814.0,
3084,1229581,1,1,,103166463,896,Active,,,,,Induction of primary neuronal stem cell maturation derived from subgranular zone of dentate gyrus of Wistar rat hippocampus assessed as upregulation of MAP-2 expression at 10 uM incubated for 7 days by DAPI staining-based fluorescence microscopic analysis,Other,26023814.0,
3085,1229582,1,1,,103166463,896,Inactive,,,,,Induction of primary neuronal stem cell differentiation derived from subgranular zone of dentate gyrus of Wistar rat hippocampus assessed as upregulation of TuJ1 expression at 10 uM incubated for 7 days followed by 48 hrs incubation in presence of serum and absence of EGF by DAPI staining-based fluorescence microscopic analysis in presence of melatonin receptor antagonist luzindole,Other,26023814.0,
3086,1229583,1,1,,103166463,896,Inactive,,,,,Induction of primary neuronal stem cell maturation derived from subgranular zone of dentate gyrus of Wistar rat hippocampus assessed as upregulation of MAP-2 expression at 10 uM incubated for 7 days by DAPI staining-based fluorescence microscopic analysis in presence of melatonin receptor antagonist luzindole,Other,26023814.0,
3087,1229587,1,1,,103166463,896,Unspecified,,,,,Solubility in the water,Other,26023814.0,
3088,1252810,1,1,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity preincubated for 15 mins followed by addition of AAPH solution measured for 80 mins by ORAC-FL method,Other,26363866.0,
3089,1252815,1,1,,103166463,896,Active,,,,,Neuroprotective activity against H2O2-induced oxidative stress-associated death in human SH-SY5Y cells assessed as increase in cell viability at 10 uM incubated for 24 hrs prior to H2O2 challenge measured after 24 hrs by MTT assay,Other,26363866.0,
3090,1252816,1,1,,103166463,896,Unspecified,,,,,Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity,Other,26363866.0,
3091,1252837,1,1,,103166463,896,Unspecified,1346544.0,4543.0,,,Displacement of 2-[125I]iodomelatonin from human recombinant MT1 expressed in CHO cell membranes at 100 nM incubated for 60 mins by liquid scintillation spectrometry,Other,26367450.0,
3092,1252838,1,1,,103166463,896,Unspecified,1346548.0,4544.0,,,Displacement of 2-[125I]iodomelatonin from human recombinant MT2 expressed in CHO cell membranes at 100 nM incubated for 60 mins by liquid scintillation spectrometry,Other,26367450.0,
3093,1252840,1,1,,103166463,896,Active,,,7.4e-05,EC50,Agonist activity at melatonin receptor in Xenopus laevis melanophores assessed as effect on pigment aggregation after 60 mins by microtiter plate reader assay,Confirmatory,26367450.0,
3094,1252842,1,1,,103166463,896,Unspecified,,,,,Agonist activity at melatonin receptor in Xenopus laevis melanophores assessed as effect on pigment aggregation at 10'-12 to 10'-5 M after 60 mins by microtiter plate reader assay,Other,26367450.0,
3095,1252843,1,1,,103166463,896,Active,1346544.0,4543.0,9.1e-05,Ki,Displacement of 2-[125I]iodomelatonin from human recombinant MT1 expressed in CHO cell membranes incubated for 60 mins by liquid scintillation spectrometry,Confirmatory,26367450.0,
3096,1252844,1,1,,103166463,896,Active,1346548.0,4544.0,0.00015,Ki,Displacement of 2-[125I]iodomelatonin from human recombinant MT2 expressed in CHO cell membranes incubated for 60 mins by liquid scintillation spectrometry,Confirmatory,26367450.0,
3097,1259241,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3098,1259241,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3099,1259241,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3100,1259242,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3101,1259242,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3102,1259242,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3103,1259243,1,1,,144208725,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3104,1259243,1,1,,144213243,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3105,1259243,1,1,,170465589,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3106,1259244,1,1,,144208725,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3107,1259244,1,1,,144213243,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3108,1259244,1,1,,170465589,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3109,1259247,1,1,,144208725,896,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3110,1259247,1,1,,144213243,896,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3111,1259247,1,1,,170465589,896,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3112,1259248,1,1,,144208725,896,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3113,1259248,1,1,,144213243,896,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3114,1259248,1,1,,170465589,896,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3115,1259252,1,1,,124880739,896,Active,169655958.0,,1.177,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3116,1259253,1,1,,124880739,896,Active,169655958.0,,1.0490000000000002,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3117,1259255,1,1,,124880739,896,Active,169655958.0,,2.9566,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3118,1259256,1,1,,124880739,896,Active,169655958.0,,3.3173,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3119,1259309,1,1,,178126079,896,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3120,1259310,1,1,,321942228,896,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3121,1259310,1,1,,332949344,896,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3122,1259310,1,1,,332949363,896,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3123,1259310,1,1,,332949790,896,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3124,1259311,1,1,,178126079,896,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3125,1259313,1,1,,46500483,896,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3126,1259318,1,1,,49718192,896,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3127,1259344,1,1,,144203746,896,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3128,1259354,1,1,,348435516,896,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
3129,1259355,1,1,,26752764,896,Inconclusive,,,3.9811,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3130,1259356,1,1,,144203746,896,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3131,1259364,1,1,,144208725,896,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3132,1259364,1,1,,144213243,896,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3133,1259364,1,1,,170465589,896,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3134,1259365,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3135,1259365,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3136,1259365,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3137,1259366,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3138,1259366,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3139,1259366,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3140,1259367,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3141,1259367,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3142,1259367,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3143,1259368,1,1,,144208725,896,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3144,1259368,1,1,,144213243,896,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3145,1259368,1,1,,170465589,896,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3146,1259369,1,1,,144208725,896,Inconclusive,109731339.0,2737.0,27.7231,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3147,1259369,1,1,,144213243,896,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3148,1259369,1,1,,170465589,896,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3149,1259370,2,2,,124636683,896,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3150,1259370,2,2,,124636683,896,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3151,1259370,2,2,,124636683,896,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3152,1259377,1,1,,144208725,896,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3153,1259377,1,1,,144213243,896,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3154,1259377,1,1,,170465589,896,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3155,1259378,1,1,,144208725,896,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3156,1259378,1,1,,144213243,896,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3157,1259378,1,1,,170465589,896,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3158,1259379,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3159,1259379,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3160,1259379,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3161,1259380,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3162,1259380,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3163,1259380,1,1,,170465589,896,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3164,1259381,1,1,,144208725,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3165,1259381,1,1,,144213243,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3166,1259381,1,1,,170465589,896,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3167,1259382,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3168,1259382,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3169,1259382,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3170,1259383,1,1,,144208725,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3171,1259383,1,1,,144213243,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3172,1259383,1,1,,170465589,896,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3173,1259384,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3174,1259384,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3175,1259384,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3176,1259385,1,1,,144208725,896,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3177,1259385,1,1,,144213243,896,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3178,1259385,1,1,,170465589,896,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3179,1259386,1,1,,144208725,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3180,1259386,1,1,,144213243,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3181,1259386,1,1,,170465589,896,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3182,1259387,1,1,,144208725,896,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3183,1259387,1,1,,144213243,896,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3184,1259387,1,1,,170465589,896,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3185,1259388,1,1,,144208725,896,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3186,1259388,1,1,,144213243,896,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3187,1259388,1,1,,170465589,896,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3188,1259389,1,1,,124636683,896,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3189,1259390,1,1,,144208725,896,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3190,1259390,1,1,,144213243,896,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3191,1259390,1,1,,170465589,896,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3192,1259391,1,1,,144208725,896,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3193,1259391,1,1,,144213243,896,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3194,1259391,1,1,,170465589,896,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3195,1259392,1,1,,144208725,896,Inconclusive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3196,1259392,1,1,,144213243,896,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3197,1259392,1,1,,170465589,896,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3198,1259393,1,1,,144208725,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3199,1259393,1,1,,144213243,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3200,1259393,1,1,,170465589,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3201,1259394,1,1,,144208725,896,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3202,1259394,1,1,,144213243,896,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3203,1259394,1,1,,170465589,896,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3204,1259395,1,1,,144208725,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3205,1259395,1,1,,144213243,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3206,1259395,1,1,,170465589,896,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3207,1259396,1,1,,144208725,896,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3208,1259396,1,1,,144213243,896,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3209,1259396,1,1,,170465589,896,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3210,1259400,1,1,,170465589,896,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3211,1259401,1,1,,144208725,896,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3212,1259401,1,1,,144213243,896,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3213,1259401,1,1,,170465589,896,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3214,1259402,1,1,,144208725,896,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3215,1259402,1,1,,144213243,896,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3216,1259402,1,1,,170465589,896,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3217,1259403,1,1,,144208725,896,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3218,1259403,1,1,,144213243,896,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3219,1259403,1,1,,170465589,896,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3220,1259404,1,1,,144208725,896,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3221,1259404,1,1,,144213243,896,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3222,1259404,1,1,,170465589,896,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3223,1259407,1,1,,363901422,896,Inactive,,,,,CCRIS mutagenicity studies,Other,,
3224,1259409,1,1,,363901422,896,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
3225,1259415,1,1,,49718192,896,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3226,1259416,1,2,,340079383,896,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3227,1259416,1,2,,375174668,896,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3228,1259421,1,1,,340079383,896,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3229,1259421,1,1,,375174668,896,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3230,1259423,1,2,,354798411,896,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3231,1259423,1,2,,354926785,896,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3232,1259423,1,2,,355014461,896,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
